PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2025

7-10 May Amsterdam

N. Poster

Poster title

Applicant name

Status


LBP-001	Preclinical profiling of ABI-6250, a first-in-class oral therapeutic candidate for chronic hepatitis D	Marc P. Windisch	Received

TOP-001	Community-based screening of viral hepatitis infections among high risk migrant and refugee populations in Greece, Italy and Spain: 2-year results of the VH-COMSAVAC project	Camila A Picchio	Received

LBP-2	High-throughput combinatorial CRISPR screening in hepatic progenitor cell-derived organoids reveals genetic determinants of response to standard-of-care chemotherapy in cholangiocarcinoma	Michael Girma Mamo	Received

TOP-002	Disparities in hepatocellular carcinoma screening and in its detection rates in individuals with hepatitis B or C and cirrhosis in Canada	Jean Damascene Makuza	Received

SAT-003	A global survey of practice patterns in the management of hepatitis C virus (HCV)-related fibrosis	Ira Jacobson	Received

FRI-003	Changing prevalence and risk factors of metabolic dysfunction associated steatotic liver disease in Taiwan	Jee-Fu Huang	Received

THU-3	One-stop shop: a bespoke single-point-of-referral clinic enhances linkage to care for ultrasound surveillance of hepatoma in patients diagnosed with advanced fibrosis and cirrhosis via targeted community screening	Basil Ahmad	Received

THU-004	Hospital-based and individual disparities in liver transplantation access in France: a national health data system analysis	José URSIC BEDOYA	Received

WED-004	Global burden of liver cancer related to viral hepatitis attributable to high body mass index from 1990 to 2021	Sitao Ye	Received

SAT-004	Emergency department opt-out testing for hepatitis B: a 2-year multicentre study of outcomes across 7 sites	Jennifer Plunkett	Received

LBP-005	DA-1241, a GPR119 agonist, demonstrates hepatoprotective and glucose-regulating effects in a 16-week randomized placebo-controlled trial in presumed metabolic dysfunction-associated steatohepatitis (MASH) patients	Ji Eun Lee	Received

WED-005	Current hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus across Europe	Anders Boyd	Received

SAT-005	From screening to treatment: the impact of opportunistic hepatitis screening in emergency departments on hepatitis C prevalence	Juan Carlos Ruiz Cobo	Received

FRI-005	Metabolic dysfunction-associated steatotic liver disease as the leading cause of hepatocellular carcinoma in mexican cirrhotic patients: a perspective consistent with trends observed in europe	Nahum Méndez-Sánchez	Received

THU-005	The largest, exhaustive in-depth analysis and concerning report on 386 complementary and alternative medicinal products belonging to the Indian-systems of medicine (AYUSH) retrieved from patients that caused liver-related harm at the consumer level	Cyriac Philips	Received

FRI-006	Reference blood-based biomarkers SteatoTest-2 (ST2) and NashTest-2 (NT2) permit assessment of the prevalence of steatosis and MASH in large general population of UK-Biobank (UKB), stratified by cardiometabolic risk factors (CRF) and alcohol consumption (A	Olivier Deckmyn	Received

THU-006	Bridging the gap between primary care physicians and hepatology with electronic consultations	Aviel Hankin	Received

WED-006	Liver stiffness and AST-to-platelet ratio index (APRI) predict all-cause mortality in untreated people living with hepatitis B across Africa: a multi-centre cohort analysis in the hepatitis B in Africa collaborative network (HEPSANET)	Alexander Stockdale	Received

LBP-006	MELD 3.i: a bayesian approach for consecutive updates to model for end-stage liver disease	Tomohiro Tanaka	Received

SAT-006	Emergency department blood-borne virus screening and the revealed burden of hepatitis B-driven liver disease	Kartikeya Khanna	Received

LBP-007	Macrophage Nrf1-Foxo1 axis controls liver fibrosis by modulation of mitochondrial reprogramming	Qiong Wu	Received

WED-007	Implementation of a multicenter reflex testing program for hepatitis D detection of and registration of positive cases in Catalonia	Adriana Palom	Received

FRI-007	An algorithm based on the liver risk score to identify subjects at-risk for advanced liver disease in the general population	Patrick Ingiliz	Received

THU-007	Real-world experience using serial transient elastography by FibroScan in a community outreach service for the earlier detection of liver disease	Ann Archer	Received

SAT-007	National hepatitis C virus (HCV) screening pilot using rapid HCV antibody tests in Kazakhstan	Kulpash Kaliaskarova	Received

LBP-008	Safety, tolerability, and remarkable hepatitis B surface antigen reduction in chronic hepatitis B patients treated with BW-20507	Zhuo Chang	Received

FRI-008	Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers	Pietro Guerra	Received

SAT-008	Population-based hepatitis C screening and elimination program in Lithuania: 26-month results	Limas Kupcinskas	Received

THU-008	The placebo project - comprehensive analysis of 134 commonly prescribed homeopathic remedies in India uncovers potential for severe hepatotoxicity	Arif Theruvath	Received

WED-008	Micro-elimination of hepatitis C utilizing hepatitis C virus self-testing in a district prison of northern India: a demonstration project	AJEET SINGH BHADORIA	Received

WED-009	Return to Care (R2C) - the missing link in hepatitis C elimination	Alistair Story	Received

SAT-009	Risk of advanced liver disease among individuals with hepatitis B virus infection with low-level viremia compared to individuals with no evidence of hepatitis B virus infection	Olivia Harwood	Received

FRI-009	External validation of Dallas steatosis index (DSI) in the diagnosis of steatotic liver disease (SLD) in thai population	Pimsiri Sripongpun	Received

LBP-009	Globally derived and externally validated cut offs for liver failure and inclusion of infections improve prognostication for inpatient death: towards ACLF harmonization	Jasmohan Bajaj	Received

WED-010	Complex multiple morbidity and social vulnerability among hep C patients with delays accessing care	Alistair Story	Received

FRI-010	Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis	Pisit Tangkijvanich	Received

LBP-010	Short-term intravenous albumin administration increases serum sodium levels in hospitalized patients with decompensated cirrhosis and dilutional hyponatremia. A randomized, multicenter, controlled trial (ALBUCAT)	Adrià Juanola	Received

SAT-10	Peer-led mass testing in prisons to support hepatitis C elimination	Leila Reid	Received

FRI-011	What is known about the relationship between food insecurity and metabolic dysfunction-associated steatotic liver disease? A systematic review	Patricia Treseder-Griffin	Received

WED-011	Treatment for chronic hepatitis C infection in Pakistan – in a high prevalence country treatment initiation is sub-optimal and may impact elimination programs	Aliya Hasnain	Received

LBP-011	Modeling the epidemic of metabolic dysfunction associated steatohepatitis in Europe shows a growing clinical and economic burden in France, Italy and United Kingdom	Carey Escheik	Received

THU-011	Incidence-based mortality trends of primary liver cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in Scotland between 2000 and 2021	Berkay Yanik	Received

SAT-011	Survival and inactivation of hepatitis A virus on inanimate surfaces	Lilli Pottkämper	Received

LBP-012	Multicenter, open-Label, randomized non-inferiority study comparing 8-week vs 12-week Sofosbuvir/Ravidasvir treatment for non-cirrhotic chronic hepatitis C patients (EASE trial)	Muhammad Radzi bin Abu Hassan	Received

WED-012	A comparative analysis of carbon footprints: nucleic acid test vs. rapid antigen test for preventing mother-to-child transmission of hepatitis B in the gambia	Alassane NDIAYE	Received

SAT-012	Evaluating and aiding hepatitis C elimination efforts through natural language processing (Cogstack): analysis of electronic health records including diagnosis, demographics and outcomes	Mahd Siddiqi	Received

FRI-012	Unveiling the burden of cirrhosis among Ontario, Canada´s refugee population	Saloni Aggarwal	Received

THU-012	Circulating metabolites, gallstones, and gallbladder cancer	Felix Boekstegers	Received

WED-013	Clearing the road for viral hepatitis microelimination in croatian prisons: the Hepatos project	Tatjana Reic	Received

THU-013	First nations australians with cirrhosis have higher and premature mortality and multiple cofactors	Catherine Brown	Received

FRI-013	Age-related trends in FIB-4 scores among MASLD risk groups: insights from primary care data	Hiroko Setoyama	Received

LBP-013	Novel hepatitis B virus biomarkers-guided nucleos(t)ide analogues withdrawal strategy promotes hepatitis B surface antigen clearance in chronic hepatitis B patients: results from a randomized controlled trial (BIO-STOP study)	Rui Deng	Received

SAT-013	Knowledge and perception of chronic hepatitis B infection and attitude towards point-of-care testing among the general population in primary care settings in Hong Kong	Marco Tsun Lee	Received

SAT-014	Setting the record straight: utility and outcomes in patients with HCV related HCC	Maria Guerra	Received

LBP-014	HBsAg loss and seroconversion after 16-week or 24-week AHB-137 treatment in HBeAg-negative chronic hepatitis B participants on NA therapy: results from an ongoing multicenter, randomized phase IIb study	Junqi Niu	Received

WED-014	Evaluation of Belgium´s progress towards HBV elimination: results from a national serosurvey	Arno Furquim dAlmeida	Received

FRI-14	Impact of COVID-19 pandemic on racial/ethnic disparities in liver transplant waitlist outcomes among U.S. adults with end-stage liver disease	Shyam Patel	Received

THU-014	Chronic liver diseases are often diagnosed at an advanced stage despite identification of risk factors: insights from a french national study	Charlotte Costentin	Received

LBP-015	Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements	Irina Dragomir	Received

TOP-15	Emergency department opt out testing for HBV and HCV in London with integrated linkage to care: an effective initiative to diagnose hepatitis or work in progress?	Rachel Hill-Tout	Received

TOP-016	Genetic determinants of hepatitis B surface antibody disappearance in Taiwan´s vaccinated generations: a genome-wide association study	CHUN-YI CHANG	Received

LBP-016	Efficacy and safety of elebsiran and pegylated interferon alfa combination therapy versus pegylated interferon alfa in participants with chronic hepatitis B virus infection: follow-up results from the ongoing phase 2, randomized, open-label ENSURE study	David Margolis	Received

TOP-017	Global association between metabolic dysfunction policies and the burden of metabolic dysfunction-associated steatotic liver disease (MASLD)	Luis Antonio Diaz	Received

LBP-018	Chronic hepatitis B virus infected participants responding to prior BRII-179 treatment achieved faster and higher rate of hepatitis B virus surface antigen seroclearance on elebsiran plus peginterferon-alfa: end of treatment data from ENSURE study	Grace Lai-Hung Wong	Received

TOP-018	Examining the causal link between alcohol consumption and fatty liver disease using Mendelian randomization	Yun-Chen Wu	Received

SAT-019	Knowledge of hepatitis D epidemiology and access to hepatitis D diagnostic testing among healthcare providers in Africa: a multi-country survey	Maria Buti	Received

THU-19	Gaps in palliative care for liver cirrhosis in Singapore: an analysis on disease burden, timing and utilization of palliative services	Charlene Yeo Li Xin	Received

FRI-019	Patient safety, cross-sectoral quality of care, cost efficiency, and interprofessional competence: a comparison of the interprofessional training wards A-STAR with conventional hepatology-focused wards at Regensburg university hospital	Schlosser Sophie	Received

WED-019	Direct measurement of incidence and prevalence of Hepatitis C infection using the gold-standard of prospective HCV re-testing of people at risk. A national needs assessment of people who inject drugs and of all people who use addiction services in England	Beatrice Emmanouil	Received

SAT-020	Patient perspectives on barriers and enablers to a treatment for all approach for hepatitis B	Marvad Ahad	Received

THU-020	Assessing awareness of fatty liver disease among people in Scotland: a cross-sectional survey study (ADIPOSE)	Damien Leith	Received

LBP-020	Off-treatment antiviral efficacy and safety of repeat dosing of imdusiran followed by VTP-300 with or without nivolumab in virally-suppressed, non-cirrhotic subjects with chronic hepatitis B (CHB)	Grace Wong	Received

THU-21	Advanced care planning (ACP) for liver cirrhosis patients in Singapore: barriers to ACP and influence of hepatocellular carcinoma diagnosis on ACP preferences	Danelle Lai	Received

LBP-21	Prolonged reduction of hepatitis B surface antigen in virologically suppressed participants treated with concurrent or sequential use of pegylated interferon alpha with xalnesiran-based therapy: results after 120 weeks of follow-up of an observational stu	xieer liang	Received

SAT-021	Initiation of direct acting viral therapy in prison is associated with a significant loss to follow-up: relevance to WHO elimination metrics?	Matthew Foxton	Received

FRI-021	Differential liver-related mortality among native hawaiian / pacific islander (NHPI) and asian subpopulations: a national cohort study	Tiange Zhang	Received

WED-021	Emergency department screening and linkage to care for undiagnosed hepatitis C infection: an effective initiative to reach elimination targets	Kartikeya Khanna	Received

SAT-022	Screening for risk factors for hepatitis C infection with a large metropolitan primary care population - The size of the problem	Matthew Foxton	Received

FRI-022	Ultra-processed foods significantly increase liver and metabolic injury among younger adults, lessons from the liver screening program SIRIUS	Tomas Koller	Received

WED-022	Automated universal testing for hepatitis B in the emergency department improves screening and characterises the undiagnosed and untreated cohort in an australian setting	Bonita Gu	Received

LBP-023	Validation of quantitative magnetic resonance cholangiopancreatography metrics in the prediction of event-free survival in primary sclerosing cholangitis: an International PSC study group collaboration	Tim Middelburg	Received

WED-23	Three-year evaluation of retention in specialist care among migrants and refugees living with HBV in Catalonia following a community-based intervention	Camila Picchio	Received

SAT-023	Treatment of Hepatitis C in the over-80s in the direct anti-viral therapy era: age is no barrier!	Matthew Foxton	Received

THU-023	Health behaviors significantly modify the sex-specific alcohol-attributable liver-related mortality in the United States. A population-based study	Eduardo Vilar Gomez	Received

LBP-024	Metabolic dysfunction- and alcohol-associated steatotic liver disease is associated with higher risk of advanced fibrosis and mortality than metabolic dysfunction-associated steatotic liver disease: data from a large global biopsy-proven cohort	Carey Escheik	Received

SAT-024	Semi-qualitative feedback from individuals living with HBV newly diagnosed in the emergency department ED opt-out testing program – high acceptability but better platforms of advocacy and support required	Mia Olsen	Received

WED-024	Linking community-based organizations and specialized prescribing pharmacist teams to improve testing and treatment in hard-to-reach hepatitis C-infected groups: the LiveRx experience in Alberta, Canada	Cari Egan	Received

WED-025	Engaging hard-to-reach individuals through community-based holistic care health and wellness fairs linked to HCV testing and treatment in Alberta, Canada	Cari Egan	Received

LBP-25	Elafibranor impacts inflammatory, fibrotic and symptom-associated markers in patients with primary biliary cholangitis: Proteomic results from the ELATIVE® trial	Costello Medical	Received

SAT-025	Epidemiological, economic and budgetary implications of expanding screening strategies for hepatitis C virus in Brazil: a modelling study	Everton Macdo	Received

THU-025	Prevalence of and outcomes related to metabolic dysfunction-associated steatotic liver disease (MASLD) in a nationwide cohort: insights from over 23 million individuals in Taiwan´s national health insurance research database	Huei-Tyng Huang	Received

FRI-026	Metabolic dysfunction-associated steatohepatitis (MASH) prevalence in germany – results from a claims analysis	Thomas Ramezani	Received

SAT-026	Delta in Denmark: prevalence of hepatitis delta virus infection	Hugh Watson	Received

WED-026	Development of a predictive model using artificial intelligence (AI) for the detection of hepatitis C based on real-world data from the population health database (BPS) of Andalusia, Spain	Carmen Lara Romero	Received

THU-026	Population study of hepatocellular carcinoma survival in northest region of Spain	ISABEL SERRA MATAMALA	Received

LBP-027	Elafibranor improves fatigue versus placebo in patients with primary biliary cholangitis, with limited correlation with pruritus: analyses from the phase III ELATIVE® trial	Costello Medical	Received

FRI-027	Metabolic dysfunction-associated steatohepatitis as a risk factor for hepatocellular carcinoma mortality	Gish Robert	Received

SAT-027	Therapy of HCV infections among patients of ukrainian origin during the influx of war refugees to Poland	Robert Flisiak	Received

THU-027	Vibration-controlled transient elastography dynamics in the general population: longitudinal results from the LiverScreen consortium	Jesse Pustjens	Received

WED-027	Changes in hepatitis C virus screening and treatment rates in pregnant individuals before and after implementation of universal screening guidelines compared to hepatitis B virus screening during the same time frame	Chandler Shapiro	Received

THU-028	Hospital wide approach to limiting and treating alcohol use disorder	Rohit Gupta	Received

LBP-028	Variceal hemorrhage outcomes are worse in patients with prior decompensating events. Systematic review with individual patient data meta-analysis	Vincenzo La Mura	Received

FRI-28	Shortfalls and obstacles in sexual function assessment by healthcare providers in patients with liver disease and liver transplantation	Yooyun Chung	Received

SAT-028	The impact of peers on sustaining hepatitis C elimination in people who inject drugs - a network based model	Ryan Buchanan	Received

SAT-029	Hepatitis C incidence in Pakistan – large scale test and recall analysis shows that infection rates can be reduced by pro-active ´find and treat´ programs	Saad Niaz	Received

WED-029	Patient-reported outcomes measuring an individual´s overall self-rated health after long-term treatment with bulevirtide 2 mg for chronic hepatitis delta in the phase 3 MYR301 trial	Marvin Rock	Received

LBP-29	Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezolizumab + bevacizumab in patients with advanced HCC	Marta Piqué-Gili	Received

THU-029	Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in four cities in the United States, including among people with diabetes and primary care providers	Jeffrey Lazarus	Received

FRI-29	The global prevalence and mortality of metabolic dysfunction associated steatotic liver disease-related cirrhosis	Carey Escheik	Received

THU-030	Risk factor awareness for liver disease in four United States cities	Jeffrey Lazarus	Received

WED-030	Trends in the effect of direct acting antivirals on mortality in people diagnosed with hepatitis C in England using routine surveillance data	David Etoori	Received

SAT-030	Eliminating hepatitis C in Nouvelle Aquitaine, the largest region of France: the SCANVIR® project	Sandrine Francois	Received

LBP-030	Pitfalls in creatinine measurement and their impact on model for end stage liver disease score	Eda Kaya	Received

FRI-030	In patients with metabolic dysfunction-associated steatotic liver disease, sleep disturbance is highly prevalent and associated with a profound impairment of health-related quality of life	Carey Escheik	Received

SAT-031	The cost of HCV elimination in Kazakhstan based on the current disease burden	Samantha Hall	Received

FRI-031	Performance of chronic liver disease questionnaire – metabolic dysfunction-associated steatohepatitis (CLDQ-MASH) against non-invasive tests	Carey Escheik	Received

THU-031	MASLD impacts quality of life and work productivity	Leen Heyens	Received

LBP-032	Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline	Raji Nair	Received

TOP-32	Prevalence of the spectrum of steatotic liver disease and associated fibrosis and cirrhosis among adults in the United States	Carey Escheik	Received

SAT-033	Using community partnerships to achieve micro-elimination of HCV and HIV in inner-city Vancouver	Shana Yi	Received

FRI-033	TIGIT blockade on CD8+T cells induces hepatocyte apoptosis	Amber Bozward	Received

THU-033	The "Traffic Light System" – a radiology-led pathway for hepatocellular carcinoma surveillance in patients with liver cirrhosis	Lusyan Dayalan	Received

SAT-034	Early diagnosis of HCV in people who inject drugs in the Czech Republic: preliminary results of a pilot project	Sona Franková	Received

FRI-034	Crohn´s associated invariant T (CAIT) cell subphenotype analysis for inflammatory bowel disease and primary sclerosing cholangitis	Aya Mahdy	Received

LBP-034	Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients	Filippo Gabrielli	Received

WED-34	Prevalence of HBV and HCV among migrants in EU-27: the impact of the ukrainian refugee crisis	Devin Razavi-Shearer	Received

THU-035	Bortezomib improves advanced fibrosis by selectively inducing stellate cell apoptosis via downregulation of LGALS2 and CDH3 expression	Ling Wu	Received

WED-035	A National web self-testing portal for hepatitis C: an empowering solution with good uptake and linkage to care - preliminary data	Ewan Glassey	Received

FRI-35	The role of FOXP3+ regulatory T (Treg) cells in mouse models of liver disease	Caitlin Abbott	Received

SAT-035	Results of the national program for the elimination of viral hepatitis in Uzbekistan	Shakhlo Sadirova	Received

WED-036	The impact of cardio-metabolic risk factors on liver-related diseases and mortality after hepatitis C virus eradication: insights from a multi-center taiwanese cohort	Ming-Lung Yu	Received

SAT-036	Physician perspectives on hepatitis C treatment for women of childbearing age and during pregnancy: results from a global multispecialty survey	Tatyana Kushner	Received

LBP-036	Suboptimal performances of Baveno VII and AASLD 2024 criteria for detecting clinically significant portal hypertension with varices in untreated patients with HDV cirrhosis	Maria Paola Anolli	Received

FRI-036	Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure	Alina Bauschen	Received

THU-036	Integrating spatial lipidomics with imaging mass cytometry: a novel approach for metabolic profiling of liver fibrosis	Aleksandra Gruevska	Received

WED-037	Hepatitis C knowledge and perceptions among Singapore´s LGBTQ+ Individuals: barriers and opportunities for outreach	Garrett Kang	Received

THU-037	Lycorine reduces liver fibrosis by inactivating hepatic stellate cells (HSCs) in mouse models of metabolic dysfunction-associated steatohepatitis (MASH)	Alma Diaz Ruiz de Zarate	Received

FRI-037	miRNA/mRNA signature of mouse Kupffer cells during the progression of chronic liver disease from fibrosis to hepatocellular carcinoma	Ananya Ajith	Received

FRI-038	Unraveling the liver immune rheostat: How contact-dependent regulation causes dysfunction of antigen-specific CD8 T cells over the course of chronic hepatitis B	Anna Fürst	Received

THU-038	Patients with chronic liver disease present elevated plasma levels of peptidylprolyl isomerase C associated with the degree of fibrosis	Ana Blas-García	Received

SAT-038	Atherosclerotic cardiovascular disease risk in chronic hepatitis C patients with metabolic dysfunction-associated steatotic liver disease after viral eradication: a multi-center cohort study	Wan-Long Chuang	Received

WED-038	The impact of COVID-19 outbreak from February to June 2022 on chronic hepatitis B patient management in Shanghai: a cross-sectional study	Simin Guo	Received

THU-039	Sex differences in aging rates and superoxide dismutase activity in patients with metabolic dysfunction-associated steatotic liver disease: implications for fibrosis risk	Anastasiia Radchenko	Received

WED-039	A comparative study on liver disease severity and comorbidity profile in patients with chronic hepatitis B virus infection and hepatitis B virus/hepatitis D virus co-infection: a korean nationwide study	Hoyoung Na	Received

FRI-039	Single-cell profiling of hepatic dendritic cells in metabolic-associated steatotic liver disease	Camilla Klaimi	Received

SAT-039	Revisiting hepatitis B and delta viral infections in the brazilian Amazon: current epidemiological, clinical and molecular characteristics	Maria Mendes-Correa	Received

THU-040	Efficacy of CRV431 and Semaglutide on liver fibrosis in a mouse model of MASH	Asha Goodman	Received

WED-040	Trends and cross-country inequalities in the global burden of acute hepatitis A, 1990–2021: a population-based study	Deliang Huang	Received

SAT-40	Identifying people who are HBV positive but undiagnosed : a model-based approach informed by health administrative data	William WL Wong	Received

FRI-040	Transcriptional and functional profiling of HBV-specific CD8 T cells in chronic HBV infection for the design of novel targeted T cell correction strategies for HBV cure	Carolina Boni	Received

THU-041	Investigating the role of Fn14 in metabolic associated steatohepatitis: effects on fibrosis, inflammation, and proliferation in a mouse model	Anouk Oldenburger	Received

THU-042	Targeting metabolic dysfunction-associated steatohepatitis with microRNA therapeutics	Cinzia Chinnici	Received

FRI-042	Defining the role of tissue-resident Kupffer cells in the pathogenesis of chronic liver disease	Fabio Colella	Received

SAT-042	Rapid multiplex liver gene editing in mice using adeno-associated virus 8 or lipid nanoparticles	Dandan Wu	Received

WED-043	Targeting the gut-liver crosstalk: the role of Gardenin A in alleviating alcohol-associated liver disease	Prashsti Chadha	Received

THU-043	Nuclear factor I-B delays liver fibrosis by inhibiting chemokine ligand 5 transcription	Qianwen Zhao	Received

FRI-043	Safety and efficacy of everolimus in autoimmune hepatitis – a single center retrospective analysis	Florian Seltsam	Received

SAT-044	Dynamic hepatocyte adaptations in acute biliary hypertension: role of canalicular remodeling, mechanosensors activation and alternate bile transport	Himanshi Himanshi	Received

THU-044	CCN5 promotes fibrogenic activation of hepatic stellate cells and serves as a biomarker for liver fibrosis	Yunhao Duan	Received

FRI-044	Dynamic adaptations of CD8+?d T cells in acute and chronic hepatitis E virus infection	Erich Freyer	Received

WED-044	Microbial changes resulting from vertical sleeve gastrectomy attenuate obesity by modulating bile acid metabolism and the intestinal farnesoid X receptor?fibroblast growth factor 15/19 axis	Yi Xia	Received

SAT-45	10 year analysis and trends in liver biopsy; a single centre experience	Jennifer Cathcart	Received

WED-45	PPAR a is a key molecule mwdiating the diurnal variation of sepsis in mice	Junzhou Zhao	Received

THU-045	Neo-epitope biomarkers for fibrogenesis and neutrophil activity predict liver-related events in advanced chronic hepatitis C infection	Emilie Skovgaard	Received

FRI-045	Hepatic stellate cells orchestrate the retention and functional impairment of tissue-resident CD8+ T-cells in the fibrotic human liver	George Finney	Received

THU-046	Engineering liver fibrosis in a three-dimensional, extracellular matrix-hydrogel, ex-vivo disease model	Frederik Hbjerg Svejs	Received

WED-046	The intestinal virome related clinical outcomes, systemic inflammation and immune functions in hospitalized cirrhosis patients – the foremost work in an indian patient cohort	Cyriac Philips	Received

FRI-047	Low-dose lipopolysaccharide administration improves the survival rate of septic shock by enhancing the bactericidal activity of Kupffer cells and reducing hepatic infiltration of pro-inflammatory monocyte-derived macrophages in mice	Hiroyuki Nakashima	Received

WED-047	A single center experience from India on associations of fungal microbiota (mycobiome) in cirrhosis - orally-predominant fungal dysbiosis in the gut and immune-escaping Candida species drive outcomes in hospitalized patients	Cyriac Philips	Received

THU-047	Inhibition of Adipocyte triglyceride lipase (ATGL) reduces fibrosis and portal hypertension in murine CCl4 liver fibrosis	Henriette Horstmeier	Received

FRI-048	Establishing an optimised method for single-cell RNA-seq based immunophenotyping from cryopreserved human liver needle biopsies	Juliet Luft	Received

THU-048	Cell-type specific roles of TGF-ß2 signaling in cholestatic liver disease progression and therapeutic targeting	Ida Harst	Received

WED-048	Deep insights on gut bacterial associations with long-term clinical events, host immunology, and inflammatory cytokines in hospitalized Indian cohort of patients with cirrhosis	Cyriac Philips	Received

SAT-048	Regulation of thyroid hormone metabolism by HNF4A via modulation of deiodinase activity in hepatocytes	Xinru Zhang	Received

FRI-049	Influence of T cell exhaustion versus senescence in the development of spontaneous operational tolerance following liver transplantation	Jorge P. Torres-Yaguana	Received

WED-049	Dietary bacterial D-lactate modulates liver steatosis and ameliorate experimental MASLD	André Santos	Received

THU-049	Extracellular vesicle-dependent crosstalk between hepatic stellate cells and Kupffer cells promotes their mutual activation	Junyu Wang	Received

SAT-049	Harnessing antioxidant nano-chimeras for combining targeted transforming growth factor ß receptor I degradation and transforming growth factor ß reduction to attenuate liver fibrosis	Hanshu Liu	Received

THU-050	Dual inhibition of glutaminolysis and de novo amino acid synthesis underpins Pirfenidone´s suppression of hepatic stellate cell activation	Jia Li	Received

WED-50	Fecal microbiota transplant activates hepatic PPAR-alpha resulting in remission of alcohol-related liver disease in murine model	Ashi Mittal	Received

FRI-050	CD155 blockade modulates monocyte responses in acute-on-chronic liver failure	Joseph Delo	Received

TOP-052	Baseline oral microbiome composition in liver transplant recipients can help predict graft dysfunction	Rosmy Babu	Received

TOP-053	The mechanisms of transcription factor ZEB2 in regulating hepatic stellate cell activation and liver fibrosis	Qianwen Zhao	Received

TOP-054	Single cell fixed RNA-seq revealed HSCLMCD1+LIMK2+ is a driver of liver fibrosis by modulating SMAD3-AKT-PRAS40-4EBP1	Minh Duc Pham	Received

SAT-055	Echinococcus multilocularis infection induces pathological angiogenesis in mouse liver via PDGFR/PI3K/AKT/FAK signaling pathway	Xiaojuan Bi	Received

FRI-055	Inhibition of the lysophatidylcholine-autotaxin-lysophosphatidic acid axis restores monocytic pro-inflammatory cytokine production in patients with acute-on-chronic liver failure	Joseph Wilson	Received

THU-055	Novel natural killer cell immunotherapy through synthesized Neuroligin-4 peptides improved liver fibrosis	Johnny Amer	Received

WED-055	Microbiota-derived S-equol ameliolates inflammatory pathway in metabolic dysfunction-associated fatty liver disease	Goo Hyun Kwon	Received

FRI-056	Investigating macrophage- phenotype and organ injury in acute-on-chronic liver failure	Juan Wang	Received

SAT-56	Regulation of interleukin-6- and epidermal growth factor receptor-dependent pathways by augmenter of liver regeneration is mediated by activation of ADAM17	Christoph Voigt	Received

WED-056	Absence of cholesterol gallstone formation in male C57BL/6 mice by abrogation of hepatic thyroid hormone action	Denise Zwanziger	Received

SAT-057	Time-restricted feeding modulates genes involved in liver regeneration and damage regression processes in a rat model treated with diethylnitrosamine	Christian Molina-Aguilar	Received

WED-057	Microbially conjugated bile salts undergo hepatobiliary secretion in humans and mice	Frank Schaap	Received

FRI-057	Mucosal-associated invariant T (MAIT) cells possess direct cytotoxic potential against HCC, but are rendered dysfunctional within the tumour microenvironment	Junika Pohl-Topcu	Received

SAT-058	MAIT cells mediate liver tissue repair via VEGF and VIM secretion	Katia Sayaf	Received

WED-058	An integrative multi-omics and machine learning framework for diagnostic biomarker identification in patients with liver cirrhosis	In Gyu Park	Received

FRI-058	Time-resolved liver fibrosis regression at single-cell resolution in a murine CCl4-cessation model	Katharina Bonitz	Received

THU-058	Blockage of microfibrillar-associated protein 4 (MFAP4) decreases liver fibrosis in two murine models of steatotic liver disease	Maximilian Joseph Brol	Received

THU-059	Use of the LiverRisk score for prediction of moderate to advanced liver fibrosis in United States adults	Mary E. Rinella	Received

SAT-059	A comprehensive study on acute and chronic liver injury response in Acomys (Spiny mice): insights into the role of p21 in liver regeneration	Karen Ching	Received

FRI-059	Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma	Luc Magre	Received

WED-059	The role of the gut microbiota in high-fat diet-induced hepatic steatosis in juvenile and adult mice	Milos Vrataric	Received

SAT-060	Extending the lifespan of human chemically derived hepatic progenitors by treating with Drug A	Seunghee Kim	Received

FRI-060	Lnk/Sh2b3 regulates the development of hepatic memory CD8+ T cells via IL-15 signaling and suppresses the pathogenesis of MASLD	Taizo Mori	Received

WED-060	Gut microbial antibiotic resistance genes in clinicians taking care of cirrhosis patients shows wide variation according to country income and could be a risk factor for bidirectional transmission	Jasmohan Bajaj	Received

FRI-061	Glucocorticoid receptor inhibits Th2 immune responses by down-regulating Pparg and Gata3 in schistosomiasis	Xiaojuan Bi	Received

THU-061	The study of pathogenesis of the progression of liver cirrhosis	Oksana Shapoval	Received

SAT-061	Impact of NEDDylation on aging and liver senescence: key insights	Leidy Estefanía Zapata-Pavas	Received

WED-061	Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis	Jasmohan Bajaj	Received

THU-062	Human umbilical cord mesenchymal stem cells attenuate liver fibrosis in mice and inhibit hepatic stellate cell activation via secreting soluble factors	QI ZHOU	Received

FRI-062	Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure	Bingqi Li	Received

SAT-062	Generation and functional profiling of injury-resistant ductal organoids with biliary tree networks optimized by genipin	Shiwen Ma	Received

WED-063	Gut fungi in liver cirrhosis: characterizing mycobiota alterations and links to disease stages	Juozas Kupcinskas	Received

FRI-063	Understanding the impact of the liver microenvironment on regulatory T cells	Maegen Fleming	Received

WED-064	Targeting gut-liver axis crosstalk with probiotic Lactobacillus rhamnosus attenuates ductular reaction in Mcpip1-deficient mice	Katarzyna Trzos	Received

THU-064	GPC3-based mRNA cancer vaccine for hepatocellular carcinoma immunotherapy	Yifan Jiang	Received

SAT-064	Expression and role of trefoil factor 3 (TFF3) in hepatoblastoma	Maite G Fernandez-Barrena	Received

SAT-065	Engineered extracellular vesicles derived from mesenchymal stem cell carrying insulin-like growth factor I to promote liver regeneration after partial hepatectomy	Mailín Casadei	Received

WED-065	Myricetin alleviates steatotic liver disease through gut microbiota modulation and Wnt-signaling inhibition	Min Ju Kim	Received

FRI-065	Non-neuronal role of immune cells in liver regeneration	Nastaran Fazel Modares	Received

WED-066	Bacteroides caccae alleviates hepatic fibrosis by suppressing inflammation	kyeongjin Lee	Received

SAT-066	A 3D human liver organoid model to study the impact of ischemia-reperfusion injury on liver regeneration during transplantation	maura cimino	Received

THU-66	Femoral vs hepatic vein plasma levels of collagen biomarkers confirm Pro-C3 as true marker of collagen synthesis in the fibrotic/cirrhotic liver	RAMBABU SURABATTULA	Received

SAT-067	3D assembloid model as a useful in vitro tool to study acute and chronic liver diseases	Riccardo Perriera	Received

WED-067	Akkermansia muciniphila inhibits serotonin-induced fibrosis progression in liver injury mouse model	Sung-Min Won	Received

THU-067	A simple lab based machine learning model (FAET) predicts advanced Liver Fibrosis more accurately in MASLD patients	Shobha Sharma	Received

SAT-068	Room for improvement in female authorships across leading medical journals	Sara Tnder Hauskov	Received

THU-068	EmTPx promotes liver fibrosis via enhancing IL-33 secretion from macrophage	Tuerhongjiang Tuxun	Received

FRI-068	The role of T-cell immunoglobulin and mucin domain 3 (TIM-3) in immune dysregulation and infection in patients with decompensated cirrhosis and liver failure syndromes	Roosey Sheth	Received

WED-068	Enterohepatic circulation of microbial bile acid conjugates	Alvaro Temprano	Received

SAT-069	Cathepsin L inhibitor enhances liver regeneration in fibrotic liver	SHUNHEI Yamashina	Received

FRI-069	Scar-associated macrophages demonstrate phenotypic plasticity during the progression and regression of liver fibrosis	Ravi Parhar	Received

THU-069	A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C	Thomas Wiggers	Received

WED-069	Gut microbiota composition of obesity resistant mice protects from high fat diet-induced steatosis	Milos Vrataric	Received

FRI-70	p120 catenin expression by CD8+ T cells correlates with their frequency of invasion into cholangiocytes in autoimmune liver disease	Scott Davies	Received

SAT-070	Extracellular matrix protein 1 (ECM1) as a dual regulator of liver regeneration via HGF/c-MET and TGF-ß signaling pathways	Ye Yao	Received

THU-070	Characterizing the differentiation and cellular heterogeneity of hepatic stellate cells derived from induced pluripotent stem cells	Zhengqing Xu	Received

WED-070	Fecal microbiota transplantation results in increased caproic acid which alleviates steatosis and reduces ethanol-induced hepatotoxicity (in vivo and in vitro)	Nishu Choudhary	Received

TOP-071	Integrated single-cell transcriptome and protein analysis unveils long-lasting liver NK cell dysfunction in NUC-treated chronic HBV	Andre Boonstra	Received

TOP-072	Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance	Erich Freyer	Received

TOP-073	Disruption of mitochondrial dynamics and stasis leads to liver injury, innate immune response and tumorigenesis	Wen-Xing Ding	Received

TOP-074	The reelin signaling pathway in lymphatic endothelial cells is a key driver of ductular reaction during liver injury	Aarti Sharma	Received

THU-075	A naturally derived monoterpene potentiates sorafenib´s anticancer efficacy in drug-induced-hepatocellular carcinoma animal model	Amr Amin	Received

WED-075	Restoration of gut microbiome-nitrogen metabolism post oral administration of black carrot extracellular vesicles in hepatic encephalopathy	P Debishree Subudhi	Received

SAT-075	Prediction of hepatocellular carcinoma using AI-driven MRI radiomics: development of the AI-HCC prediction model	Maureen Guichelaar	Received

FRI-075	Differential granzyme-mediated immune responses in CXCR6+PD-1+ CD8 T cells in acute versus chronic ALT flares	Roni Souleiman	Received

WED-076	Association between gut fungal microbiota and subclinical coronary atherosclerosis in patients with MASLD	Pisit Tangkijvanich	Received

THU-076	RIPK3 is a metabolic regulator impacting mitochondrial dysfunction, endoplasmic reticulum stress and tumour development during murine chemical-induced hepatocarcinogenesis	André F. L. Cardador	Received

SAT-076	Therapeutic potential of Human antigen R inhibition in chronic liver disease and hepatocellular carcinoma	Mickaël Jouve	Received

SAT-077	OGT and c-Myc promote non-canonical activation of gene expression by EZH2 in hepatocellular carcinoma	Mirjam Zeisel	Received

FRI-077	T-cell receptor analysis of circulating T cells reveals non-epitope-driven clonal expansion in metabolic-associated steatotic liver disease	Xinlei Zhao	Received

WED-077	Next-generation beneficial bacteria combined with fructo-oligosaccharides and fecal microbiota transplantation attenuates diet-induced metabolic dysfunction-associated steatohepatitis in mice	Quinten Augustijn	Received

THU-077	E7386 enhances lenvatinib´s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma	Agavni Mesropian	Received

SAT-078	Immunoregulation and T cell paralysis mediated by MDSC induction in hepatocellular carcinoma following rVSV-NDV therapy	Mirta Jimenez	Received

FRI-078	Inflammation-educated macrophages drive exacerbated re-injury patterns via innate immune memory	Yuting Wang	Received

WED-078	Sex-specific effects of beta-blockers on the gut microbiome and metabolome in liver cirrhosis	Rosa Haller	Received

THU-078	Artificial intelligence-driven prediction of biology-related poor outcome and presence of vascular invasion in hepatocellular carcinoma	Agavni Mesropian Badalian	Received

THU-079	Beta klotho as a regulator of liver cancer cell proliferation and liver cancer development	Alexandra Aaldijk	Received

SAT-079	Metabolic and functional characterization of CD8+ T-cell subpopulations in hepatocellular carcinoma: implications of tumor microenvironment on T-cell dysfunction	Gabriele Missale	Received

FRI-079	Prognostic value of early change in neutrophil to lymphocyte ratio after atezolizumab plus bevacizumab treatment for hepatocellular carcinoma	Young Mi Hong	Received

WED-079	Quantification of genes encoding bacterial sialidases and enzymes of the nan cluster in combination with cutaneous T cell-attracting chemokine (CTACK) in bile for the early detection of cholangiocellular carcinoma in patients with primary sclerosing chola	Antonia Triefenbach	Received

FRI-080	TACE combined with ICIs plus MTT after 125I irradiation stent placement in patients with hepatocellular carcinoma and main portal vein tumor thrombosis (PATENCY ?)	Mei Junhao	Received

THU-080	Platelet-derived extracellular vesicles (PEVs) in hepatocellular carcinoma. Emerging diagnostic biomarkers	Ángela Rojas	Received

SAT-080	The NLRP3 inflammasome and its downstream target Il1R, but not IL18R drive hepatocarcinogenesis	Mona Peltzer	Received

SAT-081	Development and performance of AI in supporting the diagnosis of liver tumors using B-mode ultrasound	Naoshi Nishida	Received

THU-081	Association of T cell epitope spreading with the clinical efficacy of HBV-TCR T cell therapy for HBV-related HCC	Anthony Tan	Received

WED-081	Role of alcohol-associated gut microbiota in driving liver fibrosis via tgfbr1 kinase alterations in alcohol associated liver disease	MANISHA YADAV	Received

WED-082	Gut-oral microbial translocation promotes ammonia metabolism in liver cirrhosis	Yi Jin	Received

SAT-082	The metabolic heterogeneity induced by different genetic mutations in hepatocellular carcinoma leads to a particular response to feeding a lipid-enriched diet	Natalia Sainz	Received

SAT-083	Clinical potential and non-canonical roles of the cytosolic aspartyl-tRNA synthetase (DARS1) in hepatocellular carcinoma	Natalia Herman-Sánchez	Received

WED-083	Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma	Abelina Kreuter	Received

FRI-083	Histologic predictors of response to atezolizumab and bevacizumab in hepatocellular carcinoma biopsies	Alexandre Sayadi	Received

THU-084	Comprehensive characterization of the peripheral immune landscape through single-cell transcriptomics in hepatocellular carcinoma patients undergoing immunotherapy	Beatriz Minguez	Received

SAT-084	Microscale detection of selenium in liver tissue using laser ablation-inductively coupled plasma time-of-flight mass spectrometry	Nataliya Rohr-Udilova	Received

WED-084	Added-value of PET imaging to AFP score in predicting HCC recurrence after liver transplantation	Alina Pascale	Received

FRI-084	Real world treatment patterns and outcomes for hepatocellular carcinoma (HCC) patients receiving transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) in the TARGET-HCC registry	Andrea Mospan	Received

SAT-085	The role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential	Naroa Goikoetxea-Usandizaga	Received

THU-85	SMG7 as a potential driver of chronic liver disease progression to hepatocellular carcinoma	Betsaida Ojeda-Perez	Received

WED-085	Bone mineral density predicts survival in patients with hepatocellular carcinoma and portal vein tumor thrombosis	Aline Mähringer-Kunz	Received

SAT-086	Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma	Niloufar Safinia	Received

WED-86	Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients	Aliya Sarmanova	Received

THU-86	Translational approaches to evaluating novel antifibrotic and anticancer drugs for hepatocellular carcinoma: strategies for prevention and treatment	Caecilia Sukowati	Received

FRI-086	Long-term survival outcomes in patients receiving atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: an update of the AB-real study	Bernardo Stefanini	Received

THU-087	TIGAR SUMOylation: a key modulator of metabolic balance in hepatocellular carcinoma	Carolina Conter	Received

SAT-087	MiR-485-3p as a predictor of therapeutic response and its role of the PIAS3/STAT3/VEGF signal in Atezolizumab plus Bevacizumab therapy for hepatocellular carcinoma	Kyoko Oura	Received

WED-087	Prognosis after resection or ablation of hepatocellular carcinoma: a danish population-based multi-state cohort study	Clara Stenderup	Received

WED-088	Prognostic influence of clinically significant portal hypertension in patients with compensated cirrhosis and hepatocellular carcinoma receiving systemic therapy: The HIPERIA study	Antonio Guerrero	Received

THU-088	MicroRNA-372-3p impairs fatty acid metabolism in hepatocellular carcinoma cells by targeting CPT1A and ACSL4	Chaiyaboot Ariyachet	Received

SAT-088	Integrated multi-omics profiling of pan heat shock proteins in hepatocellular carcinoma identifies CCT3 and CCT7 as druggable oncogenes in hepatocytes	Manju Nidagodu Jayakumar	Received

WED-089	Development and validation of PSU´s AI-assisted ultrasound (AI-US) algorithm for focal liver lesion detection	Apichat Kaewdech	Received

THU-089	Tumor microenvironment differences in liver cancer are lineage-dependent when controlled for oncogenic pathway activation	Chun-Shan Liu	Received

FRI-089	Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis	Ciro Celsa	Received

SAT-089	mRNA-based vaccination for tumor neoantigens to induce a therapeutic T cell response in HCC	Paul Schneider	Received

THU-090	Glutaminolysis-driven iron accumulation in the liver: a mechanism for aging through Lysosomal dysfunction	Claudia M. Rejano-Gordillo	Received

WED-090	The mind and monitoring: The psychological impact of hepatocellular carcinoma surveillance	Azzra Maricar	Received

SAT-090	MFAP-5 siRNA nanohydrogels for antiangiogenic stromal-targeting HCC therapy	Paul Schneider	Received

FRI-090	Incidence of radiation pneumonitis following resin-based yttrium-90 selective internal radiation therapy	Kaina Chen	Received

FRI-091	The "A-B-C" cluster-based classification reveals distinct outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab	Claudia Campani	Received

SAT-091	Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma	Paula Olaizola	Received

WED-091	Delta hepatitis versus HBV monoinfection associated hepatocellular carcinoma: spot the difference	Mirela Chitul	Received

WED-092	Lower allele frequency of the TERT-rs2242652 in sub-saharan african than american populations and hepatocellular carcinoma risk	Perapa Chotiprasidhi	Received

FRI-092	Patterns and outcomes of recurrence after thermal ablation for hepatocellular carcinoma	CHI-PING TAN	Received

SAT-092	Brown adipose tissue activation: a novel strategy to prevent/treat the hepatocarcinogenesis promoted by metabolic lipotoxicity	Marion Peyrou	Received

TOP-093	Development and external validation of preoperative prediction model for early recurrence of intrahepatic cholangiocarcinoma	Sang Hyun Choi	Received

TOP-094	Breaking barriers: intensive care admission in patients with advanced HCC on immunotherapy	Marta Fortuny	Received

FRI-096	Effects of pre-transplant locoregional therapies on dropout rates and survival outcomes in patients with hepatocellular carcinoma: a propensity-matched analysis of the United Network for Organ Sharing (UNOS) database	Nariman Nezami	Received

THU-096	FSP1 inhibitor icFSP1 enhances lenvatinib sensitivity for hepatocellular carcinoma treatment by promoting ferroptosis through the FSP1/MIR4435-2HG pathway	Congyue Zhang	Received

SAT-096	Reduction in lipid accumulation, inflammation and hepatocellular carcinoma development after protease-activated receptor 2 inhibition through 1-Piperidinepropionic acid	Pietro Guerra	Received

WED-097	Identification of diagnostic markers based on spectral infrared fingerprints of bile samples from endoscopic drainage of patients with biliary stenosis due to extrahepatic cholangiocarcinoma or pancreatic adenocarcinoma	Elia Gigante	Received

FRI-097	Bridging and long-term impact of pre-orthotopic liver transplant transjugular intrahepatic portosystemic shunt (TIPS) creation: a propensity-matched analysis using the united network for organ sharing (UNOS) database	Nariman Nezami	Received

THU-097	A syngeneic and orthotopic HCC mouse model demonstrating the high efficacy of combination therapies targeting the ECM and immune microenvironment	Emma Eichler	Received

SAT-097	Protein kinase R-like endoplasmic reticulum kinase in hepatic stellate cells promotes hepatocellular carcinoma progression via the p38delta mitogen-activated protein kinase/interleukin-1beta axis	Makoto Morita	Received

THU-98	miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment	Elisa Monti	Received

WED-098	Predictive microRNA panel of hepatocellular carcinoma occurrence in patients with chronic hepatitis C achieving sustained virological response after direct-acting antiviral therapy	Emanuela De Santis	Received

SAT-099	The liver artificial intelligence (lai) consortium: a benchmark dataset and optimised machine learning methods for MRI-based diagnosis of solid-appearing liver lesions	Ruben Niemantsverdriet	Received

THU-099	Atorvastatin and gene expression signatures in hepatocarcinogenesis	Ezequiel Ridruejo	Received

FRI-099	Systematic review of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma with tumor thrombus extension to the inferior vena cava or right atrium	Divya Khosla	Received

WED-099	Insights into the GALAD Score: a new optimal cut-off for hepatocellular carcinoma	Endrit Shahini	Received

THU-100	Functional properties of unannotated, small RNA clusters during hepatocarcinogenesis	Francesca Pagani	Received

FRI-100	Laparoscopic liver resection as a treatment for early-stage hepatocellular carcinoma in patients with and without portal hypertension: a case-control study	Alvaro Urzua	Received

SAT-100	Multiomic insights into bile acid dysregulation, microbiome dysbiosis, and epigenetic modifications in metabolically associated non-B, non-C hepatocellular carcinoma: findings from multi-cohort studies and implications for early detection and therapeutic	Royston Liew	Received

SAT-101	Defective liver endothelial autophagy occurring in metabolic dysfunction-associated steatotic liver disease promotes hepatocellular carcinoma	SAMIRA LAOUIREM	Received

WED-101	Hepatocellular carcinoma in the MENA region differs in presentation and outcomes: an analysis of 2736 patients from Saudi Arabia, Oman, Egypt and Turkiye	Faisal M Sanai	Received

FRI-101	Viral etiology of hepatocellular carcinoma as an independent determinant of survival for patients receiving tyrosine kinase inhibitor treatment	Lu Li	Received

THU-101	Selective targeting of class I histone deacetylases with new derivatives of ursodeoxycholic acid as a novel treatment strategy for bile duct cancer	Francisco Javier Caballero-Camino	Received

FRI-102	Selective internal radiation therapy (SIRT) for HCC: real-world experience from a tertiary care center	Ilkay Ergenc	Received

SAT-102	The role of Activating Factor 4 (ATF4) in the immunosuppressive phenotype of beta-catenin mutant hepatocellular carcinoma	Stefany Infante	Received

WED-103	Impact of statin therapy on survival in hepatocellular carcinoma: a single-center study	Christos Triantos	Received

FRI-103	Prognosis of patients undergoing curative surgery for combined hepatocellular-choloangiocarcinoma	Eung-Ho Cho	Received

THU-103	Impact of PNPLA3 and TM6SF2 single nucleotide polymorphisms in metabolic dysfunction-associated steatohepatitis-linked hepatocellular carcinoma development in 3D extracellular matrix models	Giulia Lupo	Received

FRI-104	Sorafenib plus transarterial chemoembolization versus sorafenib alone in advanced hepatocellular carcinoma (SELECT): a multicenter, phase 3, randomized, controlled trial	Guohong Han	Received

WED-104	Surrogate survival endpoint in hepatocellular carcinoma patients on first-line Atezolizumab-Bevacizumab: RECIST 1.1 vs modified RECIST	Hyo Jung Park	Received

THU-104	A large-scale genetic analysis of hepatocellular carcinoma reveals novel mutational patterns and ancestry-linked mutations	Christoph Gerdes	Received

SAT-105	Spatiogenomic characterization of malignant transformation in dysplastic nodules	Jihyun An	Received

THU-105	Liver-derived mesenchymal stem cells promote epithelial-mesenchymal transition in a hepatocellular carcinoma spheroid coculture model	Grégory de Bodt	Received

FRI-105	Evolutionary learning-derived multimodal models integrating comprehensive imaging features to predict early recurrence of hepatocellular carcinoma after curative resection	I-Cheng Lee	Received

FRI-106	Real-world treatment patterns and survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC): the OREIOS - Middle East and North Africa (MENA) cohort	Imam Waked	Received

WED-106	Impact of metformin on the prevention of hepatocarcinoma in chronic hepatitis C with advanced fibrosis after sustained virologic response	Henar Calvo Sánchez	Received

THU-106	Macrophage-targeted biodegradable polymer nanocarriers loaded with a cytokine pathway activator effectively suppress orthotopic HCC growth in immune-competent mice	Hicham El Mard	Received

SAT-106	CD40–Integrin a5ß1 and CD27-CD70 axes: novel mechanisms driving HCC progression in chronic hepatitis C	Le Thi Thanh Thuy	Received

TOP-107	Machine learning approaches for hepatocellular carcinoma risk stratification across various aetiologies	Pierre Nahon	Received

TOP-108	Prevalence and impact of clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC): a multicenter cohort study on the ITA.LI.CA database	Rusi Chen	Received

TOP-109	Treatment of cholangiocarcinoma with Claudin-1 antibodies reprograms the tumor microenvironment to improve survival in an orthotopic mouse model	Romain Desert	Received

TOP-110	Longitudinal analyses of Innate Lymphoid Cells in patients with HCC identifies patterns associated with disease stage and response to therapy with atezolizumab and bevacizumab	Tijana Ristic	Received

FRI-111	The role of immune cell composition potentially predicts response to atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma	Jana Knorr-Klocke	Received

THU-111	Cryptochrome proteins as key regulators in circadian rhythm-enhanced photodynamic therapy for cholangiocarcinoma	Tianxiao Huang	Received

SAT-111	Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab	Takahiro Kodama	Received

THU-112	Proinflammatory cytokines drive peripheral Foxp3high Tregs into tumor sites: a reliable and accessible prognostic biomarker for HCC patients	Chien-Hao Huang	Received

FRI-112	Local control and survival after stereotactic body radiotherapy for hepatocellular carcinoma without macrovascular invasion	Jose Paul	Received

WED-112	Tumor burden score as a surrogate prediction marker in patients with hepatocellular carcinoma: prognostic role of performance status	Hung-Ting Tseng	Received

SAT-112	Role of hypoxia on the progression and survival of hepatocellular carcinoma in hypoxia-inducible factor 1 alpha knockout bi- and tri-dimensional in vitro models	Tania Payo-Serafín	Received

THU-113	Distinct roles of SOS1 and SOS2 in lipid metabolism and tumorigenesis: implications for therapeutic targeting in cancer and metabolic disorders	Andrea Olarte	Received

FRI-113	Clinical outcomes of stereotactic body radiotherapy for hepatocellular carcinoma with macrovascular invasion in a predominantly non-viral cohort	Jose Paul	Received

WED-113	Targeted immunotherapy combined with TACE for conversion therapy of unresectable hepatocellular carcinoma: metabolomic biomarker insights	YUHAI HU	Received

SAT-113	The intratumoral microbiome in HCC and its impact on treatment response	Ugne Balaseviciute	Received

SAT-114	Modulation of mitotic stress-induced activation of the cGAS/STING signaling pathway by DNA demethylation	Umar Mukhamedaliev	Received

THU-114	Liposomal doxorubicin and atezolizumab promote EMT regression by acting on the tumor microenvironment: preclinical in vitro and in vivo studies	Ilaria Zanotto	Received

WED-114	Outcome in patients with liver cirrhosis and hepatocellular carcinoma : comparing MRI and ultrasound for HCC surveillance	Jasper van Leengoed	Received

FRI-114	Liver resection versus trans-arterial chemoembolization for huge hepatocellular carcinoma (>10cm): a nationwide propensity score adjusted analysis	Jai Young Cho	Received

SAT-115	A novel panel of Methylated DNA markers for hepatocellular carcinoma	William Chung	Received

FRI-115	Improving outcomes in unresectable hepatocellular carcinoma through proactive adverse event management with Atezolizumab-Bevacizumab therapy	Jeayeon Park	Received

THU-115	Targeting UBE2I-mediated protein hyper-SUMOylation halts cholangiocarcinoma progression and rewires the tumor-stroma crosstalk	Irene Olaizola	Received

WED-115	Differential gene expression in hepatocellular carcinoma: a bioinformatic approach to correlate with HIF1A	Jennifer Martínez-Geijo	Received

WED-116	Statin and its effects on hepatocellular carcinoma risk and liver fibrosis in chronic liver disease	Jonggi Choi	Received

THU-116	Novel chemotherapy selectively induces double-strand DNA breaks and death in naïve and Cisplatin-resistant cholangiocarcinoma tumours	Irene Olaizola	Received

WED-117	Challenges and adherence to hepatocellular carcinoma screening program in patients with advanced chronic liver disease	José Presa	Received

FRI-118	Statins in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an italian prospective multicentric dataset	Marco Vicardi	Received

WED-118	Shifting etiologies and emerging metabolic factors of hepatocellular carcinoma from 2005 to 2020: a german nationwide population-based study	Josune Cabello Calleja	Received

FRI-119	Evaluation of the intratumoral immune microenvironment in hepatocellular carcinoma treated with liver surgery after selective internal radiation therapy	Maria Stella Franzè	Received

WED-119	Increasing prevalence of hepatocellular carcinoma in the Netherlands: changing etiologies, tumor characteristics and survival rates	Koen van Son	Received

SAT-119	Detection of Candida species via shotgun sequencing in patients with decompensated cirrhosis is associated with impaired survival and higher risk of acute-on-chronic liver failure	Sarah Lisa Schütte	Received

SAT-120	DOACs offer superior safety and survival over traditional agents in anticoagulant therapy for cirrhosis	Eun Young Cho	Received

WED-120	Machine learning-based survival analysis and risk stratification for patients with cholangiocarcinoma	CHUN-TING HO	Received

FRI-120	Recompensation before first-line systemic therapy for hepatocellular carcinoma yields comparable survival to compensated cirrhosis	Manuel Mendizabal	Received

WED-121	Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection	CHUN-TING HO	Received

THU-121	Claudin-1 modulates cell plasticity, carcinogenic signaling and proliferation in patient-derived cholangiocarcinoma organoids in vivo	Jade Brochon	Received

SAT-121	Hybrid care models in liver disease management: lessons from telemedicine during the COVID-19 pandemic	Nada Abedin	Received

FRI-122	Impact of hepatocellular carcinoma multidisciplinary team on treatment outcomes: an analysis from the Middle East and North Africa region	Al Naamani Khalid	Received

THU-122	Can fractal descriptors distinguish vascular organization within the tumor microenvironment?	Jake Penney	Received

SAT-122	Acute kidney disease in acutely decompensated cirrhosis: impact on clinical outcomes	Alberto Calleri	Received

SAT-123	5-year outcomes of a dedicated, multidisciplinary clinic for decompensated cirrhosis	Alexander Mitropoulos	Received

FRI-123	The dose of radiation absorbed by the tumor and the non-tumoral compartments does not impact peripheral immune markers after SIRT	Elisa Pinto	Received

THU-123	YAP activity in cancer-associated fibroblasts is relevant for immune escape in cholangiocarcinoma	Kieu Trinh Dinh	Received

WED-123	Prognostic significance of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in hepatocellular carcinoma: a retrospective multicentre study on overall survival following hepatectomy or orthotopic liver transplantation	Konstantinos Arvanitakis	Received

FRI-124	Sub-symptomatic Child-Pugh score 7 shows comparable survival outcomes to Child-Pugh score 6 in hepatocellular carcinoma patients treated with Atezolizumab and Bevacizumab	Jung Hyun Kwon	Received

THU-124	3,4-dihydroxyphenylpropionic acid deficiency in chronic hepatitis B promotes hepatocellular carcinoma	Zhixian Lan	Received

SAT-124	Harnessing human immune system mouse models to validate NADPH oxidase 1 inhibition as a treatment for hepatocellular carcinoma	Zenzi De Vos	Received

WED-124	National burden of MASH-related liver cancer in the United States 1990 – 2021: a systematic analysis for trends and patterns of geographic variations of the global burden of disease study	Seung Up Kim	Received

FRI-125	Real-world treatment patterns and outcomes among patients with hepatocellular carcinoma managed at a single centre in Switzerland	Iuliana Pompilia Radu	Received

THU-125	Activation of coagulation system and platelet aggregation in patients with primary sclerosing cholangitis and cholangiocarcinoma	Luca Fabris	Received

SAT-125	Targeting Annexin A1 improves immunotherapy efficacy by remodeling the macrophage-related immunosuppression for hepatocellular carcinoma	Zhenghui Song	Received

WED-125	The Liver Frailty Index predicts survival in hepatocellular carcinoma: an australian multicentre prospective cohort study (APriCa study)	Leo Ye	Received

FRI-126	Predictors for postembolization syndrome in a cohort of patients with hepatocellular carcinoma	Letitia Toma	Received

WED-126	Treatment of hepatocellular carcinoma according to multiparametric therapeutic hierarchy approach: a prospective multicenter validation study	Lorenzo Canova	Received

THU-126	So hot, yet so cold: bacterial lipopolysaccharides hinder tumor adaptive immunity by producing inflammatory and suppressive innate immunity in non- or poorly-infiltrated hepatocellular carcinoma	Lugien AL ASADI	Received

TOP-127	Primary cilia loss promotes neoplastic outgrowth in intrahepatic cholangiocarcinoma through suppression of neutrophilic immune surveillance	Sara Teles	Received

TOP-128	Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma	Ugne Balaseviciute	Received

TOP-129	Perineural invasion drives hilar cholangiocarcinoma progression via epithelial-mesenchymal transition augmented by cancer-associated Schwann cell-derived nerve growth factor inducible (VGF)	Honghua Zhang	Received

TOP-130	Deep learning derived radiomics with advanced machine learning outperforms clinical biomarkers in predicting outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma	Mathew Vithayathil	Received

FRI-131	Updated network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: consistent role of TACE	Jihyun An	Received

THU-131	Expression signatures of IL-18 and IL-18BP characterize stages of cirrhotic decompensation	Aenne Harberts	Received

SAT-131	Physical frailty is associated with myosteatosis and physical frailty assessment tools may predict the presence of myosteatosis in liver cirrhosis	ALEXANDRA ALEXOPOULOU	Received

WED-131	Low FIB-4 in multinational hepatocellular carcinoma cohort	Margaret Teng	Received

THU-132	Hepatocyte derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p – pyroptosis axis	Anabel Fernández-Iglesias	Received

WED-132	Serologic and immunologic biomarkers for the identification of patients with hepatocellular carcinoma with high tumour burden and poor survival	Marta Guariglia	Received

SAT-133	Adherence to a remote monitoring platform for the liver cirrhosis population, a multicenter feasibility study	Britt van Ruijven	Received

WED-133	A machine learning model to predict the treatment response of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma incorporating computed tomogram-derived imaging biomarkers	Moon Haeng Hur	Received

THU-133	Risk of hypoglycemia in people with cirrhosis without diabetes	Alan Hutchison	Received

FRI-133	Immunoprofiling-based machine learning model predicts outcomes to pembrolizumab plus lenvatinib in patients with unresectable hepatocellular carcinoma	Pei-Chang Lee	Received

FRI-134	Impact of radiation dose on treatment response and survival outcomes in solitary hepatocellular carcinoma treated withY90 selective internal radiation therapy: a retrospective single-center study	Lu Yang	Received

SAT-134	Impact of parenteral nutrition on the risk of infections and the disease course of malnourished patients with decompensated liver cirrhosis	Laura Buttler	Received

THU-134	Bone morphogenic protein 9 (BMP9): a novel therapeutic agent for the prevention of circulatory and renal failure in animal models of acute-on-chronic liver failure (ACLF)	Alexandra Phillips	Received

FRI-135	Pre-treatment serum IgG levels predict immune-related adverse events in HCC patients treated with atezolizumab plus bevacizumab	Yutaka Yasui	Received

SAT-135	SHiNE-UK: a national evaluation of hepatocellular carcinoma surveillance and treatment pathways	Christopher Mysko	Received

THU-135	Associations between cardiorespiratory fitness and physical frailty in patients with cirrhosis	Alexis Couret	Received

WED-135	Metabolic response to locoregional treatment for hepatocellular carcinoma measured by 18F-FDGal PET/CT	Mona Kristiansen	Received

SAT-136	Identification of prognosis determining risk factors in outpatients with cirrhosis	Clara Guntlisbergen	Received

WED-136	Proton-pump inhibitors and gut microbiome are associated with survival in patients with hepatocellular carcinoma under immunotherapy	Marco Sanduzzi Zamparelli	Received

THU-136	Clinical relevance of the evaluation of cardiorespiratory fitness in patients with cirrhosis: a systematic review with meta-analysis	Alexis Couret	Received

FRI-137	Flavin-containing monooxygenase 3 (Fmo3) knockout mouse reveals the role of Fmo3 in female tolerance to acetaminophen-induced liver injury	Chibuisi Alimba	Received

SAT-137	Community-acquired infections requiring hospitalization in patients with alcohol-related cirrhosis	Clara Stenderup	Received

WED-137	Hepatocellular carcinoma after liver transplantation: development of a machine learning-based risk score for safely ruling out recurrence	Pedro Passos	Received

THU-137	The metabolome of patients with cirrhosis hospitalized with overt hepatic encephalopathy and association with clinical course	Anindro Bhattacharya	Received

WED-138	Somatic copy number alterations in circulating cell-free DNA as a predictive biomarker for hepatocellular carcinoma: insights from a proof-of-concept study	Elisa Pinto	Received

THU-138	Albumin infusion improves albumin binding capacity in patients with cirrhosis and MHE on gut-specific therapy	Anna Mestre	Received

FRI-138	Enhanced prediction of drug-induced liver injury in keratinocyte-based high-content single-cell screening integrating machine learning	ANGELA REMESAL DOBLADO	Received

SAT-138	Functional and structural evaluation of patients with cirrhosis to consider recompensation	JOSE LUIS PEREZ-HERNANDEZ	Received

FRI-139	Lipid metabolites in acute and chronic liver damage: Do N-acyl taurines protect the liver?	Anna Hassing	Received

THU-139	Glycated albumin is increased in patients with cirrhosis and hepatic encephalopathy already on gut-directed therapy and links with cognitive and quality of life impairment	Anna Mestre	Received

WED-139	Evaluating the performance of large language models at hepatobiliary tumor boards: a prospective study	Robert Oehring	Received

SAT-139	Prevalence and determinants of reduced muscle status among adults with cirrhosis attending liver clinics	Damian Harding	Received

THU-140	The in vitro immune response of mononuclear cells to Escherichia coli is not dependent on antibiotic multidrug resistance	Berta Cuyàs	Received

FRI-140	Drug-induced hepatic sinusoidal obstruction syndrome: clinical characteristics analysis and preliminary exploration of mechanisms	Mingyan Ji	Received

WED-140	Liver function and tumor stage determines adherence to tumor board recommendation in HCC	Fabian Jänick	Received

SAT-140	Predictive value of systemic inflammation biomarkers towards recompensation versus progression to further decompensation in patients with decompensated cirrhosis	Dalila Costa	Received

WED-141	MicroRNA profiling of hepatocellular carcinoma can improve the prediction of tumor recurrence after liver resection	Per Stl	Received

SAT-141	Chronic Liver Disease and Autoimmune Haemolytic Anaemia: A Case Series	Dorien Pint	Received

FRI-141	A comparison of the protective effects of Rimtoregtide (HTD4010) and DUR-928 on acute liver failure in mice	Kjersti Swearingen	Received

WED-142	Impact of hepatocellular carcinoma surveillance on survival in a contemporary international cohort	Ryan YanZhe Lim	Received

SAT-142	Liver frailty index: a prognostic tool for predicting mortality in cirrhotic patients	Burcu Gurbuz	Received

THU-142	Early detection of hepatic encephalopathy using wearable sensors: preliminary data	Clelia Asero	Received

SAT-143	Cirrhotic cardiomyopathy: diagnostic challenges and debating role in mortality prediction in cirrhosis	Burcu Gurbuz	Received

FRI-143	Metabolomic profiling to differentiate drug-induced liver injury from other liver diseases using machine learning models	Daniel E. Di Zeo-Sánchez	Received

WED-143	Ki-67 and CK19 as predictors of hepatocellular carcinoma recurrence after liver transplantation	Saur Hajiev	Received

WED-144	Clinicopathological features of liver tumors in Guilin: a region with significant Aflatoxin contamination in food crops in China	Wenhua Shao	Received

THU-144	Epigenetic regulation of LSECtin in hepatic antigen presenting cells during experimental cirrhosis	Angel Gomis Enrique	Received

FRI-144	Abrogation of hepatic TRb action protects the liver from acute liver injury	Denise Zwanziger	Received

SAT-144	FastPHES offers a rapid but valid alternative for the detection of cognitive impairment in patients with liver cirrhosis	Julius Egge	Received

SAT-145	Clinical trajectories of patients with cirrhosis and ascites receiving long-term albumin. A proposal for a personalized management based on real-world experience	Giacomo Zaccherini	Received

THU-145	Propranolol reverses splanchnic ß-adrenergic induced small intestinal barrier disruption stabilizing gut-liver axis in experimental cirrhosis	Alejandro Miranda González	Received

WED-145	Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study	Spyridon Pantzios	Received

SAT-146	A novel non-invasive diagnostic model for high-risk varices in cirrhosis: a multicenter retrospective and prospective study	Wang Yanhu	Received

FRI-146	Genetic polymorphisms associated with idiosyncratic drug-induced liver injury: a systematic review and bioinformatic analysis	Gonzalo Matilla-Cabello	Received

THU-146	Global trends in antimicrobial resistance in chronic liver disease patients with bacteremia: a systematic review and meta-analysis of observational studies	Ellis Paintsil	Received

WED-146	HCC detection using LI-RADS ultrasound surveillance algorithms: a comparative analysis of v2024 and v2017	Subin Heo	Received

TOP-148	Microwave ablation versus single-needle radiofrequency ablation for the treatment of HCC up to 4 cm: a randomized control trial	SHUNSUKE NAKAMURA	Received

THU-149	Sex-specific estradiol signaling in liver cirrhosis and portal hypertension	Fabian Schachteli	Received

SAT-149	Hospital acquired infection is associated with higher mortality in patients hospitalised with acute decompensation of liver cirrhosis and infection	Gemma Wells	Received

WED-149	Machine learning-based decision tree model for predicting survival in patients with single-large hepatocellular carcinoma	Yi-Chen Lin	Received

FRI-149	Serum levels of immune checkpoints in drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease	Juan Pedro Toro Ortiz	Received

SAT-150	Highly variable antibiotic prescribing practices in a real world cohort of patients in the United Kingdom with decompensated cirrhosis	Gemma Wells	Received

FRI-150	Dynamic transition of hepatocyte subtypes highlights novel repair pathways in acute liver failure after hBMSC transplantation	Jun Li	Received

WED-150	Cost-effectiveness of ultrasound plus alpha-fetoprotein and biomarker-based strategies for hepatocellular carcinoma surveillance in patients with chronic hepatitis B	Tanat Saeoui	Received

THU-150	Comparative analysis of surrogate markers of intestinal permeability, bacterial translocation, and gut vascular barrier damage across different stages of cirrhosis	Frederic Haedge	Received

WED-151	Development and external validation of a weakly supervised deep learning algorithm for the diagnosis of focal liver lesions on contrast-enhanced ultrasound	Tobias Seraphin	Received

SAT-151	Mortality in patients hospitalised with decompensated cirrhosis and infection is associated with higher baseline measures of infection and organ dysfunction	Gemma Wells	Received

FRI-151	Drug-induced liver injury in biopsy-scaled precision-cut liver slices	Milan Lobo	Received

THU-151	Aberrant monocyte function promotes systemic inflammation in decompensated advanced chronic liver disease and can be therapeutically targeted	Malgorzata Grzelka	Received

THU-152	CLM-022, a dual inhibitor of priming and activation steps of NLRP3 inflammasome, as a potential treatment for acute and chronic inflammatory late-stage liver diseases	guillaume vidal	Received

FRI-152	Validation of markers of hepatocyte senescence for the prognosis of patients with severe acute hepatitis	MohammadMahdi Saeidinejad	Received

SAT-152	Optimising management of patients discharged from hospital following an acute decompensation of cirrhosis – a multicentre UK perspective	Giovanna McGinty	Received

WED-152	An arti?cial intelligence-based risk prediction model for early-onset hepatocellular carcinoma	Won Kim	Received

WED-153	A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care	Diane Langenbacher	Received

FRI-153	Prognostic significance of very high and towering peak alanine aminotransferase (ALT) values with normal or near normal total bilirubin in patients with idiosyncratic drug-induced liver injury	Naga Chalasani	Received

THU-153	Immunometabolism of mononuclear cells from blood and ascites in patients with decompensated cirrhosis: compartment-specific features of metabolic dysfunction	Hasan Tarik Cosgun	Received

SAT-153	COVID-19 pandemic significantly increased anxiety and depression in patients with cirrhosis, but not in patients without liver disease	Greta Priebe	Received

WED-154	Artificial intelligence foundation models for histological diagnosis of hepatocellular carcinoma based on 121,344 digitalized whole slide image patches	Yan Miao	Received

FRI-154	Gadoxetate-enhanced MRI detects acute rifampicin-induced inhibition of hepatocellular transporter function in rats and normalization of function after chronic dosing	Paul Hockings	Received

SAT-154	A metagenomics approach to frailty in patients with cirrhosis undergoing a multifactorial intervention	German Soriano	Received

THU-154	Downregulation of interleukine-6 receptors on ascitic T cells may shape the immune compartment in the peritoneal cavity	Helena Stadler	Received

FRI-155	The PPAR agonists Saroglitazar and Rosiglitazone provide hepatoprotection after APAP-induced liver injury in E2f1-/- mice	Paul Gómez	Received

THU-155	Cyclooxygenase-2 promote hepatic microvascular thrombosis and portal hypertension via AKT/mTOR-Thbs1 pathway in partial inferior vena cava ligation mice	Jisen Xu	Received

WED-155	Validation of hepatocellular carcinoma risk scoring tools in patients with chronic hepatitis B virus and hepatitis C virus infection– results from a large multicentre cohort study	Yun Jung Kim	Received

FRI-156	Coordinated liver tissue regeneration becomes ineffective with increasing injury in patients with acute indeterminate liver failure	Richard Sittner	Received

SAT-156	Role of renal biomarkers on sarcopenia and frailty in patients with cirrhosis	Won Sohn	Received

THU-156	An antimicrobial peptide, melittin attenuates gut urease activity and ammonia production in experimental model of cirrhosis	DEEPIKA JAKHAR	Received

WED-156	Evaluation of elevated tumor markers in the absence of detectable hepatocellular carcinoma during post-curative ablation follow-up	Makoto Moriyama	Received

FRI-157	Longitudinal assessment of liver stiffness for up to 96 weeks by magnetic resonance elastography and correlation with fibrosis markers in alpha-1 antitrypsin deficiency-associated liver disease: results from phase 2 studies of fazirsiran	Zehrah Nanji	Received

WED-157	A prospective multicenter study for comparison of standard-dose repeated bolus injection vs. low-dose continuous intravenous infusion of terlipressin for acute esophageal variceal bleeding in patients with liver cirrhosis	Hyung Joon Yim	Received

SAT-157	Identification of sarcopenia in patients with liver cirrhosis by combining anthropometry and ultrasound of thigh and psoas	Isabel Campos Varela	Received

THU-157	Novel potential metabolomic mechanisms for albumin-related improvement in cognitive function in patients with patients with hepatic encephalopathy	Jasmohan Bajaj	Received

WED-158	A metabolomic model based on portal venous functional metabolites for predicting post-TIPS overt hepatic encephalopathy using machine learning methods	Xiaoze Wang	Received

SAT-158	Factors predicting response to long-term albumin administration and impact on survival in patients with decompensated cirrhosis. A single-centre real-world experience	Isabel Payeras	Received

SAT-159	Increasing ´Liver Frailty Index´ scores are associated with increased mortality and unplanned hospital admission in patients with cirrhosis: a retrospective cohort study	Isobel Phillips	Received

WED-159	The role of hepatic venous pressure gradient in patients with porto-sinusoidal vascular disease	Xiaofeng Zhang	Received

FRI-159	Adrenomedullin as an immunomodulator of CD14+MerTK+ circulating monocytes in liver failure syndromes	Francesca Maria Trovato	Received

THU-159	Development and validation of dimethylarginines (DAS) as a novel biomarker to identify pre-ACLF and predict outcomes following acute decompensation of cirrhosis in two prospective multicentre european cohorts	Kohilan Gananandan	Received

WED-160	Long-term outcome of interventional radiological management of Budd-Chiari syndrome: a retrospective, multicenter survey of 10 years	Guohong Han	Received

SAT-160	Phase angle as a predictive factor for mortality in hospitalized patients with cirrhosis	Javier Fajardo	Received

THU-160	Characterization of the muscle-liver axis in a murine model of liver injury	Karen Rischmüller	Received

THU-161	Proximity extension assay-based proteomics: a reliable tool for prediction of major adverse liver outcomes	Katharina Remih	Received

FRI-161	Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure	Yang Zhi	Received

SAT-161	Prevalence and prognosis of cirrhotic cardiomyopathy in hospitalized patients with decompensated cirrhosis	cristina Solé	Received

SAT-162	Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition	Jeanette Pei Xuan Ng	Received

THU-162	Profiling of intestinal blood vessel-associated macrophages in cirrhosis	Lena Smets	Received

SAT-163	Factors associated with AKI development and external validation of the AKI prediction score	Jeanette Pei Xuan Ng	Received

THU-163	Attenuation of inflammatory bystander CD8+ T cell activation in decompensated cirrhosis via non-selective beta-blockers	Christian Niehaus	Received

FRI-163	Human cytomegalovirus reactivation in cirrhotic individuals with acute decompensation	Changze Hong	Received

THU-164	Mitochondrial transfer from mesenchymal stem cells to hematopoietic stem cells mitigates bone marrow failure and promotes liver regeneration in pre-clinical model of cirrhosis	Manisha Bhardwaj	Received

WED-164	Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results	Jia jia He	Received

FRI-164	Efficacy of Granulocyte Colony-stimulating factor in hepatitis B virus-associated acute-on-chronic liver failure patients: a multicenter study	Jinhua Hu	Received

SAT-164	Periodontal diseases in cirrhosis: prevalence, microbiome profile and dental assessment safety and tolerability	Ji Jade King	Received

FRI-165	Prevalence and characteristics of bacterial and fungal infections in end-stage liver disease: a multi-center, cross-sectional study from central China	Wei Liu	Received

THU-165	Spleen Area affects the predictive performance of the platelet count-based non-invasive tools in MASLD	Carmine Napolitano	Received

SAT-165	Oral health and microbiome: do they influence cirrhosis outcomes? A comparison of cirrhotic patients with periodontitis versus those with good oral health	Ji Jade King	Received

WED-165	Baveno VII algorithm was able to stratify the risk of portal hypertension-related events in patients with HBV-related cirrhosis	Haiyu Wang	Received

SAT-166	Use of light-EEG to rule out covert hepatic encephalopathy in advanced chronic liver disease	Juliana Goediker	Received

THU-166	NTZ alleviates stress-induced hepatocyte cell death through modulation of oxidative stress and DNA damage signaling pathways in ACLF models	Marie Gerard	Received

WED-166	Prophylactic antibiotics cannot prevent infection in patients undergoing trans jugular intrahepatic portosystemic shunt or plug assisted retrograde transvenous obliteration electively for portal hypertension complications- a double-blind pilot randomized	Aashika Bhashyakarla	Received

FRI-166	Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decompensations in alcohol-related end-stage liver disease	Cyriac Philips	Received

FRI-167	AI-AD score: a novel machine learning-based model for predicting acute liver decompensation progression – a prospective observational study	Dalbeni Andrea	Received

WED-167	The efficacy of HCP407 in reducing dysphagia and chest pain following esophageal variceal ligation in patients with cirrhosis. Preliminary results of a prospective randomized study	Alejandro Fernandez-Simon	Received

THU-167	Recombinant ADAMTS13 attenuates LPS-induced acute kidney injury and renal microangiopathy in mice with liver cirrhosis by cleaving vWF	Hiroyuki Masuda	Received

SAT-167	Obesity decreases liver-related death in patients with cirrhosis: a retrospective, propensity score-matched study	Kei Endo	Received

TOP-168	Endoscopic ultrasound-guided portal pressure gradient predicts hepatic decompensation in compensated cirrhosis	Michael Yu	Received

TOP-169	Impact of physical exercise and protein-enriched nutritional support on the development of post-TIPS hepatic encephalopathy	Anna Baiges	Received

SAT-170	Variables associated with postoperative mortality in advanced chronic liver disease patients undergoing urgent or elective surgery. a multicentre spanish cohort	Lidia Canillas Alavés	Received

THU-170	HBV-specific metabolic footprints and impact on mortality in patients with HBV reactivation and acute-on-chronic liver failure	Mirco Glitscher	Received

FRI-170	Acute-on-chronic liver failure in Australia: a non-transplant centre experience	Annie Zhou	Received

WED-170	Descriptive study of the impact of using non-cardioselective beta-blockers in cirrhotic patients after a first episode of ascites	Alejandro Fernandez Soro	Received

WED-171	Safety of seladelpar in primary biliary cholangitis patients with cirrhosis and clinical signs of portal hypertension: data from the ENHANCE and RESPONSE studies	Sefa Basci	Received

SAT-171	The novel classification as acute vs. non-acute decompensation provides prognostic value in cirrhosis patients developing ascites	Lucie Simonis	Received

THU-171	Statins as an alternative therapy to improve the cardiac chronotropic dysfunction in cirrhotic cardiomyopathy in cirrhotic rats	Muhammad Shafique	Received

FRI-171	Oral anticoagulants are safe and may reduce risk of hepatic decompensation in patients with cirrhosis and atrial fibrillation	Axel Wester	Received

FRI-172	Intraperitoneal administration of VS-01 captures accumulated metabolites in patients with acutely decompensated liver cirrhosis	Berenice Alard	Received

SAT-172	Branched-chain amino acids in liver cirrhosis and hepatic encephalopathy: a meta-analysis of clinical evidence	Luise Aamann	Received

WED-172	Outcomes following transjugular intrahepatic portosystemic shunt in patients with hepatorenal syndrome and acute-on-chronic liver failure	ANAND KULKARNI	Received

THU-172	A disintegrin and metalloproteinase with a thrombospondin type 1 motif 13 and von Willebrand factor axis regulates acute kidney injury in mice with liver cirrhosis	Norihisa Nishimura	Received

WED-173	Machine and deep learning for non-invasive detection of esophageal varices in hepatocellular carcinoma patients	Asier Rabasco Meneghetti	Received

FRI-173	Severe liver disease patients had dysfunctional platelets hypoergic to adenosine diphosphate	Xiuhua Jiang	Received

SAT-173	History of overt hepatic encephalopathy is associated with worsen cognitive tests and cerebral atrophy in a prospective cohort of outpatients with cirrhosis with multimodal evaluation and brain magnetic resonance imaging with diffusion tensor imaging	Lyès Kheloufi	Received

WED-174	Utility of spleen elastography in predicting transjugular intrahepatic porto-systemic shunt dysfunction in patients with liver cirrhosis	Asunción Ojeda Gómez	Received

THU-174	Activated intestinal fibroblasts induce inflammatory Th17 differentiation in experimental cirrhosis	Oriol Juanola	Received

SAT-174	The impact of anticoagulant therapy on safety of variceal ligation in cirrhotic patients: a systematic review and meta-analysis	Madeleine Corkery-Hayward	Received

FRI-175	Loss of hepatic leptin clearance is associated with development of acute-on-chronic liver failure	Frederike Krus	Received

THU-175	Characterising renal dysfunction in chronic liver disease rodent models	Olivia Greenham	Received

WED-175	Anemia following portal hypertension-related bleeding in liver cirrhosis: incidence and impact on prognosis	Asunción Ojeda	Received

SAT-175	Natural history of overt hepatic encephalopathy defining factors associated with progression, resolution and mortality	Maria Pilar Ballester	Received

WED-176	Role of splenic stiffness in predicting outcomes in decompensated cirrhosis: an ambispective cohort study	Ayush Agarwal	Received

FRI-176	Elevated lipase levels during acute-on-chronic liver failure are linked to increased mortality	Georg Kramer	Received

SAT-176	Minimal serum creatinine fluctuations impact on prognosis in acutely decompensated cirrhosis	Marco Tizzani	Received

THU-176	Sex-specific differences in preclinical models of advanced chronic liver disease and portal hypertension	Peio Aristu	Received

FRI-177	HDL-C, Cholesterol and the ALT/HDL-C ratio are predictors of survival in patients with acute-on-chronic liver failure	Georg Kramer	Received

SAT-177	Specialist palliative care is under-utilized at end of life in chronic liver disease, especially in patients without liver cancer	Maria Valjus	Received

THU-177	Albumin as a therapeutic target for endothelial dysfunction in patients with decompensated cirrhosis	Susan Fischer	Received

WED-177	Cirrhotic cardiomyopathy in patients underwent transjugular intrahepatic portosystemic shunt (TIPS): clinical impact of the updated diagnostic criteria for diastolic dysfunction	CHIARA BECCHETTI	Received

FRI-178	Development of an AI-driven predictive model and decision support system for managing acute-on-chronic liver failure: insights from the KACLiF cohort	Hyung Joon Yim	Received

THU-178	Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis	Sachiyo Yoshio	Received

SAT-178	Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study	Markus Maagaard	Received

WED-178	Dynamics in hepatic venous pressure gradient (HVPG) during the course of recompensated alcohol-related cirrhosis	Benedikt Hofer	Received

FRI-179	Integrated analyses of cytokine and metabolomics profiles uncover pathways regulating acute-on-chronic liver failure induced mortality	Hai Li	Received

SAT-179	The prognostic role of LiverRisk score in patients with compensated cirrhosis	Marta Tonon	Received

THU-179	Comparison of hepatocellular carcinoma risk scores in people with cirrhosis: concordance analysis of four prediction tools	Sude Yarar	Received

WED-179	CT-based imaging indices predict hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients	Xinyu Chen	Received

FRI-180	Establishment of a sarcopenia decline curve for patients with liver cirrhosis to develop hepatic rehabilitation medicine	Hiroteru Kamimura	Received

WED-180	Rate of recurrent gastrointestinal bleeding and outcomes in patients undergoing balloon-occluded retrograde obliteration (BRTO) versus transjugular intrahepatic portosystemic shunt (TIPS) for gastric variceal bleeding	Cristina Angelo	Received

SAT-180	Determinants of muscle mass in patients with liver cirrhosis	Martin Philipp	Received

THU-180	Toll-like receptor 4 inhibition restores cytochrome C oxidase mitigating hyperammonemia-induced hepatocyte mitochondrial dysfunction	Supachaya Sriphoosanaphan	Received

WED-181	Role of spleen stiffness measurement by vibration-controlled transient elastography at 100Hz in guiding invasive hemodynamic reassessments after underdilated TIPS	Dario Saltini	Received

FRI-181	Plasma interleukin-33 as a novel diagnostic marker for invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure: a prospective study	Lanyue Huang	Received

SAT-181	Attitudes towards exercise among patients with advanced chronic liver disease: a survey	Matthew McKenna-Barry	Received

THU-181	Plasma-induced neutrophil dysfunction is a novel approach to identification of acutely decompensated cirrhosis patients at risk of infection	Supachaya Sriphoosanaphan	Received

FRI-182	Prediction of circulatory failure in patients with liver cirrhosis and acute-on-chronic liver failure on the intensive care unit	Hendrik Matthias Rogge	Received

WED-182	Predicting post-TIPS hepatic encephalopathy risk in patients with cirrhosis and refractory ascites: a proof-of-concept study using a 4D MRI perfusional model	Dario Saltini	Received

THU-182	Transcriptomic and metabolic insights into hyperammonemia: the complementary therapeutic roles of toll-like receptor 4 inhibitor and ornithine phenylacetate	Supachaya Sriphoosanaphan	Received

SAT-182	Transjugular intrahepatic portosystemic shunt implantation is associated with resolution of hepatopulmonary syndrome	Jim Benjamin Mauz	Received

WED-183	Cardiopulmonary hemodynamics and liver stiffness changes in predicting cardiac decompensation after TIPS: a prospective study	Dario Saltini	Received

THU-183	Mesenchymal stem cells restore gut-liver axis integrity by targeting intestinal barrier dysfunction and MLN inflammation in cirrhotic mice	Sandeep Kumar	Received

FRI-183	Supporting unified management for patients with prior or first decompensation: evidence from three ACLF criteria	Meiqian Hu	Received

SAT-183	The association between familial mediterranean fever and incidence liver cirrhosis: a population based matched cohort study	Michal Carmiel-Haggai	Received

THU-184	Synergy between ornithine phenylacetate and strategies targeting endotoxemia with either a toll-like receptor 4 antagonist (TAK-242) or Yaq-001 for the treatment of hyperammonemia in cirrhosis and ACLF	Tingting Qi	Received

FRI-184	Multidrug-resistant organism colonization and outcomes in critically Ill patients with cirrhosis: evidence from a tertiary care center	Iva Kouta	Received

THU-185	Neuropathological basis of brain failure in acute-on-chronic liver failure (ACLF): insights into the roles of hyperammonaemia and neuroinflammation	Tingting Qi	Received

WED-185	Exploring point-of-care ultrasound for diagnosis of spontaneous bacterial peritonitis in patients of decompensated cirrhosis - proof of concept study	Sunil Taneja	Received

FRI-185	Outpatient sbp prophylaxis associates with higher sbp reccurence in a global cohort of cirrhosis inpatients with greatest impact in high- income countries	Jasmohan Bajaj	Received

SAT-185	Impact of PPIs, PCABs, and Rifaximin on SBP risk in cirrhotic patients with moderate-to-severe ascites	Satoshi Miuma	Received

WED-186	TIPS for hydropic decompensation improves short-term outcome: a case-control study	Eduardo Cervantes-Alvarez	Received

THU-186	Endotoxin induced Liver sinusoidal endothelial cell metabolic reprogramming promotes vascular dysfunction and contribute to portal hypertension in experimental cirrhosis	Vaibhav Tiwari	Received

SAT-186	Comparison of the animal naming test 1 minute versus 2 minutes for the screening of covert hepatic encephalopathy in a prospective cohort of outpatients with cirrhosis	Clara Modolo	Received

FRI-186	Rifaximin use does not significantly affect the rate of 30-day mortality or liver transplant in patients with cirrhosis on Daptomycin in two national US-based cohorts	Jasmohan Bajaj	Received

THU-187	Efficacy of the apoptosis-signal-regulating kinase 1 (ASK1) inhibitor SRT-015 in in vivo and in vitro pathogen-associated molecular patterns (PAMPs)-induced disease models	Vanessa Legry	Received

WED-187	Shunt cross-sectional area is a better predictor of overt hepatic encephalopathy than minimal hepatic encephalopathy	Elise Humerfelt	Received

SAT-187	Rehabilitation classes for sarcopenic cirrhotics, a proof of concept	Mariana Verdelho Machado	Received

FRI-187	Long term abdominal drains: a five-year study of safety and efficacy of long-term abdominal drains in a tertiary referral centre	Jemma Mickleburgh	Received

TOP-188	Incidence and clinical implications of abstinence-induced hepatic recompensation in decompensated alcohol-related cirrhosis	Benedikt Hofer	Received

TOP-189	Vibration-controlled transient elastography of the liver and the spleen for hepatic decompensation risk stratification in a european multicentre study of contemporary cACLD patients	Mathias Jachs	Received

TOP-190	Biomarkers of pathophysiological mechanisms identify stage-specific divers of disease progression in ACLD	Georg Semmler	Received

WED-191	De novo decompensation and portal vein thrombosis are both linked to similar pathophysiologic alterations associated with advanced liver disease	Erica Villa	Received

THU-191	Immunocompetence in outpatients and hospitalized chronic liver disease patients: gene expression profiles and cell-type estimation from stimulated whole blood	Xiaomian Tan	Received

SAT-191	Regulation and prognostic value of Fibroblast Growth Factor 23 in advanced chronic liver disease	Clemens Renhardt	Received

SAT-192	Identifying potential baseline risk factors for further decompensation in patients with cirrhosis and early decompensation: analysis of data from a phase 2 randomized trial	Allyson Wagner	Received

WED-192	Real-world outcomes and treatment response to terlipressin in patients with hepatorenal syndrome - acute kidney injury: a multicenter study from the German cirrhosis/Terli-CKD study group	Eva Maria Schleicher	Received

THU-193	Therapeutic plasma exchange improves outcomes in Amanita phalloides induced acute liver failure – results from an interim analysis of the Amanita-PEX study	Alejandro Campos Murguía	Received

FRI-193	A machine-learning algorithm using real-world data identified subpopulations at risk for adverse outcomes in patients with acute-on-chronic liver failure	Pierbruno Ricci	Received

WED-193	Resolution of portal hypertension by transjugular intrahepatic portosystemic shunt (TIPS) implantation reverses markers of gut-barrier dysfunction, systemic inflammation and anti-inflammatory monocyte alterations in patients with decompensated liver cirrh	Felix Piecha	Received

SAT-193	Economic evaluation of LivR Well, a multidisciplinary, multimodal, home-based program for acute hepatic decompensation: interim analysis	Natalie Ngu	Received

WED-194	Treatment response to terlipressin in patients with acute kidney injury - hepatorenal syndrome and preexisting chronic kidney disease – the german liver cirrhosis / CKD-Terli study group	Frank Erhard Uschner	Received

FRI-194	Impact of home-based hepatology nurse-led care on disease knowledge in recently hospitalised patients with cirrhosis	Leya Nedumannil	Received

SAT-194	Transcatheter closure of acquired portosystemic shunts for the management of refractory hepatic encephalopathy. A case-series	Natalie Ngu	Received

FRI-195	Single-cell multimodal analysis reveals cellular dynamics underlying divergent immune response trajectories in HBV-ACLF progression	Jun Li	Received

THU-195	Haemophagocytic lymphohistiocytosis – a rare but deadly cause of acute liver failure	Esme Gardiner	Received

WED-195	Frequency and impact of early and sustained hepatic recompensation after TIPS	Sophia Geielbrecht	Received

SAT-195	Daily step count using pedometer for sarcopenia management in patients with cirrhosis: a randomized controlled trial	Witchuta Niamsanit	Received

WED-196	Validation of the blood-based Vienna 3P/5P portal hypertension risk models in patients with compensated advanced chronic liver disease	Georg Kramer	Received

FRI-196	Outperformance of the COSSH diagnostic framework for acute-on-chronic liver failure: a global aetiology cohort	Jun Li	Received

THU-196	Effects of universal early antimicrobial treatment in acute liver failure patients at a large volume transplant centre in the United Kingdom	Gladson Thomas	Received

SAT-196	Prognostic performance of MELD and MELD 3.0 in 777 patients hospitalized with an acute decompensation of cirrhosis	Nikolaj Torp	Received

WED-197	Prognostic performance of the enhanced liver fibrosis (ELF) test in patients with advanced chronic liver disease in tertiary care	Georg Kramer	Received

SAT-197	Smoking aggravates inflammation, fibrogenesis, angiogenesis and cancer risk in patients with cirrhosis	Nina Dominik	Received

FRI-197	The AMMON-OHE model predicts liver-related complications in outpatients with cirrhosis: a prospective cohort study of the AMMON consortium	María Pilar Ballester	Received

THU-198	Combination therapy with plasma exchange and continuous renal replacement therapy improves transplant free outcomes in acute liver failure: a tertiary care center experience	Manasa Alla	Received

SAT-198	Clinical and hemodynamic factors associated with hemoglobin levels in patients with liver cirrhosis	Natalia Jimenez-Esquivel	Received

FRI-198	Benefit-to-risk profile in the label-specific population of patients with hepatorenal syndrome-acute kidney injury treated with terlipressin	Michael Curry	Received

WED-198	Incidence and clinical significance of recompensation after HCV-cure	Georg Semmler	Received

THU-199	Evaluation of different large language models´ performance in answering common questions from drug-induced liver injury patients	Yinuo Dong	Received

SAT-199	A systematic review and meta-analysis of the ability of novel biomarkers to differentiate subtype of acute kidney injury and predict response to terlipressin treatment	Olivia Greenham	Received

WED-199	Advanced chronic liver disease in the context of further decompensation & recompensation – a multistate analysis of a contemporary prospective study	Georg Semmler	Received

FRI-199	Fibroblast growth factor 19 (FGF-19) predicts transplant free-survival in critically ill patients with acute-on-chronic liver failure	Maike Rebecca Pollmanns	Received

WED-200	Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced chronic liver disease of different aetiologies	Giulia Francesca Manfredi	Received

THU-200	Checkpoint inhibitor-induced liver injury in patients with advanced skin cancer: a single center experience	Sebastiano Archilei	Received

FRI-200	Interleukin-22 is a predictor for pre-ACLF and short-term mortality in cirrhosis	Nikola Mareljic	Received

TOP-201	MeCP2 as epigenetic mechanosensor of liver sinusoidal endothelial cells in cirrhosis	Manuel Prampolini	Received

TOP-202	Matrix remodeling and versican upregulation in mesenteric lymph nodes modulate bacterial phagocytosis and migration of activated CD4+ T cells, fueling systemic bacterial infections in cirrhosis	Pinky Juneja	Received

TOP-203	Recombinant insulin-like growth factor-1: a novel therapy for patients with cirrhosis and ACLF	Wenting Tan	Received

SAT-205	Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma	Paolo Gallo	Received

WED-205	A pan-elastographic machine learning model for non-invasive diagnosis of clinically significant portal hypertension	Mauro Giuffre	Received

THU-205	Increased risk of hepatic steatosis in young adults treated for first-episode psychosis; a retrospective study	Tristan Rocheleau	Received

FRI-206	Excess ICU mortality in septic patients with cirrhosis compared to a population without cirrhosis in two contemporary prospective cohorts	Natalia Jimenez-Esquivel	Received

SAT-206	Hepatic perfusion measured with 15Oxygen-water-Positron emission tomography/computed tomography correlates with severity of cirrhosis	Paul Runeson	Received

WED-206	Influence of low-dose acetylsalicylic acid on renal function in patients with liver cirrhosis and ascites	Henrik Karbannek	Received

SAT-207	High mortality of further decompensation of liver cirrhosis: validation study	Petra Dinjar Kujundic	Received

FRI-207	A retrospective study of puncture counts and diagnostic accuracy in 119 patients undergoing transjugular liver biopsy	Asako Nogami	Received

THU-207	Clinical follow up in patients treated for hepatitis C	Arron Jones	Received

WED-207	Effectiveness of carvedilol plus variceal band ligation compared to carvedilol alone in primary prophylaxis of variceal bleed in cirrhosis with high-risk oesophageal varices	JATA SHANKAR KUMAR	Received

THU-208	Post-treatment outcomes for patients with hepatitis C cirrhosis treated through west London operational delivery network	Ashley Brown	Received

FRI-208	Pre-existing sarcopenia as the 7th organ failure and one of the leading predictors of 90-day mortality in acute decompensated cirrhosis	Yan Ling Ong	Received

SAT-208	Elevated serum ammonia is a poor prognostic marker for 1 year liver related outcomes and external validation of AMMON-OHE prediction model in stable outpatient cirrhosis	Pooi Ling Loi	Received

WED-208	The GEMA score predicts mortality in patients undergoing TIPSS for ascites	Jemima Finkel	Received

THU-209	Impact of hepatitis C eradication with direct-acting antivirals on metabolic and liver-related outcomes in diabetic patients	Clelia Asero	Received

SAT-209	Randomized, open-label, phase 2a comparator study to assess the pharmacodynamics, safety and pharmacokinetics of oral administration of mnk6106 (l-ornithine phenylacetate) vs. rifaximin in subjects with hepatic cirrhosis and a previous history of hepatic	Rajiv Jalan	Received

FRI-209	Prevalence of advanced liver fibrosis and accuracy of non-invasive tests in primary, secondary and tertiary care in Austria	Paul Thöne	Received

WED-209	Early need for paracentesis after TIPS is linked to further ascitic decompensation and impaired survival	Martin Kabelitz	Received

SAT-210	Development and validation of the modified hepatic encephalopathy staging tool (mHEST) for grading of hepatic encephalopathy for accurate assessment and regulated clinical trials	Rajiv Jalan	Received

FRI-210	Impact of blood cell count derived inflammatory markers on the outcome of critically ill cirrhotic patients	Paulo Bittencourt	Received

WED-210	Growth differentiation factor 11 increases after TIPS insertion, correlates with muscle mass and is an independent predictor of survival	Martin Kabelitz	Received

THU-210	Evaluation of transient elastography and platelets count for predicting hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to direct-acting antivirals	Cristiane Villela-Nogueira	Received

FRI-211	Vasopressin is safe and effective as a second vasopressor in patients with cirrhosis and septic shock: results of the VITEL-C trial. NCT05315557	Rakhi Maiwall	Received

WED-211	Non-invasive evaluation of portal hypertension in patients with advanced chronic liver disease undergoing major abdominal surgery	Lidia Canillas Alavés	Received

THU-211	PRO-Link HCV: automated detection and Re-engagement of hepatitis C patients lost to follow-up. A pilot study in southern Spain	Federico Garcia	Received

SAT-211	Risk of hepatocellular carcinoma and cirrhosis decompensation in a large retrospective cohort of cirrhotic patients with autoimmune hepatitis	Rawi Hazzan	Received

THU-212	Overweight, but not alcohol is associated with increased risk for advanced liver disease in patients with chronic hepatitis C infection- results from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

SAT-212	Lipopolysaccharide-binding protein indicates risk for infections and liver-related death in patients with compensated and decompensated liver cirrhosis	Rhea Veelken	Received

WED-212	Determining the optimal portal pressure gradient after small-diameter TIPS for ascites: a cohort study	Guofeng Liu	Received

WED-213	Right heart function on hemodynamic alterations and survival outcomes after transjugular intrahepatic portosystemic shunt	Yaozu Liu	Received

SAT-213	Muscle mass assessed by rectus femoris ultrasound predicts clinical outcomes in cirrhosis: a step beyond the "black-and-white" classification of sarcopenia	Roberta Gagliardi	Received

THU-213	HCC risk stratification scores: insights from large multi-center national cohort study	Imam Waked	Received

FRI-213	The presence of chronic kidney disease does not worsen 28- or 90-day survival in cirrhotic patients with acute on chronic liver failure	Sakktivel Elangovan	Received

SAT-214	Micronutrients supplementation in patients with liver cirrhosis: a single-arm prospective cohort study	Yiran Wang	Received

WED-214	The safety and efficacy of trans-splenic portal vein recanalization-assisted TIPS for the treatment of portal vein obliteration: a multicenter retrospective study	Yaozu Liu	Received

FRI-214	Predicting the risk of clinically relevant bleeding in patients with acute-on-chronic liver failure and acute decompensated liver cirrhosis	Sanna Norén	Received

THU-214	An innovative peer-led, smartphone-based intervention to enhance engagement for patients with untreated hepatitis C	Jennifer Plunkett	Received

FRI-215	An argument for risk-based case-finding in chronic liver disease	Sava Handjiev	Received

WED-215	Factors associated with clinical deterioration in patients with ascites that may be preventable by TIPS	Lorenz Balcar	Received

THU-215	Characterising prevalence and unmet needs in the setting of funded hepatitis C therapy - automated hepatitis screening in australian emergency departments can assist	Julia Di Girolamo	Received

SAT-215	A retrospective review of reduced dose argatroban in liver impairment	Sarah Sawieres	Received

THU-216	A step toward eliminating recalls and follow-up testing: first australian implementation of hepatitis C RNA reflexive testing utilising a single blood sample collected in the emergency department setting	Julia Di Girolamo	Received

WED-216	Inter-assay/inter-laboratory comparison of von Willebrand Factor antigen as diagnostic and prognostic biomarker in advanced chronic liver disease	Lorenz Balcar	Received

FRI-216	Interprofessional therapeutic drug monitoring of Piperacillin/Tazobactam enhances care for patients with acute-on-chronic liver failure in the ICU	Stephan Schmid	Received

SAT-216	The most common bacterial isolates in spontaneous bacterial peritonitis in a tertiary hospital center in Croatia and their antibiotic resistance	Sanja Stojsavljevic Shapeski	Received

TOP-217	Pathophysiological basis of acute on chronic liver failure (ACLF) triggered by alcohol-related hepatitis or infection using circulating biomarkers of inflammation, circulatory dysfunction and albumin modifications	Julian Pohl	Received

TOP-218	Yaq-001 positively impacts gut microbiome composition, virulence, antimicrobial resistance gene profile resulting in significant effects on ammonia, endotoxemia and inflammation in cirrhosis patients	Jinxia Liu	Received

TOP-220	Prevalence and clinical impact of rectal colonization by multidrug-resistant (MDR) bacteria in patients with acute decompensation of cirrhosis	Nicola Zeni	Received

SAT-221	High incidence of diuretic derived complications among patients with refractory ascites undergoing either TIPS implantation or insertion of tunneled peritoneal catheter	Sarah Lisa Schütte	Received

WED-221	Copeptin decrease after TIPS is linked to portal pressure and kidney function	Lukas Hartl	Received

THU-221	Sex-related differences in patients with chronic hepatitis c virus infection treated with direct-acting antiviral drugs	Krystyna Dobrowolska	Received

SAT-222	Liver cirrhosis detection by canine olfaction using randomized controlled blinded testing: a proof-of-concept study	suwadee Aramwittayanukul	Received

THU-222	Development of a hepatitis C infection integrated care model for prisoners in chinese population	Lung Yi Mak	Received

FRI-223	Intermediate-term survival in patients with hepatorenal syndrome-acute kidney injury treated with terlipressin	R. Todd Frederick	Received

WED-223	Colonization with multidrug resistant organisms is associated with poor outcomes in patients with decompensated cirrhosis of liver: a tertiary care center experience	Manasa Alla	Received

SAT-223	Novel sex-specific cut-offs for subcutaneous adipose tissue radiointensity in patients with cirrhosis: a post-hoc analysis	Simone Di Cola	Received

THU-223	Implementation of a systematic hepatitis C screening program: insights from a regional approach and its impact on diagnosis and treatment outcomes	Madalena Pestana	Received

SAT-224	Management of ascites in elderly patients with cirrhosis: results of an italian survey	Simone Di Cola	Received

THU-224	Hepatocellular carcinoma risk scores and incidence during and after hepatitis C therapy with direct antiviral agents - data from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

WED-224	The AMMON-OHE model predicts post-TIPS overt hepatic encephalopathy	Maria Pilar Ballester	Received

FRI-224	Time-varying effect of acute-on-chronic liver failure on post-liver transplant survival accounting for selection bias	Tomohiro Tanaka	Received

THU-225	Systematic screening for HBV, HCV and HIV in hospitalised psychiatric patients: a feasible approach on the road towards elimination of viral hepatitis	Marie Coessens	Received

SAT-225	Current incidence of decompensating events, HCC and their prognostic impact on patients with compensated advanced chronic liver disease	Susana G. Rodrigues	Received

WED-225	Risk factors of post-banding ulcer bleeding in patients with cirrhosis at a large tertiary center in Switzerland	Maria De Brito Nunes	Received

SAT-226	Impact of infections on the natural history of compensated advanced chronic liver disease: data from an individual patient data meta-analysis	Susana G. Rodrigues	Received

WED-226	Unveiling the economic burden of decompensated cirrhosis: a comprehensive cost analysis	Mariana Esteves	Received

FRI-226	The burden of extrahepatic organ failures in european patients with cirrhosis	Wenyi Gu	Received

THU-226	Hepatitis C treatment in arterial hypertension is safe and highly effective: real-world study	Micha&322; Brzd&281;k	Received

THU-227	Relinking lost to follow up patients with hepatitis C: a modeling approach to assess liver-related outcomes	Manuel Mendizabal	Received

SAT-227	Cirrhotic cardiomyopathy: Prevalence and clinical impact on liver cirrhosis outcomes	Takashi Kitagataya	Received

FRI-228	CD300A+CD8+T cells promote functional cure in patients with chronic hepatitis B under PEG-IFN-a	Wen-Xin Wang	Received

SAT-228	L-ornithine-L-aspertate improves quality of life and ammonia levels but not microbiome dysbiosis in cirrhosis: results of a phase 4 study	Vanessa Stadlbauer	Received

THU-228	Effectiveness of automatic alerts from microbiology laboratories to liver units for linking to hepatitis C treatment	Montserrat Garcia-Retortillo	Received

WED-228	Frailty, malnutrition, and sarcopenia are prevalent among patients with liver disease and are associated with worse health-related quality of life and complications of cirrhosis	Helma Cotrim	Received

WED-229	Prognostic performance of MELD 3.0 in patients undergoing transjugular intrahepatic portosystemic shunt placement - a retrospective multicentre study	Markus Kimmann	Received

THU-229	Increasing risk of hepatic decompensation in patients with HCV related liver cirrhosis during long-term follow up after sustained virological response (SVR) - data from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

SAT-229	Urinary microbiome alterations in patients with cirrhosis: a link to an increased urinary tract infection risk	Vanessa Stadlbauer	Received

THU-230	Predictors of hepatocellular carcinoma risk after hepatitis C viral clearance - data from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

FRI-230	Naïve C57BL/6 mice immunized with CLB-405 and CLB-505 combined with a saponin-based adjuvant TQL-1055 exhibit a dose-dependent humoral and cellular immune	Aditi Deshpande	Received

WED-230	A novel MELD-copeptin score accurately predicts ACLF and liver-related death in patients with decompensated cirrhosis	Marlene Hintersteininger	Received

SAT-230	Biomarker-based profiling of pathomechanisms across distinct clinical stages of cirrhosis	Vlad Taru	Received

FRI-231	Inflammatory and oncogenic gene signatures in chronic hepatitis delta infection	Arshi Khanam	Received

WED-231	Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study	Maria Paola Anolli	Received

THU-231	Microelimination project for HCV in patients with elevated ALT using pooling PCR technique in a health area. Preliminary results	Natalia Marcos Carrasco	Received

SAT-231	Improved glycaemic control over time in patients with type 2 diabetes mellitus (T2DM), with and without cirrhosis: a territory-wide cohort study of 1.2 million patients in Hong Kong	Mary Yue Wang	Received

THU-232	Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir	saeed hamid	Received

FRI-232	Prolonged exposure to HBV suppresses the immunogenicity and antiviral efficacy of therapeutic vaccination	Anna D. Kosinska	Received

WED-232	Assessing portal hypertension with endoscopic ultrasound portal pressure gradient (eus-ppg): clinical correlations and procedural outcomes	Francesco Martini	Received

TOP-233	Sustained improvement in minimal hepatic encephalopathy and quality of life in patients with cirrhosis through two-session fresh fecal microbiota transplantation: An open-label pilot randomized controlled trial (The FLAME trial)	Ankit Agarwal	Received

TOP-234	An optimized diagnostic strategy for MHE in cirrhotic patients based on PHES normalization and Stroop-CN: a prospective multicenter study	Junliang Fu	Received

TOP-235	Impact of growth hormone therapy on complications, disease severity, and frailty in decompensated cirrhosis: a randomized controlled trial	Parminder Kaur	Received

TOP-236	Neurofilament light chains and glial fibrillary acidic protein in serum for predicting post-TIPS hepatic encephalopathy	Simon Johannes Gairing	Received

WED-237	Development and validation of a novel fibrosis digital pathology biomarker to predict portal pressure in patients with MASH cirrhosis	Mathieu Petitjean	Received

FRI-237	Sustained off-treatment inhibition of HBV replication and HBsAg levels after long-term treatment with ABI-4334 in differentiated HepaRG cells and primary human hepatocytes	Barbara Testoni	Received

THU-237	Effectiveness and outcomes of routine opt-out screening for hepatitis C in a UK emergency department	Samuel Hey	Received

THU-238	Previous hepatitis B virus infection and the risk of liver-related complications in patients after HCV cure - Data on more than 6,000 patients from the german hepatitis C-registry (DHC-R)	Yvonne Serfert	Received

SAT-238	To construct a prediction model of recompensation in HBV-related decompensated cirrhosis patients combined with the inflammation index MLR	Tang shanhong	Received

WED-238	ANT at discharge can predicts further development of overt hepatic encephalopathy after elective TIPS placement	Mélisande Jorus	Received

WED-239	Prognostic performance of MELD variants and CLIF-C AD in 958 patients with cirrhosis and ascites	Nikolaj Torp	Received

FRI-239	Detecting hepatocellular carcinoma by circulating cell-free DNA in patients with chronic hepatitis B	Bootsakorn Boonkaew	Received

THU-239	Long-term prognosis and changes in liver function after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus	Yuki Tahata	Received

FRI-240	Hepatitis B surface antigen specific CD4 T cell response in hepatitis B vaccinated individuals	Carolin Heni	Received

SAT-240	Evaluation of the clinical utility of wearable fitness tracking devices to diagnose frailty in patients with liver cirrhosis – A proof-of-concept study	Jonna Friederike Zimmermann	Received

WED-240	External validation of prognostic scores for post-TIPS mortality in a contemporary, australian cohort	Nirbaanjot Walia	Received

FRI-241	Longitudinal analysis of viral profiles in chronic HBV/HDV coinfected patients	Teresa Pollicino	Received

WED-241	Changes in spleen stiffness as assessed via vibration-controlled transient elastography at 100Hz reflect acute hepatic venous pressure gradient response to i.v. propranolol: a european multicenter study	Paul Thöne	Received

SAT-241	Over the years, diagnostic problems in cirrhosis continue, but its etiology changes: chronic viral hepatitis is decreasing, steatotic liver disease is increasing	Zülal &304;stemihan	Received

THU-242	Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184	Andreas Jekle	Received

WED-242	The Impact of lactulose on the gut microbiome and barrier function in patients with decompensated cirrhosis	Patricia Bloom	Received

THU-243	SOLSTICE week 24 subgroup analysis: impact of baseline viral parameters and cirrhosis status on virological and biochemical responses in participants with chronic hepatitis delta virus infection treated with tobevibart and elebsiran	Alina Jucov	Received

FRI-243	VDAC1-mediated lipid droplet-mitochondria tethering promotes tumorigenesis and inhibits HBV replication in CHB patients concurrent with MASLD	Zhe Dai	Received

FRI-244	Analysis of intrahepatic cccDNA and HBV-DNA in patients with hepatocellular carcinoma attributed to non-HBV etiologies	Elena Vargas-Accarino	Received

SAT-244	Impact of HDV RNA levels on the risk of liver-related outcomes in patients with CHD: a european multicenter validation cohort study	Adriana Palom	Received

WED-244	Evaluation of the Baveno VII criteria for predicting liver-related events in patients with advanced chronic liver disease – a single centre retrospective study	Steven Trinh	Received

THU-244	Tissue virological response is the main predictor of hepatitis D relapses	Pavel Bogomolov	Received

SAT-245	Treatment duration, adherence and persistence in patients with chronic hepatitis B virus infection treated with long-term nucleos(t)ide analogues in Germany	Dipika Morgan	Received

WED-245	Personalized biomarkers scores outperform established scores in the short- and long-term prediction of hepatocellular carcinoma and decompensation	Rosina Maria Critelli	Received

FRI-245	Hepatitis E virus entry requires the cholesterol transporter Niemann–Pick C1	Emely Richter	Received

THU-246	Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants	Edward J. Gane	Received

WED-246	Long-term outcomes of patients with porto-sinusoidal vascular liver disorder. A single-centre 10 year-follow-up study	sanchit sharma	Received

FRI-246	HBV cccDNA: The molecular reservoir of hepatitis B persistence and challenges in eradication	Gulce Sari	Received

SAT-246	Long-term perspectives on treating or observing immune-tolerant chronic hepatitis B	Mai Kilany	Received

WED-247	Targeted nutrition intervention improves frailty and quality of life in patients with liver cirrhosis	Saniya Khan	Received

FRI-247	In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus	Gregory Camus	Received

SAT-247	Molecular epidemiology of chronic HDV infection in Italy: HDV genotypes and subgenotypes distribution in the HDV describe study cohort	Antonella Olivero	Received

FRI-248	Description of tenofovir levels in south african adults in the EVOLVE study: a pilot project to support therapeutic drug monitoring in HBV infection	Gloria Sukali	Received

THU-248	Preliminary safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in healthy and chronic hepatitis B subjects	Edward Gane	Received

WED-248	CT-based clinically significant portal hypertension: predicting complications in HCC hepatectomy	Eun Sun Choi	Received

SAT-248	End of treatment anti-HBc IgG and HBcrAg predict severe flares after nucleos(t)ide analogue withdrawal in CHB – interim analysis from the multicenter prospective COIN-B trial	Arno Furquim dAlmeida	Received

TOP-249	Signaling interaction between TGF-ß and EGF controls LPC proliferation and performing liver function in ALF	Chenhao Tong	Received

TOP-250	Polyreactive immunoglobulin G is elevated in autoimmune hepatitis and acute liver failure	Theresa Kirchner	Received

TOP-251	Efficacy and safety of Bemnifosbuvir and Ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection	Alina Jucov	Received

TOP-252	HBsAg decline and clearance with peg-IFN add-on therapy – an individual participant data meta-analysis of prospective trials (PROSPER)	Edo J. Dongelmans	Received

SAT-253	DM type 2 is a significant risk factor for HCC and decompensation of liver disease in HBV s Ag positive patients	Assaf Issachar	Received

FRI-253	Large spatial variation of intrahepatic HDV RNA levels without association with HBV core or S RNA levels in patients with HDV induced cirrhosis	Gustaf Rydell	Received

THU-253	IM-PROVE I: Rapid loss followed by transient increases in HBV RNA in chronic hepatitis B subjects during treatment with imdusiran and pegylated interferon alfa-2a is associated with HBsAg seroclearance	Emily P. Thi	Received

THU-254	First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models	Emily P. Thi	Received

WED-254	Deeplearning allows prediction of portal hypertension from liver biopsies	Thomas Sorz-Nechay	Received

SAT-254	Healthcare resource utilisation and costs associated with hepatitis delta virus infection compared with hepatitis B virus monoinfection prior to death among adults in Spain	Marvin Rock	Received

FRI-254	Early immune responses define Peg-IFNa-mediated treatment outcome in chronic hepatitis D virus infection	Manfred Anim	Received

SAT-255	Performance evaluation of the Elecsys anti-HBc II quant assay	Christian Voitenleitner	Received

THU-255	The safety and efficacy of PD-1 antibody combined with pegylated interferon-a therapy to promote the clinical cure in nucleoside (acid) analogues-suppressed chronic hepatitis B patients	Junliang Fu	Received

FRI-255	Discordance between peripheral hepatitis B surface antigen (HBsAg) titres and hepatic expression in chronic HBV infection	James Lok	Received

WED-255	Three-dimensional computed tomography angiography-based computational fluid dynamics simulation for noninvasive assessment of portal hypertension in patients with cirrhosis	Yang Tai	Received

FRI-256	Circulating miRNAs are downregulated in hepatitis delta patients that control viral replication	Javier Pérez Garreta	Received

THU-256	The safety and antiviral effect of oral daily 300 mg ALG-000184 in combination with Entecavir for up to 96 Weeks in untreated HBeAg-positive subjects with chronic hepatitis B virus infection	Jinlin Hou	Received

SAT-256	Role of HBV RNA in predicting nucleos(t)ide analogues initiation and risk of relapse after cessation	Chen-Ta Chi	Received

FRI-257	Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates	Jin Hong	Received

THU-257	Genetic prediction of causality of immune cell-mediated plasma metabolites and acute hepatitis B: a Mendelian randomization study	Size Li	Received

WED-257	Long-term albumin treatment improves outcomes in patients with cirrhosis and ascites	Valeria Santori	Received

SAT-257	The correlation of P62 expression in predicting outcomes of HBV-related HCC after surgical resection	Chien-Wei Su	Received

SAT-258	Efficacy and safety of Tenofovir Amibufenamide and Tenofovir Alafenamide in patients with hepatitis B cirrhosis: a retro-prospective observational study	Jun Chen	Received

THU-258	Patient characteristics and treatment patterns amongst hepatitis D patients: results from a real-world survey in Europe	Megan Rudolph	Received

WED-258	TIPS for portal hypertensive gastropathy bleeding reduces further decompensation and mortality	Zeyu Wang	Received

FRI-258	No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes	Jill Werner	Received

THU-259	Up to 18 months´ functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: B-Sure third report	Alexandra Walker	Received

WED-259	Limited value of liver frailty index to predict symptom control after insertion of a transjugular intrahepatic portosystemic shunt	Jonna Friederike Zimmermann	Received

FRI-259	Phenotypic characterization of untreated chronic hepatitis B infected individuals in an ethiopian cohort using fixed whole blood samples	Julia MacLeod	Received

SAT-259	Long-term outcomes of ´Grey Zone´ (GZ) individuals living with HBeAg-negative chronic hepatitis B in a tertiary UK centre	Evangelos Chalatsis	Received

FRI-260	Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy	Laura Partington	Received

WED-260	Plasma exchange to treat hepatitis A related acute liver failure – a retrospective multicentre cohort study	Asisha Janeela.M	Received

THU-260	IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran plus short courses of pegylated interferon alfa-2a (IFN) and discontinuation of nucleos(t)ide analogue (NA) therap	Karen Sims	Received

SAT-260	Autoimmunity in chronic hepatitis D: results from the HDV describe study cohort	Eleonora Dileo	Received

FRI-261	Persistent immune defects in innate-like CD8 T cells despite antiviral therapy in chronic hepatitis B	Loey Mak	Received

THU-261	Monotherapy with the novel capsid assembly modulator ALG-000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection	Man-Fung Yuen	Received

SAT-261	Field evaluation of a novel hepatitis B core-related antigen rapid test (HBcrAg-RDT) for the identification of highly viremic pregnant women, the Gambia: preliminary results from a prospective diagnostic accuracy study	Erwan Vo Quang	Received

FRI-262	Isogenic studies of basal-core promoter and precore mutations in hepatitis B genotype c	Leon Louis Seifert	Received

WED-263	Hepatitis E virus persistence in cerebrospinal fluid: a rare phenomenon observed in immunosuppressed patients beyond 18 months post-viremia clearance under Ribavirin therapy	Swetha Chalissery	Received

FRI-263	Viral N6-methyladenosine modifications regulate hepatitis E virus infections	Mara Klöhn	Received

SAT-263	Enhancing hepatitis delta virus detection in Spain with the Delta Double Reflex (DDR) study	Federico Garcia	Received

WED-264	Glecaprevir/pibrentasvir in chronic HCV: an integrated analysis of patients on concomitant opioids, antipsychotics and cardiovascular medications	Tarik Asselah	Received

THU-264	Safety and pharmacokinetics of bepirovirsen, delivered subcutaneously by vial, or prefilled syringe fitted with a safety syringe device in healthy adult participants, and syringe device ease of use: a randomised phase 1 trial	Poonam Shah	Received

FRI-264	Variability of the hepatitis delta virus and the role of the interferon I in a superinfected mice model	Maria Francesca Cortese	Received

SAT-264	New strategies to enhance molecular diagnosis of hepatitis Delta	Federico Garcia	Received

TOP-265	Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D)	Elisabetta Degasperi	Received

TOP-266	Association between sustained virological response and adverse liver-related outcomes in patients with decompensated HCV cirrhosis	Lisa M. van Velsen	Received

TOP-267	Refining HCC risk prediction in non-ACLD chronic hepatitis patients after antiviral therapy: insights from a multicenter study	Rachel Wen-Juei Jeng	Received

TOP-268	Up to 2 years´ functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: B-Sure third report	Vanesa Navarro	Received

THU-269	Interim results of a phase I/II study to determine the safety, immunogenicity and efficacy of therapeutic hepatitis B virus synthetic long peptide vaccination	Sonja Buschow	Received

FRI-269	Developing personalised treatment pathways for hepatitis B using novel assays and fine needle liver aspirates	Mark Douglas	Received

WED-269	The annual incidence of HCV RNA positivity detected by rapid on-site RT PCR doesn´t decrease and remains relatively high over the last 3 years among drug users	denis OUZAN	Received

SAT-269	Molecular epidemiology of hepatitis delta virus in Spain using whole-genome sequencing	Federico Garcia	Received

FRI-270	T helper 17 cell differentiation and the functional cure of chronic hepatitis B: insights from proteomic analysis and microRNA expression profiling of plasma-derived exosomes	Meng Zhao	Received

SAT-270	Burden of hepatitis D virus infection in Italy: results from the HDV describe study	Gian Paolo Caviglia	Received

WED-270	A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes	Fadi Abu Baker	Received

SAT-271	Impact of drugs for hepatocellular carcinoma development in chronic hepatitis B patients who treated with entecavir and tenofovir disoproxil as initial therapy: population-based study	Hyung Joon Yim	Received

FRI-271	Immune response patterns in HBeAg (-) chronic hepatitis B patients during NA treatment depends on the viral activity at baseline	Miriam Frisch	Received

WED-271	8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension	Fiona Marra	Received

THU-271	Evolution of the United Kingdom´s national immunoglobulin G4-related disease multidisciplinary meeting in guiding diagnosis and management of complex cases	Roshni Patel	Received

SAT-272	Comparing Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in reducing hepatocellular carcinoma risk in chronic hepatitis B: a propensity score matching study	Hyung Joon Yim	Received

WED-272	Real-world efficacy and safety of universal 8-week Glecaprevir/Pibrentasvir in CHC patients with early CKD or Pre-ESRD: insights from a nationwide HCV registry in Taiwan	Michael Huang	Received

SAT-273	Characteristics and predictors for elevated alanine transferase in 3,399 treatment-naïve HBV/HDV co-infected patients, with comparison to propensity score-matched mono-HBV infected patients	Habiba Kamal	Received

FRI-273	Experimental HCV infection identifies ribosomal RNA 2´-O-methylation sites also affected across all etiologies and stages of chronic liver diseases	Pélagie Huchon	Received

THU-273	Evaluation of the association between biomarkers and patient-reported outcomes in patients with primary biliary cholangitis	Alan Bonder	Received

WED-273	Exploring a hepatitis C elimination model among ex-drug users in community drug rehabilitation centers insights from Guangdong, China	Hong Li	Received

THU-274	Efficacy and safety of seladelpar in patients previously treated with fibrates or OCA	Jake Wilmot	Received

WED-274	Real-world outcomes in patients with Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment failure: a follow-up study	Julia Dietz	Received

FRI-275	Characterization of antigen specificity of T cell responses and HBV neutralization activity in a cohort of patients who achieved HBV HBsAg loss	Andrey Verendeev	Received

SAT-275	Likelihood level of a functional HBV-specific CD8 cell response upon discontinuation of eAg(-) chronic hepatitis B treatment correlates with long-term clinical outcome	Henar Calvo Sánchez	Received

WED-275	Retreatment of HCV in a large metropolis – implications for WHO elimination targets? The London experience	Matthew Foxton	Received

THU-275	Terminology, diagnosis and management of primary biliary cholangitis -autoimmune hepatitis variant syndrome (PBC-AIH): results from an international Delphi consensus process	Alessio Gerussi	Received

THU-276	Introduction of an advanced pharmacist clinic leads to improved assessment and treatment of patients with PBC	Alison Boyle	Received

WED-276	The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe	Candido Hernandez	Received

SAT-276	Investigation the persistent effects following HBsAg clearance in chronic hepatitis B patients treated with Interferon therapy	xiang huiling	Received

FRI-276	Early kinetics of HBV and HDV serum and intrahepatic markers during and after liver transplantation: impact of HBIG and baseline HBsAg levels	Sara Battistella	Received

THU-277	Psychometric evaluation of the pruritus numeric rating scale in patients with primary biliary cholangitis with moderate-to-severe pruritus	Andreas Kremer	Received

WED-277	Efficacy and safety of glecaprevir/pibrentasvir in acute HCV participants with a history of prior infection(s)	Thomas Reiberger	Received

SAT-277	Accurate prediction of long-term hepatitis B surface antigen seroclearance with machine learning: prognostic and management implications	Rex Wan-Hin Hui	Received

FRI-277	CD16+ ?d T cells are associated with antibody-dependent cellular cytotoxicity and viral control in chronic HBV infection	Paulina Schröter	Received

FRI-278	Ubiquitinated hepatitis D antigen induced specific cytotoxic T lymphocyte responses inhibited HDV replication via JAK/STAT pathway in HDV infected liver organoids	leer shen	Received

SAT-278	A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients	Ivana Carey	Received

WED-278	Pharmacokinetics of bemnifosbuvir in participants with hepatic impairment	Xiao-Jian Zhou	Received

THU-278	Clinical diagnostics of autoimmune hepatitis enabled by mass spectrometry-based proteomics	Anne-Sofie Houlberg Jensen	Received

WED-279	No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/Emtricitabine/Tenofovir Alafenamide	Xiao-Jian Zhou	Received

FRI-279	Adaptive NK cells are expanded in CMV-positive patients with chronic hepatitis B or hepatitis D and remain elevated after initiation of antiviral treatment	Smaranda Gliga	Received

THU-279	One-year efficacy and safety of tacrolimus in chronic autoimmune hepatitis	Alessio Gerussi	Received

SAT-279	Infants with chronic hepatitis B can achieve functional cure through a definite duration of antiviral treatment	Jing Li	Received

WED-280	Pharmacokinetics of bemnifosbuvir in participants with renal impairment	Xiao-Jian Zhou	Received

FRI-280	Hepatitis delta virus infection hotspots in Ethiopia: a multicenter study	Teklu Shiferaw Simbo	Received

THU-280	Efficacy, safety and long-term clinical outcomes of a low-dose versus high-dose prednisolone induction in autoimmune hepatitis: a propensity score matched analysis	Arnav Aggarwal	Received

TOP-281	The impact of HBV genotypic diversity and temporal variations on hepatocellular carcinoma risk in chronic HBV infected patients	Ding-Lian Wang	Received

TOP-282	Clinicial ulility of novel HBV serological marker HBcrAg and immunological markers in the second trimester of pregnancy for predicting post-delivery ALT flares	Ivana Carey	Received

TOP-283	Transition of immune tolerant to immune active chronic hepatitis B and potential implications for monitoring and treatment	Lisa M. van Velsen	Received

TOP-284	Accelerated HBsAg reduction rate and increased proportion of HBsAg <100 IU/mL through repeated finite Nuc therapy in HBeAg-negative chronic hepatitis B patients	Rachel Wen-Juei Jeng	Received

THU-285	Prognostic factors in autoimmune hepatitis: a french multicenter study	Anna SESSA	Received

FRI-285	A novel quintuplex long-amplicon droplet digital PCR assay reveals greater quantities of hepatitis B virus splice variants in people with HBV/HIV co-infection compared to HBV mono-infection	Tanner Grudda	Received

WED-285	Real-world evidence shows comparable Bulevirtide effectiveness in hepatitis D patients with and without cirrhosis: results from the prospective nationwide D-Shield multicenter study	Maria Paola Anolli	Received

SAT-285	Performance of the PAGE-B score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients with metabolic dysfunction	Lesley Patmore	Received

THU-286	Seladelpar treatment of patients with primary biliary cholangitis improves the GLOBE score and predicts improved transplant-free survival	Shannon Rossi	Received

SAT-286	Risk of hepatocellular carcinoma and other liver-related events in chronic hepatitis B patients with or without hepatitis D virus co-infection	Lesley Patmore	Received

WED-286	Comparative renal safety of besifovir dipivoxil maleate and tenofovir disoproxil fumarate in chronic hepatitis B patients: insights from a nationwide cohort study	sang gyune kim	Received

THU-287	Alberta has the highest prevalence of primary biliary cholangitis in North America	Bryce Tkachuk	Received

FRI-287	Epigenetic viral footprint of chronic HDV infection in HBV co-infected chimeric mice	Valerio Taverniti	Received

SAT-287	Metabolic comorbidities are risk factors for adverse liver-related events in individuals with HIV-HBV on tenofovir-based antiretroviral therapy	Lesley Patmore	Received

SAT-288	Predictive performances of PAGED-B and reREACH-B models in non-cirrhotic, treatment-naive patients with chronic hepatitis B	Ho Soo Chun	Received

THU-288	Prognostic value of liver stiffness dynamics in patients with autoimmune hepatitis	Lukas Burghart	Received

WED-288	HBV reactivation in HBV/HDV coinfected patients during bulevirtide monotreatment	Alexander Killer	Received

FRI-288	Synthetic interferon exhibits potent antiviral activity against HBV with the potential for an improved safety profile	Wade Blair	Received

WED-289	Patient centered-outcomes in HDV-treated patients with Bulevirtide	Francesco Paolo Russo	Received

SAT-289	Scaling up treatment of chronic hepatitis B in Africa: 1-year results from a simplified public-sector treatment program in Ethiopia	Lasse Olsen Rossvoll	Received

THU-289	Efficacy of tioguanine and mycophenolate mofetil as second-line immunosuppressive treatment in autoimmune hepatitis management	Catherine Tian	Received

THU-290	Addressing primary biliary cholangitis symptoms during consultations: an international survey of those who see patients	Caz Canavan	Received

FRI-290	NTCP intronic polymorphism rs17556915 had no impact on HDV RNA levels and bulevirtide response in patients treated with bulevirtide	Coover Robert	Received

SAT-290	Staging liver fibrosis using non-invasive tests in people with chronic hepatitis B (CHB) to inform WHO 2024 guidelines: a systematic review and meta-analysis	Antonio Liguori	Received

WED-290	Effectiveness and renal safety following switching to tenofovir alafenamide in patients with chronic hepatitis B: Results from a five-year, multicenter cohort study	Eiichi Ogawa	Received

THU-291	Clinical meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate-to-severe pruritus	Cynthia Levy	Received

FRI-291	Targeting hepatitis E virus with an innovative CRISPR-Cas13-based therapeutic approach	Yannick Brüggemann	Received

SAT-291	Characterizing serum HBcAg and phosphorylated HBcAg in the natural history of chronic hepatitis B infection	Lung Yi Mak	Received

WED-291	Long risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D)	Elisabetta Degasperi	Received

THU-292	Serum levels of IL-31 and autotaxin are independently associated with pruritus severity in patients with primary sclerosing cholangitis	Cynthia Levy	Received

WED-292	A cross-sectional, intrahepatic analysis of HBV and HDV markers in liver trasplants of untreated and Bulevirtide-treated patients with chronic hepatitis Delta	Elisabetta Degasperi	Received

FRI-293	Peripheral helper CD4+ T cell functionality distinguishes between acute resolving and chronic hepatitis B	Peng Zhang	Received

SAT-293	High FIB-4 index predicts liver decompensation in chronic hepatitis B patients who develop clinical relapse after antiviral therapy cessation	Chun-Hsun Liao	Received

THU-293	Disparities in treatment response and liver decompensation by race and ethnicity in primary biliary cholangitis: results from the ELLA-PBC cohort	Lily Dara	Received

SAT-294	Should EASL expand its 2017 treatment criteria for chronic hepatitis B virus infection to ineligible people: analysis from a UK-based cohort	Monika Prabhaker-Kaushal	Received

THU-294	Change in pruritus in patients with primary biliary cholangitis and moderate-to-severe pruritus: a pooled analysis from the Response and Enhance studies	Sefa Basci	Received

WED-294	Virological response and safety of combination treatment with bulevirtide and pegylated interferon in chronic hepatitis D patients with advanced fibrosis/cirrhosis: 48 weeks interim results from SEE-D trial	Soo Aleman	Received

SAT-295	Functional cure of chronic HBV: natural history, determinants, and outcomes: a real-world experience from a tertiary liver center	Mai Kilany	Received

FRI-295	Pharmacological modulation of hepatocyte glucocorticoid receptor alpha can toggle enclysis, the deletion of regulatory T cells by hepatocytes	Yiyu Fan	Received

WED-296	Impact of long-term tenofovir-based treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B using the reREACH-B score	Robert Coover	Received

SAT-296	High rates of advanced chronic liver disease in patients with chronic hepatitis D virus infection in Uzbekistan	Malika Khodjaeva	Received

FRI-296	Bile and plasma metabolome reveals association of TMA-TMAO pathway metabolites with gallstone disease progression	Vipin Yadav	Received

THU-296	Evaluation of response to Ursodeoxycholic acid (UDCA) in a nationwide population with primary biliary cholangitis	Ellen Werner	Received

TOP-297	STING activation suppresses viral replication but promotes liver inflammation and fibrosis in chronic hepatitis B concurrent with metabolic dysfunction-associated steatotic liver disease	Wenhui Wu	Received

TOP-298	Long non-coding RNA SNHG4 is regulated by hepatitis B virus and promotes hepatocarcinogenesis	Belal Ahmad	Received

TOP-299	HDV infection induces cellular refractoriness to IFN-?, but not IFN-? treatment	Claudie EBER	Received

WED-300	Impact of long-term oral antiviral treatment on hepatocellular carcinoma risk in patients with chronic hepatitis B who are hepatitis B e antigen positive using the PAGED-B score	Megan Rudolph	Received

THU-300	Long term efficacy, effectiveness and side effects of third line therapies in autoimmune hepatitis	Ilkay Ergenc	Received

SAT-300	The effect of antiviral therapy on the outcomes of baseline grey-zone (GZ) patients with HBeAg-negative chronic hepatitis B virus infection (CHBVe-)	George Papatheodoridis	Received

THU-301	Fibrates in primary sclerosing cholangitis: a multicenter retrospective observational study	Laura Cristoferi	Received

FRI-301	Reactive cholangiocyte-derived orosomucoid-2 (ORM2) drives a pathogenic modulation of the injured biliary niche through macrophage reprogramming	Adrien Guillot	Received

SAT-301	Prevalence and burden of hepatitis delta virus infection in a large cohort of hepatitis B- infected individuals in the Brazilian Amazon	Maria Cassia Mendes-Correa	Received

SAT-302	Dynamics of HBsAg isoforms during up to 9 years in treated and untreated HBeAg-negative chronic hepatitis B patients	Maria Pfefferkorn	Received

FRI-302	MUCIN1 positive biliary epithelial cell heterogeneity contributes to cholestatic liver injury and promotes early liver fibrosis	Aishwarya Bhatnagar	Received

THU-302	Impact of social determinants of health on outcome of autoimmune liver diseases: insights from the european reference network on hepatological diseases (ERN RARE-LIVER)	Franziska Stallbaum	Received

THU-303	Prevalence and impact of extrahepatic autoimmune disease in patients with primary biliary cholangitis	Gemma Weijsters	Received

WED-303	Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. The ARISTOTELE study	luca rinaldi	Received

SAT-303	Comprehensive analysis of the intrahepatic immune microenvironment and gene expression profiles in a large cohort of patients with untreated hepatitis B virus infection	Maria Stella Franzè	Received

THU-304	Non-invasive prediction of clinically significant portal hypertension in patients with compensated advanced primary biliary cholangitis	Giulia Francesca Manfredi	Received

SAT-304	Insufficient implementation of pretherapeutic hepatitis B and C screening guidelines in academic and general belgian hospitals	Marie Coessens	Received

WED-304	HERACLIS_BLV_D: Increasing response rates during 2-year bulevirtide real-life therapy in chronic hepatitis D	George Papatheodoridis	Received

FRI-304	Bioinformatic analysis of the spatial transcriptomes of inflamed portal tracts in human primary biliary cholangitis	Atsumasa Komori	Received

FRI-305	Protectin DX as a novel anti-inflammatory and anti-fibrotic therapeutic candidate for the treatment of autoimmune cholangitis	Audrey-Anne Lavoie	Received

SAT-305	Qualitative interviews to explore multicultural appropriateness and content validity of the hepatitis B quality of life (HBQOL) among highly impacted populations (chinese and vietnamese) with chronic hepatitis B (CHB) in the US	Marvin Rock	Received

THU-305	Quantitative morphometric analysis via artificial intelligence-driven image analysis in autoimmune hepatitis: a multi-center study	University Milano-Bicocca	Received

WED-305	Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071	Maria Paola Anolli	Received

SAT-306	Assessment of hepatocarcinogenesis risk using CAMP-B and PAGE-B in patients with chronic hepatitis B	Masatsugu Ohara	Received

WED-306	The kinetic of HBsAg isoforms predicts response to BLV and pegylated interferon alfa2a in patients with chronic hepatitis delta	Maria Pfefferkorn	Received

FRI-306	Protectin DX improves the efficiency of low dose obeticholic acid to reduce hepatic bile acids and mitigate inflammation, ER stress and fibrosis in liver cells	Audrey-Anne Lavoie	Received

THU-306	Efficacy and safety of odevixibat in adult patients with progressive familial intrahepatic cholestasis: results from the 72-week PEDFIC2 phase III, open-label study	Jones Louise	Received

THU-307	Analysis of histopathological diagnosis and clinical diagnosis of 1,752 patients undergoing liver biopsy	Ai-Rong Hu	Received

FRI-307	IL-27 drives activation of tissue-destructive CD8+ T cells and is functionally indispensable in immune checkpoint inhibitor-induced hepatitis	Cathrin Gudd	Received

WED-307	Good flare or bad flare? ALT variability predicts outcome after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B	Marte Holmberg	Received

SAT-308	Anti-HDV prevalence in HBsAg positive patients and virological characterization of HBV/HDV co-infected individuals at the diagnostic laboratory of the university medical center Hamburg-Eppendorf between 2008 and 2024	Marc Luetgehmann	Received

WED-308	Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response	Maurizia Brunetto	Received

FRI-308	Active transport via bile salt export pump (Bsep/Abcb11) is not required for cholehepatic shunting and choleretic actions of Norucholic acid (NCA/norUDCA) in mice	Claudia Fuchs	Received

THU-308	Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis	Ignasi Olivas	Received

SAT-309	Hepatitis B surface antigen loss after nucleot(s)ide analogue cessation in patients living with chronic hepatitis B: a model-based meta-analysis of published studies	Dipika Morgan	Received

WED-309	Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study	Michael Schwarz	Received

THU-309	Liver steatosis prevalence in primary sclerosing cholangitis	Imante Lasyte	Received

WED-310	A mathematical viral load model characterises the exposure-response relationship between bulevirtide and hepatitis delta virus and identifies the minimum duration of on-treatment viral load monitoring required for accurate prediction of long-term virologi	Parag Kumar	Received

SAT-310	Immune profiling of peripheral and intrahepatic B cells in chronic hepatitis B	Anna Pocurull	Received

FRI-310	Quantitative MRI metrics in the liver and pancreas for disease assessment in IgG4-related sclerosing cholangitis with autoimmune pancreatitis	Yameng Deng	Received

THU-310	Pruritus is not a clinical feature of early-onset primary sclerosing cholangitis during late teenage years	Jeremy Nayagam	Received

WED-311	Paediatric pharmacokinetic-pharmacodynamic extrapolation to identify suitable bulevirtide doses for children and adolescents with chronic hepatitis delta	Parag Kumar	Received

FRI-311	Restoring gene function in cholangiocyte organoids through lentiviral transduction	Enya Amundsen-Isaksen	Received

THU-311	Uncovering novel therapeutic targets for autoimmune hepatitis (AIH): detection via omics integration and validation in proof-of-concept clinical trial	Jan Philipp Weltzsch	Received

SAT-311	Prevention of HBV mother to child transmission using HBV three dose and selective use of HBV BD and treatment of high viral load pregnant women in Uganda	Ponsiano Ocama	Received

WED-312	Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with moderate hepatic impairment and in matched control participants with normal hepatic function	Andrey Verendeev	Received

THU-312	Clinical outcomes of primary sclerosing cholangitis associated with inflammatory bowel disease after liver transplantation: a systematic review and meta-analysis	Jiangrong Zhou	Received

FRI-312	A cfChIP-seq liquid biopsy for the diagnosis of autoimmune hepatitis	Eyal Shteyer	Received

THU-313	Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis	Costello Medical	Received

WED-313	Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function	Andrey Verendeev	Received

FRI-313	Epstein-Barr virus is targeted by converging T and B cell responses in primary sclerosing cholangitis	Hesham ElAbd	Received

SAT-313	Hepatitis B virus screening, antiviral prophylaxis, and reactivation in Rituximab-treated patients: insights from a large retrospective cohort study	Rawi Hazzan	Received

THU-314	The Mayo-risk model predicts postsurgical transplant-free survival in patients with Primary sclerosing cholangitis	Johannes Chang	Received

WED-314	Hepatocellular carcinoma risk in patients with chronic hepatitis B: Tenofovir Disoproxil Fumarate vs Tenofovir Alafenamide from a korean nationwide study	Jiwon Yang	Received

FRI-314	Mitochondrial dynamics and auto(mito)phagy are altered in experimental models of primary biliary cholangitis, contributing to disease pathogenesis	Irune Lasa-Elosegi	Received

WED-315	Atherosclerotic cardiovascular risk in patients with chronic hepatitis B: Tenofovir Disoproxil fumarate vs Tenofovir Alafenamide from a korean nationwide study	Jiwon Yang	Received

FRI-315	ATP8B1 deficiency causes steatosis and PDE4-mediated glucagon resistance in liver	Jung-Chin Chang	Received

THU-315	Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-life setting	Johannes Wiegand	Received

SAT-316	Sustained HBsAg loss in HIV/HBV-coinfected patients is not a rare event under HBV-active ART even if a residual risk of viral reactivation and liver disease progression still persists over time	Romina Salpini	Received

THU-316	Evidence-based digital support in hepatology: retrieval-augmented generation´s role in autoimmune liver diseases management	Ernest Saenz	Received

WED-316	Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study	Lisa Sandmann	Received

WED-317	Exploring predictive factors for treatment response to Bulevirtide in Delta-positive patients	Verdiana Zulian	Received

FRI-317	Pharmacokinetics, safety, and tolerability of seladelpar in people with renal impairment	Jake Wilmot	Received

SAT-317	HCC risk in intermediate PAGE-B patients: implications for surveillance strategies	Sara Battistella	Received

THU-317	The differential, but significant, burden of pruritus, fatigue, and sicca across cholestatic liver diseases	Kristel Leung	Received

FRI-318	Evaluation of the potential impact of seladelpar on the pharmacokinetics of midazolam, tolbutamide, simvastatin, rosuvastatin, and atorvastatin	Ellie Manca	Received

THU-318	Epidemiological trends of autoimmune hepatitis in South Korea: a population-based study from 2010 to 2023	Kyung-Ah Kim	Received

WED-318	Ethnicity and socioeconomic disparities in diagnostic and hepatic event incidences in patients with chronic viral hepatitis	Grace Wong	Received

FRI-319	Dnmt1 deletion impairs liver regeneration and stem cell activation during cholestatic liver disease	Juliana Marques Affonso	Received

THU-319	Sebepliase alfa improves lipid metabolism and liver outcomes in pediatric patients with lysosomal acid lipase deficiency	Barbara MacFee	Received

SAT-319	High GALAD scores predict hepatocellular carcinoma in hepatitis B-related cirrhosis patients who received antiviral therapy	Tung-Hung Su	Received

WED-319	Ten-year follow-up after 96?weeks treatment with peginterferon plus tenofovir in hepatitis D (HIDIT-II)	Anika Wranke	Received

FRI-320	Single-cell profiling reveals increased IGHG2+ memory and activated IGHA1+ intrahepatic B cells in primary sclerosing cholangitis	Lisa R. V. Brynjulfsen	Received

THU-320	Diagnostic distribution of patients positive for anti-mitochondrial antibodies (subtype), anti-sp100, and anti-gp210: pathological examination is necessary of PBC diagnosis: a retrospective study based on liver biopsy	Hongli Liu	Received

FRI-321	Identifying transporters of the solute carrier (SLC) group involved in cholangiocyte defense against toxic bile acids	Qinghong Li	Received

THU-321	Real-world assessment of standard of care trends in primary biliary cholangitis and cholestatic pruritus in Europe	Lina Titievsky	Received

SAT-321	Immunological correlates of rapid HBsAg decline in chronic HBV hepatitis patients undergoing Tenofovir Amibufenamide treatment	Shue Xiong	Received

SAT-322	Nucleos(t)ide analogue cessation outcomes in non-cirrhotic patients with HBeAg-negative chronic hepatitis B	Zeynep Melekoglu Ellik	Received

FRI-322	A combined immunotherapy that maintains the balance and stability of intrahepatic regulatory T cells to enhance biliary regeneration	Man Chun Wong	Received

THU-322	The risk of psychiatric disorders in patients with autoimmune hepatitis: a nationwide registry-based follow-up study	Lisbet Groenbaek	Received

FRI-323	Redundant yet distinct role of Vacuole membrane protein 1 and transmembrane protein 41B in regulating hepatic lipoprotein secretion and autophagy in metabolic dysfunction-associated steatohepatitis	Hongmin Ni	Received

SAT-323	Prognostic value of factor VIII, D-Dimer, and high mutation risk variants in re-thrombosis risk stratification for non-cirrhotic splanchnic vein thrombosis	Anna Baiges	Received

WED-323	Fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease: long-term efficacy and safety results from a phase 2 extension study	Zehrah Nanji	Received

FRI-324	Fgl2-C3aR axis mediated NETs promote intravascular coagulation and liver fibrosis in MASLD progression	Xitang Li	Received

SAT-324	Understanding treatment efficacies of progressive familial intrahepatic cholestasis via a prospective world-wide registry, TreatFIC	Alida D.E. de Groot	Received

THU-324	Does steatotic liver disease influence treatment response and clinical outcomes in primary biliary cholangitis?	Ellina Lytvyak	Received

WED-324	Single-cell sequencing reveals heterogeneity differences in cholangiocyte organoids derived from biliary atresia patients compared to non-biliary atresia controls	Adi Har-Zahav	Received

THU-325	The PSC-DM: development and validation of a clinical diagnostic model to aid the diagnosis of primary vs. secondary sclerosing cholangitis	Miki Scaravaglio	Received

SAT-325	Quantitative biliary metrics may add to predictive ability of liver stiffness in patients with primary sclerosing cholangitis	Aisha Alawi	Received

WED-325	The omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid, improve the response to fibrates in human liver cell models	Audrey-Anne Lavoie	Received

FRI-325	Sorafenib alleviates portal hypertension associated with metabolic dysfunction-associated liver disease by attenuating hepatic sinusoidal capillarization	yingjie Ai	Received

FRI-326	Spatial transcriptomic analysis of archived primary sclerosing cholangitis livers reveals distinct molecular signatures	Sayed Aseem	Received

SAT-326	HLA associations with specific anti-nuclear antibody reactivity in people living with primary biliary cholangitis	Aisha Alawi	Received

WED-326	A potent tool to study progressive familiar intrahepatic cholestasis: urine – derived human induced – hepatocytes	Benedetta Blarasin	Received

THU-326	Epidemiological and clinical differences in primary sclerosing cholangitis between men and women in Spain: a multicenter analysis of 697 patients	Magdalena Salcedo	Received

WED-327	Rare but not forgotten - comprehensive molecular and histological analysis of the primary yolk sac tumor of the liver and corresponding patient-derived cell line	Darko Castven	Received

THU-327	Rituximab therapy for autoimmune hepatitis cirrhosis is associated with a high rate of complete biochemical response and improvement in MELD score	Riveiro Barciela Mar	Received

SAT-327	Advanced phenotyping of hepatic involvement in AL Amyloidosis: the D-Amy-LIPHE study	Anna SESSA	Received

FRI-327	Genetic ablation of interleukin 17A augments fibrosis in a mouse model of cholestatic liver injury	Takashi Kitagataya	Received

THU-328	Utility of splenic stiffness as a predictor for varices needing treatment in autoimmune hepatitis and primary biliary cholangitis	Marlene Padilla-Lopez	Received

FRI-328	CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes	Raanan Greenman	Received

TOP-330	Prevalence and prognostic impact of sarcopenia in porto-sinusoidal vascular disorder	José Ferrusquía-Acosta	Received

TOP-331	Standalone medical therapy versus early endovascular intervention as the first step in the management of patients with primary Budd-Chiari syndrome: a randomized controlled trial	Sagnik Biswas	Received

TOP-332	Automated reflex testing for AAT deficiency in liver dysfunction: is it worth it?	Sava Handjiev	Received

FRI-333	Exercise protects against semaglutide-induced muscle loss in obese Ldlr-/-.Leiden mice	Eveline Gart	Received

SAT-333	Quality of life of patients living with vascular LIVEr diseaseS: Results of the LIVES european project	aurélie plessier	Received

THU-333	Non-invasive tests for liver fibrosis are stable in patients with primary biliary cholangitis with two years of treatment with elafibranor	Costello Medical	Received

WED-333	Recreating Wolman disease in human liver organoids: a new model for pathophisiology and therapeutic exploration	Davide Selvestrel	Received

SAT-334	Fatigue is common in adults with PBC and PSC: prospective analysis of two cohorts encompassing 1267 patients	Beata Kruk	Received

WED-334	Prognostic factors and regulatory pathways in porto-sinusoidal vascular disorder: a longitudinal cohort and transcriptomic study	Won-Mook Choi	Received

THU-334	Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study	Matei Mandea	Received

SAT-335	Genetic variant analysis in low phospholipid-associated cholelithiasis patients of the HiChol registry	Carola Dröge	Received

WED-335	Ex vivo application of chemically derived hepatic progenitors for the treatment of maple syrup urine disease (MSUD)	Elsy Soraya Salas Silva	Received

FRI-335	Therapeutic potential of a GHRH analog in experimental MASLD	Antonio Gil-Gómez	Received

THU-335	CM-101 impacts disease biomarkers in primary sclerosing cholangitis: assessment of the SPRING study pharmacokinetics and pharmacodynamics	Raanan Greenman	Received

THU-336	Direct nerve fiber recordings reveal functional alterations in cutaneous C-fibers linked to itch severity in cholestatic liver diseases	Miriam Düll	Received

SAT-336	Prevalence and characterization of hepatobiliary involvement in cystic fibrosis patients at a referral hospital	Jordi Sánchez	Received

WED-336	Studying the enterohepatic circulation in progressive familial intrahepatic cholestasis type I	Georg-Friedrich Vogel	Received

SAT-337	Liver disease is highly prevalent in patients with hereditary transthyretin-related amyloidosis	Carlo Saitta	Received

WED-337	Matrix metalloproteinase-7 and osteopontin secretion are specifically upregulated in a novel human precision-cut liver slices model of biliary atresia-associated liver fibrosis	Jeske Fridrichs	Received

THU-337	Is the POISE really valid as a surrogate endpoint for patients with PBC treated with UDCA and PPAR agonist? – a retrospective validation study from the real-world data in Japan	Atsushi Tanaka	Received

THU-338	Health-related quality of life and well-being of young patients with autoimmune hepatitis during transition of care from paediatric to adult site	Maciej Janik	Received

FRI-338	Genetic predisposition for hepatic fat accumulation impacts the uptake of fatty acids through fatty acid translocase in a human stem cell-based in vitro model	Alexandra Gatzios	Received

SAT-338	The role of metabolic factors in alpha-1 antitrypsin deficiency	Christina Schrader	Received

WED-338	A promising new treatment for Wilson disease: 64Cu-Methanobactin (ARBM-101) pharmacokinetics examined in animal models by whole-body PET	Julie Loft Nagel	Received

SAT-339	Comparison of pyogenic liver abscess of biliary and non-biliary origin	Cheuk Ming Chan	Received

WED-339	Modeling rare genetic cholestasis using human hepatocyte organoids	Katarina Balazova	Received

FRI-339	Identifying health-to-disease transitional biomarkers in 3D human organotypic models of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH)	Anabel Martinez Lyons	Received

THU-339	UK validation of the simple cholestatic complaints score: a patient reported outcomes measure in primary sclerosing cholangitis	Nasir Hussain	Received

FRI-340	Brain dysfunction is ameliorated by alpha 2A adrenergic receptor antagonism in experimental metabolic dysfunction-associated steatotic liver disease through vasodilatory and anti-inflammatory effects	Anne Catrine Daugaard Mikkelsen	Received

THU-340	Validation of the clinical global impression severity scale for primary biliary cholangitis: a clinical trials outcome tool	Nasir Hussain	Received

SAT-340	Liver disease and prevalence of liver transplantation in ZZ alpha-1 antitrypsin deficiency – a systematic review and meta-analysis	Dimitra Georgantaki	Received

WED-340	10 year short-term outcomes of a therapeutic stepwise approach involving low-dose systemic thrombolysis for managing acute portomesenteric thrombosis	Kohilan Gananandan	Received

FRI-341	miRNA isoforms are differentially expressed with increasing disease activity and fibrosis in metabolic dysfunction-associated steatotic liver disease	Arun Sanyal	Received

WED-341	Kinetics of copper uptake in liver cells using the novel ligand tracer method	Karina Rewitz	Received

THU-341	Implementation of a clinical global impression severity scale for primary biliary cirrhosis: results of a hepatologist focussed training programme	Nasir Hussain	Received

WED-342	Artificial intelligence-driven qFibrosis® in alpha-1-antitrypsin deficiency-associated liver disease: correlation with METAVIR stage and other disease specific features	Zehrah Nanji	Received

THU-342	Efficacy and safety of odevixibat in patients aged =10 years with Alagille syndrome: results from the 72-week ASSERT-EXT phase III, open-label extension study	Nadia Ovchinsky	Received

FRI-342	Exploring the repurposing of Telmisartan for the treatment of MASLD: characterization of its antisteatotic mechanism of action	Roger Bentanachs	Received

FRI-343	Anti-steatosis effect of telmisartan in a MASL-dietary rat model does not associates to changes in faecal bile acid metabolome	Roger Bentanachs	Received

SAT-343	Population pharmacokinetic (PK) model describing the variability of trientine pharmacokinetics in Wilson disease patients in the UNITED study	Verena Aliane	Received

SAT-344	Long-term outcome of sinusoidal obstruction syndrome secondary to hematopoietic stem cell transplantation	Edilmar Alvarado-Tapias	Received

THU-344	Clinical characteristics of a large cohort of primary sclerosing cholangitis patients undergoing liver transplant for primary sclerosing cholangitis and biochemical predictors of recurrence	Natcha Cheewasereechon	Received

WED-344	The alpha-1 Pi*MZ genotype is an independent risk factor for hepatocellular carcinoma development in patients with advanced chronic liver disease	Paul Thöne	Received

FRI-344	Sexual dimorphism of Sprague-Dawley rats in the liver inflammatory/fibrotic response to a high in sucrose and fat, choline-deficient, L-amino acid CDAA diet	Roger Bentanachs	Received

TOP-345	A 10-year review of obstetric admissions to a quaternary liver intensive care unit: learning from morbidity and mortality	Charlotte Sewell	Received

TOP-346	Statins are associated with decreased risk of disease progression and death in non-cirrhotic patients with primary biliary cholangitis	EIRINI RIGOPOULOU	Received

TOP-347	Low vitamin B6 status associates with cholangiocarcinoma in primary sclerosing cholangitis	Isma Sohail	Received

TOP-348	The association between metabolic comorbidities and clinical outcome in patients with primary biliary cholangitis	Ellen Werner	Received

THU-349	Risk factors for post-liver transplantation patient and graft survival in autoimmune hepatitis: pioneering insights from a south american cohort	Pedro Passos	Received

FRI-349	Quantifying the periportal and lobular fat distribution in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with artificial intelligence detection of portal tracts and macrovesicular steatosis	Caitlin Langford	Received

SAT-349	Liver disease in adults with fontan circulation: a cross-sectional study from a tertiary center in western Sweden	Elin Hultgren	Received

FRI-350	Effect of high-intensity interval, moderate continuous and voluntary training on body composition, hepatic steatosis and myosteatosis in a preclinical model of metabolic dysfunction-associated steatotic liver disease	Camille Lannoy	Received

WED-350	Missense mutation predominates in moldavian patients with Wilson´s disease	Veronica Cumpata	Received

SAT-350	Wilson disease: presentation, clinical course and complications in a large cohort of patients attending San Paolo hospital of Milan	Federica Samartin	Received

THU-350	Impact of non-classical phenotypes of primary biliary cholangitis on treatment response and long-term prognosis. Results from the ColHai registry	Pinelopi Arvaniti	Received

SAT-351	Biochemical and immunological markers show limited accuracy in predicting histological remission in paediatric autoimmune hepatitis: results from a multicenter study	Eleonora Munaretto	Received

WED-351	Correction of the Wilson disease H1069Q point mutation by CRISPR/Cas9-mediated gene editing in induced pluripotent stem cells	Viktoria Iwan	Received

THU-351	Advancements in autoimmune hepatitis epidemiology, treatment and complication – a 15-year retrospective study	Rawi Hazzan	Received

WED-352	Human biliary atresia extra-hepatic cholangiocyte organoids: elevated ER and oxidative stress, altered drug metabolism, and modified cell-to-cell junction	Yara Hamody	Received

FRI-352	Spatial multiplex analysis reveals distinct senescence patterns and cellular interactions in mouse models of MASLD and MetALD	Charalampos Pavlidis	Received

SAT-352	Genetic and epidemiological profile of a large brazilian cohort of acute hepatic porphyria	Cibele Franz	Received

THU-353	Comprehensive exploration of disease-specific autoantigen candidates in autoimmune hepatitis through immunocomplexome analysis	Satohi Matsuo	Received

SAT-353	Management of Wilson disease across europe: an international physician-oriented survey by the ERN-RARE liver group	Frederik Kirk	Received

FRI-353	Tirzepatide reduces diet-induced senescence and NETosis-mediated liver fibrosis in mice	Feng Chen	Received

SAT-354	Liver and spleen stiffness measure by transient elastograghy: a promising tool for the clinical management of patients after Fontan-type surgery circulation	Giovanni Petralli	Received

FRI-354	A dynamic human liver acinus-on-a-chip to model health-to-disease (MASLD-MASH) transitions	Debbie Neill	Received

FRI-355	Single-cell transcriptomics reveals THR-ß agonist treatment increases macrophage proportion and inhibits complement pathway in mice with metabolic dysfunction-associated steatohepatitis	Feng Xue	Received

SAT-355	The HepQuant DuO test finds linkage between liver blood flow, portal-systemic shunting and cardiac hemodynamics in Fontan-associated liver disease	Gregory Everson	Received

THU-356	Extra-intestinal autoimmune conditions in patients with primary sclerosing cholangitis – does age matter?	Samantha Campbell	Received

SAT-356	Porto-sinusoidal vascular disease: epidemiology, clinical features and treatments	Hamza Benazzouz	Received

FRI-356	Metabolic dysfunction-associated steatohepatitis (MASH) plays central role in western diet-induced cardiac dysfunction	Sandireddy Reddemma	Received

THU-357	The spectrum of adult cholestatic liver diseases related to ABCB4 gene mutations: genotype-phenotype correlation	Sandra Ribeiro Correia	Received

SAT-357	Etiological reclassification of cryptogenic cirrhosis after liver transplantation : insights and impact on outcomes	HEDI ARAR	Received

FRI-357	Liver disease activity measured with quantitative MRI is associated with major liver and cardiovascular events: a prospective cohort study	Edward Jackson	Received

FRI-358	Anti-inflammatory effects of a chemokine receptor mimicking peptide in obesity-associated MASH and atherosclerosis in Ldlr-/- Leiden mice	Eveline Gart	Received

THU-358	Epidemiology of primary sclerosing cholangitis in Canterbury, New Zealand, a population-based study	Sammy Benson-Pope	Received

SAT-358	Dynamics and prognostic implications of splanchnic volumetry in patients withportosinusoidal vascular liver disorder	José Ferrusquía-Acosta	Received

THU-359	Atherosclerosis in primary biliary cholangitis – more common than previously thought	Suzanne Elshafey	Received

SAT-359	Counselling young adults with liver disease on alcohol use: a survey of clinical practices across Europe	Janne Suykens	Received

FRI-359	A 5-week treatment with the GLP-1/GIP/glucagon triple receptor agonist retatrutide demonstrates multiple metabolic benefits and strong reduction in liver steatosis in a diet-induced obese MASH mouse model	FRANCOIS BRIAND	Received

SAT-360	Screening, high risk symptomatology and outcomes of Wilson´s disease in 56,606 new referrals in a large tertiary psychiatric population	James Liu Yin	Received

FRI-360	Sex-based differences in immune response and liver damage in MASLD-associated sepsis: role of neutrophil extracellular traps	MONTSERRAT MARI	Received

TOP-362	Safety and efficacy of Upadacitinib in patients with primary sclerosing cholangitis and associated colitis	Ida Schregel	Received

TOP-363	A novel orally bioavailable small-molecule inhibitor of the sodium taurocholate co-transporting polypeptide (NTCP) prevents HBV infection and ameliorates cholestasis in humanized mice models	Stan F.J. van de Graaf	Received

TOP-364	Lack of CD1d on biliary epithelial cells protects from cholangitis	Kathrine Sivertsen Nordhus	Received

WED-365	Does measuring the components of the Fibrosis-4 index (FIB-4) separately on different days affect its diagnostic and prognostic performance in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)?	Terry Cheuk-Fung Yip	Received

THU-365	Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitis	Tadashi Namisaki	Received

SAT-365	Effectiveness of cystic fibrosis transmembrane conductance regulator modulator triple therapy in patients with advanced cystic fibrosis related liver disease	Julian Yeh	Received

THU-366	Early assessment of treatment response in primary biliary cholangitis: key to timely management	Tomá Koky	Received

FRI-366	Integrated analysis of the liver tissue proteome and transcriptome in metabolic dysfunction-associated steatotic liver disease (MASLD) reveals an evolving pathophysiological milieu that may support identification of novel therapeutic targets	Georgia Graham	Received

WED-366	Enhancing the non-invasive diagnosis of fibrosis in metabolic dysfunction-associated steatotic liver disease: the role of transient elastography and a two-stage machine learning diagnostic model	Zhengao Xu	Received

SAT-366	Relative exchangeable copper: an accurate biomarker for the diagnosis of Wilson disease	Karen Dons	Received

THU-367	Prognosis of primary sclerosing cholangitis (PSC) in Hungary is independent of coexisting inflammatory bowel disease (IBD) and prognostic ability of the currently used PSC risk scores are limited	David Tornai	Received

FRI-367	Pathophysiological mechanisms involved in liver steatosis in metabolic dysfunction-associated steatotohepatitis over time : a bulk RNAseq data analysis	Guillaume HENIN	Received

WED-367	Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity and type 2 diabetes	Alba Jiménez - Masip	Received

SAT-367	UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to investigate the efficacy and safety in Wilson disease patients	Verena Aliane	Received

WED-368	Three proteins in advanced liver fibrosis: a minimalistic shallow-deep neural network approach on metabolic dysfunction–associated steatotic liver disease patients using open data	Athanasios Angelakis	Received

SAT-368	Outcomes in Navajo neurohepatopathy patients who have undergone liver transplant	Katie Cox	Received

FRI-368	Harnessing mouse genetic diversity to identify novel genetic determinants of MASLD to MASH transition	Giorgia Benegiamo	Received

THU-368	Unveiling the cholangiopathy of critical COVID-19: unique imaging patterns on magnetic resonance cholangiography	Valéria Borges	Received

FRI-369	Lysine-specific demethylase 1 modulates hepatic lipid metabolism in metabolic dysfunction-associated steatotic liver disease	HARDIK MAKWANA	Received

WED-369	A shallow-deep neural network approach combining non-invasive tests to enhance advanced fibrosis detection in metabolic dysfunction–associated steatotic liver disease patients	Athanasios Angelakis	Received

SAT-369	Isolated metabolic syndrome is a risk factor for splanchnic venous thrombosis and recurrence of vascular event	Hélène Larrue	Received

WED-370	Comparative performance of controlled attenuation parameter and ultrasound-derived fat fraction in detecting hepatic steatosis in MASLD patients	Andrea Falcomatà	Received

SAT-370	Disease penetrance and survival in HFE p.C282Y/p.H63D compound heterozygous and p.H63D homozygous individuals - a population-based cohort study	Lorenz Michael Pammer	Received

FRI-370	Hepatoprotective effects of efruxifermin treatment in GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Jacob Nhr-Meldgaard	Received

THU-370	Direct visualization of fibroblast activation protein inhibitor expression in primary sclerosing cholangitis – a novel biomarker for disease activity and inflammation?	Laura Muana Wilhelm	Received

FRI-371	Serum lipidome heterogeneity in MASH patients identifies DNA damage as predominant hit in one subtype	Idoia Fernandez Puertas	Received

WED-371	ALT is an effective screening tool for advanced MASLD in children with obesity and overweight	Anne-Sophie Stroes	Received

SAT-371	Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder	Lucia Giuli	Received

SAT-372	Spleen stiffness in porto-sinusoidal vascular disorder: link to portal hypertension and varices	Géraldine Dahlqvist	Received

FRI-372	MASH-in-a-dish: a multicellular pre-clinical model to identify targetable metabolite crosstalk in MASH	Jung-Chin Chang	Received

THU-372	Hypertension combined with hyperlipidemia increased the risk of extrahepatic malignancy in the MASLD population	Xinyue Zhao	Received

THU-373	Metabolic dysfunction-associated steatotic liver disease (MASLD) in italian women: is liver fibrosis independent from menopause?	Agnese Salamone	Received

SAT-373	Epidemiology, clinical presentation and management of Wilson´s disease in Portugal – data from a national registry	Maria Ins Canha	Received

FRI-373	Calciprotein crystallization assay as calcification biomarker in metabolic-dysfunction associated steatotic liver disease population	Joyce Xu	Received

WED-373	Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian cross-sectional study	Ahmed Cordie	Received

FRI-374	Hepatic peroxisome proliferator-activated receptor gamma coactivator-1- alpha impacts the secretion of SerpinA3N in response to obesogenic diets in mice through induction of oxidative stress response in hepatocytes	James Eng	Received

THU-374	Longitudinal dynamics and predictors of hepatic fibrosis and steatosis in people living with HIV: an egyptian cohort study	Ahmed Cordie	Received

WED-374	Utilizing AI digital pathology for quantitative measurement, grading and differentiation of lobular and portal inflammation in MASH: preliminary analysis in liver histology	Kutbuddin Akbary	Received

SAT-374	Health related quality of life in patients with porto-sinusoidal vascular disorder	Marina TORRAO GOMES	Received

THU-375	Prevalence, clinical features and determinants of MASLD in Klinefelter syndrome: a cross-sectional study	Aldo Marrone	Received

SAT-375	Frequency of ATP7B gene variants in brazilian patients with Wilson´s disease	Maria Chiara Chindamo	Received

WED-375	Relevant incidental histologic diagnoses in MASLD patients enrolled in the NASH CRN	Daniela Allende	Received

SAT-376	Children and adults with severe alpha-1 antitrypsin deficiency present a unique histological liver phenotype (Pi*ZZ genotype)	Malin Fromme	Received

FRI-376	Training non-experts to diagnose steatohepatitis on biopsy slides	Jennifer Cathcart	Received

THU-376	A systematic review and meta-analysis - does metabolic dysfunction-associated steatotic liver disease increase the risk of cardiovascular disease above and beyond shared risk factors?	Alexander Hung	Received

WED-376	Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602K during a phase IIb clinical trial	Alejandro E Mayorca-Guiliani	Received

TOP-377	The "LITMUS metabolic-dysfunction associated steatotic liver disease intention-to-treat" (LiMITT) score: a machine learning proteomic tool to select patients for therapy	Anastasia Resteu	Received

TOP-378	Dynamics in lab-based non-invasive tests predict the development of liver-related outcomes in tertiary care	Georg Semmler	Received

TOP-379	Untargeted lipidomic profiling in pediatric metabolic dysfunction-associated steatohepatitis: insights from youth enrolled in NASH CRN studies	Helaina Huneault	Received

TOP-380	Baseline liver elastography and its longitudinal changes predict liver-related outcomes in patients with metabolic dysfunction associated steatotic liver disease (MASLD)	Antonio Liguori	Received

SAT-381	Rapid liver disease progression after first hepatic decompensation in individuals with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)	Malin Fromme	Received

THU-381	Food insecurity is associated with poorer metabolic health in adults with MASLD but is not mediated by overall diet quality or total energy intake	Ani Kardashian	Received

FRI-381	Oncostatin M contributes to liver steatosis in experimental metabolic dysfunction - associated steatotic liver disease	Jessica Nurcis	Received

WED-381	Identifying risk factors for "major liver-related outcomes" in patients with metabolic dysfunction-associated steatotic liver disease	Anastasia Raptis	Received

SAT-382	Can drug metabolites predict outcome of Wilson disease?	Moinak Sen Sarma	Received

WED-382	Thrombospondin-2, a direct serum marker of fibrogenesis, to assess treatment response in MASLD in a 6-month lifestyle intervention program	Angelo Armandi	Received

THU-382	Exploring the interplay between sarcopenia, liver and cardiovascular damage in non-cirrhotic MASLD patients: a genetic perspective	Annalisa Cespiati	Received

FRI-382	The protective effect of dapagliflozin against kidney injuries by tubular mitochondrial preservation in metabolic dysfunction-associated steatohepatitis	Jee-Fu Huang	Received

FRI-383	Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Nicolas Eskesen	Received

WED-383	Change in cT1 following interventions in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis	Anneli Andersson	Received

SAT-383	Non-invasive stratification of portal hypertension in patients with BCR::ABL1-negative myeloproliferative neoplasms	Can Hopp	Received

SAT-384	Antinuclear antibodies target unknown autoantigens in porto-sinusoidal vascular disorder without portal hypertension	Nicola Pugliese	Received

WED-384	Non-invasive identification of MASLD patients eligible for resmetirom treatment – data from a multicenter biopsy-proven MASLD cohort	Katharina John	Received

THU-385	Association between polycystic ovary syndrome, steatotic liver disease in pregnancy, and adverse pregnancy outcomes: results from the prospective fatty liver in pregnancy cohort	Cecilia Katzenstein	Received

SAT-385	The prevalence and risk factors of metabolic dysfunction - associated steatotic liver disease in patients with transfusion dependent thalassemia	Nikolaos Fragkou	Received

WED-385	Prevalence and risk factors of steatotic liver disease in primary care in Slovakia	Beata Shiratori	Received

SAT-386	The Alpha-1 foundation research registry: liver disease among alpha-1 antitrypsin deficiency patients in a United States cohort	Nadine Nuchovich	Received

WED-386	Alpha-1 antitrypsin Pi*MZ variant and risk of disease progression in MASLD and MASH	Sanna Abbasi	Received

FRI-386	HK3, a novel oral anti-obesity MASH drug with direct reduction of liver fibrosis	Juergen Eckel	Received

THU-386	Both high intensity and moderate intensity exercise interventions improve steatotic liver disease: a prospective randomized trial	Chun-Jen Liu	Received

WED-387	Improved reader alignment in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis with the use of a study reading plan	Caitlin Langford	Received

SAT-387	Trajectories of serum bile acid levels and their determinants in progressive familial intrahepatic cholestasis: insights from the NAPPED consortium	Pauline Huisman	Received

FRI-387	35 kilodalton specific-sized hyaluronan ameliorates high fat diet-induced liver injury in a murine model of moderate	Laura Nagy	Received

FRI-388	Quantitative digital pathology and AI to characterize histological phenotypes of regression in a robust mouse model of human MASH	Li Chen	Received

WED-388	Artificial intelligence measurement of portal tracts enables quantification of portal, lobular and interface inflammation in metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis and autoimmune hepatiti	Caitlin Langford	Received

THU-388	Early-onset cancer risk in young adults with metabolic dysfunction-associated steatotic liver disease	Eun Ju Cho	Received

SAT-388	Integrated PK-PD model relating serum copper concentrations, urinary copper clearance and trientine pharmacokinetics in Wilson disease: initial insights from the UNITED study	Verena Aliane	Received

FRI-389	Histological phenotypes of regression in advanced liver fibrosis using quantitative digital pathology in a rodent model of cirrhotic human NASH with HCC	Li Chen	Received

THU-389	The severity of MASLD is associated with chronic kidney disease in patients with type 2 diabetes and/or obesity	Cyrielle Caussy	Received

SAT-389	Comparison of three methodologies to measure bioavailable copper in patients with Wilson disease	Peter Ott	Received

WED-389	Cost-effectiveness of hepatic fibrosis screening in suspected MASLD cases in primary care settings	DAE WON JUN	Received

SAT-390	First-line therapy with Zinc salts for Wilson disease patients: descriptive analysis from the spanish AEEH Wilson registry	Anna Pocurull	Received

WED-391	LiverPRO to diagnose and monitor liver fibrosis in patients with MASLD and obesity	Katrine Prier Lindvig	Received

THU-391	Impact of metabolic dysfunction-associated steatotic liver disease (MASLD) on serological milestones of chronic hepatitis B patients	Hui-Chun Yang	Received

SAT-391	Switching from zinc salts to Trientine Tetrahydrochloride in Wilson disease: the ZICUP study	Rodolphe Sobesky	Received

FRI-391	NEDD4 regulates TGF-beta/SMAD signaling pathway through ubiquinated decorin to ameliorate metabolic dysfunction-associated steatohepatitis	Rui Jin	Received

THU-392	Changes in liver stiffness and controlled attenuation parameters of transient elastography according to weight change in metabolic dysfunction-associated liver disease	Seong Kyun Na	Received

SAT-392	Profiling patients with Wilson´s disease using a behavioral diagnostic tool (Observia SPUR™): insights into adherence challenges and personalized care strategies	Rodolphe Sobesky	Received

WED-392	Diagnostic and clinical implications of high spleen-to-liver stiffness ratio in MASLD – a prospective, comparative study	Christian Sebesta	Received

TOP-393	Liver stiffness as a predictor of major adverse cardiac events in metabolic dysfunction-associated steatotic liver disease	Nirbaanjot Walia	Received

TOP-394	Comprehensive analysis of biomarker performance targeting "advanced fibrosis" and "at-risk" metabolic-dysfunction associated steatotic liver disease (MASH) – primary analysis of the LITMUS study cohort	Yasaman Vali	Received

TOP-395	A global analysis of patients with metabolic dysfunction associated steatotic liver disease with liver biopsy, non-invasive tests and mortality	Carey Escheik	Received

TOP-396	Multimorbidity, disease clusters and all-cause mortality in people with metabolic dysfunction association steatotic liver disease in UK Biobank	Qi Feng	Received

THU-397	Clinically meaningful fatigue is associated with the presence of systemic inflammation, lower erythrocyte count and haemoglobin level, and decreased muscle strength in patients with metabolic dysfunction-associated steatotic liver disease	Anna Sheptulina	Received

FRI-397	NMR-based metabolic signature reveals the vicious circle between fasting and feeding in homozygous carriers of the PNPLA3 I148M variant in MASLD	Lina Jegodzinski	Received

SAT-397	Long-term clinical outcomes, efficacy, and safety of transjugular intrahepatic portosystemic shunt in Budd Chiari syndrome	Shekhar Swaroop	Received

WED-398	Bone fragility and fracture risk assessment in metabolic disfunction-associated steatotic liver disease	Clelia Asero	Received

THU-398	Endothelial dysfunction and metabolic dysfunction-associated steatotic liver disease: is there a relationship?	Kateryna Pivtorak	Received

FRI-399	Impaired hepatocyte autophagy and bile dysregulation as a novel histological and genetic signature in metabolic dysfunction-associated steatotic liver disease patients with early fibrosis	Lorenzo Nevi	Received

SAT-399	Detection of rare mutations of Wilson´s disease during family screening	Veronica Cumpata	Received

THU-399	The relationship between insulin resistance, thyroid gland dysfunction and bacterial overgrowth syndrome in the development of vascular complications in patients with metabolic dysfunction-associated steatotic liver disease	Kateryna Pivtorak	Received

WED-399	Metabolic associated steatotic liver disease- related significant and advanced fibrosis´ prevalence in Brazil and the associated accuracy of FIB-4 and vibration-controlled elastography - a national register	Cristiane Villela-Nogueira	Received

WED-400	Good diagnostic performance of Hepatoscope™ in diabetology clinics for the screening of MASLD patients with high risk of advanced liver fibrosis	Cyrielle Caussy	Received

THU-400	Characterization and validation of regional variation in fibrosis within traditional fibrosis stages	Elaine Chng	Received

SAT-400	Estimating the diagnosis rate of alpha-1 antitrypsin deficiency: insights from population-based cohorts in the USA	Zehrah Nanji	Received

FRI-400	Impact of ageing on metabolic dysfunction-associated steatotic liver disease in a murine model: insights into progression, biomarkers, and therapeutic stratification	Lucia Lameroli Mauriz	Received

SAT-401	Liver disease progression in patients with alpha-1 antitrypsin deficiency and a Pi*ZZ genotype: a retrospective natural history study	Zehrah Nanji	Received

WED-401	Correlation between transient elastography, clinical scores and liver histology in patients with metabolic dysfunction-associated steatotic liver disease	Diederick van Doorn	Received

THU-401	Liver stiffness and MACE development: an intricate relationship	Agnese Salamone	Received

FRI-401	Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients	Lucrezia Petrucci	Received

SAT-402	Combination of pharmacological and surgical interruption of the enterohepatic circulation can treat cholestasis and pruritus in patients with progressive familial intrahepatic cholestasis types 1 and 2 who proved unresponsive to either treatment alone	Willem Lexmond	Received

FRI-402	The Nlrp3 inflammasome affects Kupffer cell phenotype, proliferation and triglyceride accumulation in the liver	Lukas Geisler	Received

THU-402	Real-world practice using liver stiffness measurement through two-dimensional shear wave elastography (SuperSonic Imagine) as a predictive tool for hepatocellular carcinoma risk in non-cirrhotic MASLD patients	Madalina Indre	Received

FRI-403	Spatial lipidomics applied to human liver across the spectrum of metabolic dysfunction-associated steatotic liver disease using mass spectrometry imaging	Monika Selvakumar	Received

SAT-403	Rare variants in ABCB4 in intrahepatic cholestasis of pregnancy in the national genomic research library	Xi Yang	Received

WED-403	Evaluation of liver fibrosis by FIB4, liver stiffness (Fibroscan, ShearWave), LiverRisk score and EASL 2-step approach in a cohort of 1169 patients (STEATOLIB) followed for MASLD	denis OUZAN	Received

THU-404	Genome-wide association study of noninvasive scores of fibrotic MASLD in an italian population	Francesco Malvestiti	Received

FRI-404	Leucine regulates mitochondrial function in an in vitro model of MASLD	Lizbeth Magnolia Martínez Aguilar	Received

WED-404	Fibroblast activity (PRO-C3) and liver stiffness correlate with spatial distribution of collagens in MASLD and ALD: insights from digital pathology	Diana Julie Leeming	Received

SAT-404	Accuracy of non-invasive tools in excluding advanced fibrosis in Wilson disease: results from the Wilson disease registry and Barcelona cohorts	Zoe Mariño	Received

FRI-405	Pharmacological decreases in reductive stress ameliorate lipotoxicity in hepatocytes	Mari J. Jokinen	Received

THU-405	Impact of ultra processed foods on metabolic dysfunction-associated steatotic liver disease: limitations of the NOVA classification	Franziska Beck	Received

WED-405	PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness	Diana Julie Leeming	Received

SAT-405	Efficacy of lower carbohydrate diets for reducing liver fat and improving metabolic dysfunction: a systematic review and meta-analysis	Aslihan Ozdemir	Received

WED-406	FICE-4C nomogram can help anticipating liver related complications in non-cirrhotic MASLD patients	Paloma Carrillo	Received

THU-406	Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – data from the german SLD-registry	Yvonne Serfert	Received

FRI-406	A quantitative systems pharmacology model identifies mechanisms attenuated by knockdown of HSD17B13 expression and associated with a reduction in hepatocellular ballooning	Mario Giorgi	Received

FRI-407	Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD	Martina Colognesi	Received

THU-407	Assessing muscle function in non-cirrhotic patients with steatotic liver disease : a cross-sectional study	Guillaume Henin	Received

SAT-407	Assessing early changes and responses to resmetirom therapy using real world single center data	Allysa Saggese	Received

FRI-408	MASLD-associated changes across the gut-liver-brain axis are not ameliorated by a low-fat diet intervention in an aged mouse model	Matthew Siddle	Received

THU-408	The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease	Grazia Pennisi	Received

WED-408	Can we use coronary-CT scan for screening of metabolic-associated steatotic liver disease?	Letitia Toma	Received

SAT-408	Effectiveness of bariatric surgery versus glucagon-like peptide-1 receptor agonists for prevention of adverse cardiovascular outcomes among patients with metabolic dysfunction-associated steatotic liver disease, diabetes, and obesity	Saleh Alqahtani	Received

TOP-409	Carriage of rare pathogenic APOB variants predispose to severe metabolic-associatetd steatotic liver disease and hepatocellular carcinoma	Giulia Periti	Received

TOP-410	When is a liver biopsy necessary? Predictive factors of autoimmune hepatitis in patients with metabolic dysfunction-associated steatotic liver disease and positive autoantibodies	LEIRE SANCHO SAN MARTÍN	Received

TOP-411	Disease state transitions across the spectrum of steatotic liver disease significantly affect long-term incidence of cirrhosis among a national cohort of veterans in the United States	Mai Sedki	Received

TOP-412	Long-term mortality in steatotic liver disease is greatest in those with a combination of metabolic dysfunction and excessive alcohol consumption	Carey Escheik	Received

THU-413	Metabolic-dysfunction associated steatotic liver disease in inflammatory bowel disease: prevalence and progression	Grazia Pennisi	Received

WED-413	Does hyperferritinemia predict ferroptosis in metabolic dysfunction associated steatotic liver disease? A real-world experience	Ritu Singh	Received

FRI-413	Hepatoprotective effects of fatty acid synthase inhibitor TVB-3664 in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Jacob Nhr-Meldgaard	Received

SAT-413	Cardiovascular disease risk, liver outcomes, and statin use among adults with metabolic dysfunction-associated steatotic liver disease	Saleh Alqahtani	Received

WED-414	Non-invasive assessment of fibrotic metabolic dysfunction-associated steatohepatitis by multisensorial electronic technologies	Francesca Terracciani	Received

SAT-414	Can non-diabetic patients with metabolic dysfunction associated steatotic liver disease benefit from glucagon-like peptide-1 analogs? A multicenter cohort study	Ritu Singh	Received

FRI-414	Reproducible hepatoprotective effects and clinical translatability of long-term semaglutide treatment in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Jacob Nhr-Meldgaard	Received

THU-414	Rising prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma: a comparative analysis of clinical features and outcomes	Gupse Adali	Received

SAT-415	Are glucagon-like peptide-1 analogs better answer for obese patients with metabolic dysfunction associated steatotic liver disease than bariatric surgery? Real-world evidence	Ritu Singh	Received

THU-415	Comparison of clinical characteristics and outcome of HCC patients with and without MASLD underwent surgical resection – experience from an asian tertiary center	Chia Jung Ho	Received

WED-415	The association between non-invasive tests of liver fibrosis and early diastolic dysfunction in patients with metabolic dysfunction-associated steatotic liver disease	Fabrizio Amato	Received

FRI-415	The mGluR5 blockade by MPEP inhibits PKC and triggers AMPK activation reducing hepatic steatosis in vitro	Michelangelo Trucchi	Received

THU-416	Risk assessment for carotid atherosclerosis in asymptomatic patients with metabolic dysfunction-associated steatotic liver disease	Hana Park	Received

FRI-416	Patatin-like phosphatase domain-containing 3 (PNPLA3) genotype and dietary fat modify the liver adiposity	Milla-Maria Tauriainen	Received

SAT-416	The impact of SGLT-2i and GLP-1RA on liver-related events in patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis	Lu Li	Received

WED-416	Establishing a training protocol for liver stiffness measurement by transient elastography in metabolic dysfunction-associated steatotic liver disease screening	Faisal Abaalkhail	Received

SAT-417	Sex disparities in response to low-carb, high-fat diet in MASLD	Ellen Elise Petersen	Received

WED-417	Multiparametric ultrasound-based algorithm SteatoScore 2.0 versus monoparametric controlled attenuation parameter in clinical practice: a comparison study in a monocentric MASLD cohort	Giovanni Petralli	Received

THU-417	Influence of cardiometabolic risk factors and alcohol consumption on liver stiffness in MASLD patients: a multicenter study in Colombia	Ismael de Jesus Yepes Barreto	Received

FRI-417	The HSD17B13 rs72613567:A variant is associated with reduced hepatic glycolipid content in non-obese individuals	Nils Haep	Received

SAT-418	Indication of resmetirom in patients with metabolic dysfunction associated steatohepatitis in the real-world setting - data from the german SLD-registry	Yvonne Serfert	Received

FRI-418	Plasma proteomics identifies pathways to target in metabolic dysfunction-associated steatotic liver disease	Niharika Jakhar	Received

WED-418	One-year changes in ALT and LSM, not in CAP, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease	Grazia Pennisi	Received

THU-418	The effect of a fast-food meal on endothelial function in people with metabolic dysfunction-associated steatotic fatty liver desease	James OBeirne	Received

SAT-419	A postbiotics and metabiotics reduces the hepatic steatosis indices and aminotransferase activity in MASLD patients: a randomized clinical trial (DELI_MASLD study)	Yeva Ilkiv	Received

WED-419	The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to risk stratify for the presence of advanced MASLD fibrosis	Hamish Miller	Received

THU-419	Differences in quality of life and coping strategies between patients with metabolic dysfunction-associated steatotic liver disease and liver transplant recipients. A comparison with the general spanish population	Jesús Funuyet-Salas	Received

FRI-419	Therapeutic potential of targeting processing-bodies in metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma	Noémie Gellée	Received

WED-420	Prescreening with a novel machine learning model (LiverPRO) may improve trial enrollment efficiency in metabolic dysfunction-associated steatohepatitis (MASH): a retrospective analysis of the SYNERGY-NASH trial	Mark Hartman	Received

THU-420	10 years progression of metabolic risk factors, diet quality and degree of steatosis and fibrosis in a general population cohort - ECOR liver study	Joana Estrabocha	Received

SAT-420	Natural explant with dihydromiricetin in metabolic associated steatotic liver disease (?ASLD): a double-blind, placebo controlled, randomized clinical trial	George Papatheodoridis	Received

FRI-420	Low frequency, mild gradient intermittent hypoxia still induces liver fibrogenesis in mice fed a high-fed diet	Shogo Ohkoshi	Received

THU-421	10 year progression of metabolic risk factors - correlation with steatosis and fibrosis degree in a general population cohort	Joana Estrabocha	Received

SAT-421	The reversal of MASH cirrhosis. Pooled analysis from RCTs	Henrik Hee Seung Yang	Received

FRI-421	Differential fatty acid metabolism in the liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease	Saana Palomurto	Received

WED-421	Novel metabolomics-based non-invasive test for pediatric metabolic dysfunction-associated steatohepatitis using data from youth enrolled in NASH CRN studies	Miriam Vos	Received

THU-422	Hepatic mitochondrial reductive stress predicts major adverse liver-related outcomes and is modifiable by common medications and diet	Juho V. Asteljoki	Received

FRI-422	Taurine reprograms hepatocyte metabolism and its plasma levels are inversely associated with the progression of MASLD	Pavitra Kumar	Received

WED-422	The diagnostic ability for hepatic steatosis by attenuation imaging using MRI-PDFF as reference standard ; a prospective multicenter study in Japan	Takashi Nishimura	Received

WED-423	Risk factors for hepatic steatosis- a study of deceased liver donors	Jaimie Chang	Received

THU-423	All-cause and disease-specific mortality in young adults with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study	Jeayeon Park	Received

WED-424	Fibroscan-based screening to determine the prevalence and severity of steatotic liver disease in type 1 diabetes – an australian quantentary centre experience	Raj Ashok	Received

THU-424	Patient preferences for metabolic-dysfunction associated steatotic liver disease: moving towards patient centred care	Katie Williams	Received

FRI-425	Thrombospondin-2 reflects improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy	RAMBABU SURABATTULA	Received

SAT-425	Evaluating the efficacy of a carnitine orotate and biphenyl dimethyl dicarboxylate complex in the pathogenetic treatment of metabolic-associated fatty liver disease: midterm data	Aliya Kaisina	Received

THU-425	Clinical and genetic predictors of steatotic liver disease in lean individuals: a cohort study of risk factors and fibrosis prediction	Angela Sato Espinoza	Received

WED-425	Validation of proposed non-invasive criteria for resmetirom treatment in metabolic-associated liver disease in clinical practice	Javier Ampuero	Received

TOP-426	Lipidomics crosstalk with hepatic stellate cells and macrophages in people with metabolic dysfunction-associated steatotic liver disease	Dan Wang	Received

TOP-428	Bispecific small interfering RNA targeting YAP1/WWTR1 as a novel therapeutic agent for metabolic dysfunction-associated steatohepatitis	Masayuki Sugimoto	Received

WED-429	The utility of noninvasive tests - LIVERFASt, FIB4 and vibration-controlled transient elastography (VCTE, Fibroscan) - in the initiation and monitoring of the therapy with TNR-beta agonist (resmetirom) in MASH patients	Mona MUNTEANU	Received

FRI-429	Generation of patient-derived liver organoids from needle biopsies for precision disease modeling of metabolic-associated steatotic liver disease	Raquel Ferrer-Lorente	Received

THU-429	Volatile organic compound metabolites in urine are associated with MASLD and fibrosis: an environmental health study	Laurens A. van Kleef	Received

SAT-430	Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints	Kha Le	Received

FRI-430	Hepatic estrogen receptor alpha drives liver metabolic adaptation during pregnancy	Sara Della Torre	Received

WED-430	Best buys to diagnose and treat metabolic dysfunction-associated steatohepatitis among people living with diabetes type 2: a multi-country generalized cost-effectiveness analysis	Jeffrey Lazarus	Received

THU-430	Weight loss was associated with risk reduction of MASLD, at-risk MASH and fibrosis with ongoing effects beyond the current recommendations	Laurens A. van Kleef	Received

THU-431	Influence of cardiometabolic risk factors on HCC risk in patients with metabolic dysfunction-associated steatotic liver disease	Ho Soo Chun	Received

FRI-431	A novel GLP-1/GDF15 dual-agonist reduces hepatic inflammation and fibrosis in murine models of chemical-induced liver fibrosis and metabolic associated steatohepatitis (MASH)	Yuanping Shi	Received

SAT-431	Effectiveness of a smartphone app in promoting weight loss in patients with metabolic dysfunction-associated steatotic liver disease: a pilot randomized controlled trial	Lung Yi Mak	Received

WED-432	Noninvasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease	Jimmy Che-To Lai	Received

SAT-432	Effects of Berberine Ursodeoxcholate (HTD1801) in chinese patients with T2DM and presumed MASLD	Kjersti Swearingen	Received

THU-432	Impact of metabolic dysfunction-associated steatotic liver disease on post-surgical outcomes in HBV-related hepatocellular carcinoma	Younghyeon Ahn	Received

SAT-433	Multidisciplinary management combining hepatologist counseling, cognitive/behavioral therapy, and nutritional support (the "CoCoNut" protocol) significantly improves metabolic and clinical outcomes of MASLD patients	Mario Romeo	Received

WED-433	Translating genetic information into clinical practice: Improved decision-making in advanced fibrosis assessment	Dong Yun Kim	Received

THU-433	The impact of cardiopulmonary fitness on metabolic dysfunction-associated steatotic liver disease in a combined lifestyle intervention for adolescents with obesity	Maarten Buytaert	Received

SAT-434	Efficacy of pharmacotherapy in improvement of liver fibrosis and steatohepatitis in patients with metabolic dysfunction associated steatotic liver disease (MASLD): a network meta-analysis	Shubham Mehta	Received

THU-434	Liver phenotypes in a multicentric PCOS cohort: prospective analysis including steatotic liver disease-associated genetic variants	Marcin Krawczyk	Received

FRI-434	Investigating the pharmacological potential of a new investigational drug- AD64 for treating metabolic dysfunction-associated steatohepatitis induced by a hepatopathogenic diet in rats	Shiran Shetty	Received

SAT-435	A comparative analysis of metabolic dysfunction-associated steatotic liver disease and Mediterranean diet across different races	Meng-Lun Hsieh	Received

FRI-435	Increased nuclear localization of small heterodimer partner despite incresed serum BA profile in patients with metabolic dysfunction-associated steatohepatitis	Shih-Chieh Chien	Received

THU-435	Obesity-related cognitive problems are not related to liver disease severity and remain unchanged after metabolic restoration	Mette Enok Munk Lauridsen	Received

THU-436	Histologic severity on liver biopsy is identical between normal weight and overweight adults with metabolic dysfunction associated steatotic liver disease: is it time to revise the definition of lean MASLD?	Kaela Miller	Received

FRI-436	Inhibition of hepatic bile salt uptake using the anti-HDV drug Bulevirtide attenuates inflammation in mouse models for colitis and diet-induced steatohepatitis	Thuc-Anh Nguyen	Received

SAT-436	Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study	Asahiro Morishita	Received

WED-436	Identifying risk factors linked to metabolic-associated steatotic hepatitis in people living with HIV in Newark, New Jersey	Paul Bellafiore	Received

FRI-437	Liver sinusoidal endothelial cells affect lipid metabolism in hepatocytes and form lipid droplets under steatotic conditions	Ting Chen	Received

SAT-437	Denifanstat improves multiple qFibrosis-based collagen features linked to major adverse liver outcomes in patients with metabolic dysfunction-associated steatohepatitis patients and high polygenic risk	Wen-Wei Tsai	Received

THU-437	Association of alpha-1 antitrypsin Pi*Z allele and disease severity in metabolic dysfunction-associated steatotic liver disease	Kaela Miller	Received

THU-438	Altered C-fiber function and neuropathic changes in metabolic syndrome and MASLD indicate early peripheral nerve dysfunction	Miriam Düll	Received

WED-438	Systematic review of care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD)	Kirsi van Eekhout	Received

SAT-438	General characteristics of the patients prescribed Resmetirom: data derived from six tertiary care centers in the United States	Naim Alkhouri	Received

FRI-438	Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice	Takumi Sugawara	Received

WED-439	Comparison of FibroScan© and iLivTouch© for liver stiffness and steatosis assessment in patients with MASLD	Kamela Gjini	Received

THU-439	Impact of a multidisciplinary clinic for metabolic dysfunction-associated steatotic liver disease on cardiovascular risk and liver health	Mirko Zoncapè	Received

SAT-439	The impact of metabolic surgery on metabolic dysfunction-associated steatotic liver disease	Hiromasa Namba	Received

FRI-439	Shallow-deep neural networks reveal extracellular vesicles as robust biomarkers for liver steatosis stages S0 vs. S1-S3 in metabolic dysfunction-associated steatotic liver disease patients	Eleni Trifylli	Received

WED-440	Effect of liver damage on telomere length in people with diabetic kidney disease	Viktoriia Yerokhovych	Received

FRI-440	The role of extracellular ATP (ATPe) in the progression of metabolic dysfunction – associated steatotic liver disease (MASLD)	Vanessa García-Fernández	Received

SAT-440	Effects of Berberine Ursodeoxcholate (HTD1801) in patients with at-risk MASH and T2DM	Kjersti Swearingen	Received

THU-440	The paradox of low hepatic fat content in steatotic liver disease: insights from an MRI-PDFF study	ATSUSHI NAKAMURA	Received

TOP-441	CD8+ T cells are pro-inflammatory, cytotoxic, and clonally expanded in the early stages of fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH)	Raju Kumar	Received

TOP-442	Somatic mutation in early stage metabolic-dysfunction associated steatotic liver disease (MASLD)	Georgeina L Jarman	Received

TOP-443	Paneth cells regulate intestinal lymphangiogenesis and lipid metabolism in metabolic dysfunction-associated steatotic liver disease	Sheida Moghadamrad	Received

TOP-444	Lifestyle intervention with a mediterranean diet and structured exercise promotes improved liver steatosis, steatohepatitis, and fibrosis, and allows for patient stratification. EHmet+DIA study	Carmen Lara Romero	Received

FRI-445	Deep learning analysis reveals the impact of steatosis size and density on the progression of non-alcohol-related liver disease in severe obesity	Vicente Cambra Cortés	Received

WED-445	A comparison of the prognostic value of 12 body composition markers for MASLD, at-risk MASH and Increased liver stiffness in a general population setting	Laurens A. van Kleef	Received

THU-445	Subgroup definition and monitoring of liver fibrosis evolution in patients with MASH bridging fibrosis based on objective measurements of septa parameters using digital pathology with artificial intelligence analyses	Elaine Chng	Received

THU-446	Risk stratification of liver-related complications through unsupervised partitioning clustering of alanine aminotransferase (ALT) levels and trajectories in patients with type 2 diabetes (T2D)	Nana Peng	Received

WED-446	Reliable quantitative multiparametric hepatic steatosis assessment by Steatoscore2.0 using routine liver ultrasound images	Laura De Rosa	Received

FRI-446	Metabolomic profiling reveals early biomarkers of gestational diabetes mellitus with MASLD as a mediator	Won Kim	Received

WED-447	The ultrasound multiparametric method Steatoscore2.0 measures liver steatosis with high inter- and intra- operator reproducibility	Laura De Rosa	Received

THU-447	Impact of metabolic dysfunction-associated steatotic liver disease on fatigue and pruritus in primary sclerosing cholangitis: a U.S. single-center cross-sectional study	Natalia Rojas-Amaris	Received

FRI-447	Preclinical studies of a novel hydrolysis-based prodrug for treating metabolic dysfunction associated steatohepatitis	Xiaowu Chen	Received

WED-448	Steatotic liver disease in patients with irritable bowel syndrome- a new category? Evidence based on response to therapy	Laura Iliescu	Received

SAT-448	A 10-week, randomized, double blind, placebo-controlled exploratory proof of concept study of Utreglutide (GL0034) in individuals with overweight and obesity	Rajamannar Thennati	Received

THU-448	Impact of anthoprometric and body composition on response to lifestyle intervention in patients living with MASLD	Paloma Carrillo	Received

WED-449	Exploring the evolution of circulating protein biomarkers in liver transplantation setting for MASH, ALD, and MetALD	Laura Martínez-Arenas	Received

SAT-449	Saroglitazar vs. vitamin E in metabolic-dysfunction associated fatty liver disease related compensated chronic liver disease- a cohort study	Rakhi Maiwall	Received

THU-449	Steatosis in cirrhosis: a prognostic marker for liver related outcomes in metabolic-dysfunction associated steatotic liver disease	Yiying Pei	Received

WED-450	The use of controlled attenuation parameter for the assessment of treatment response in patients with metabolic dysfunction-associated steatotic liver disease undergoing a lifestyle intervention program	Lorenza Vaira	Received

THU-450	Cryptogenic cirrhosis in Brazil: much beyond burned-out metabolic associated steatohepatitis	Paulo Bittencourt	Received

FRI-450	ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice	Xuan Luong	Received

SAT-450	ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a H	Rohit Loomba	Received

SAT-451	ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD	Rohit Loomba	Received

FRI-451	Comparative analysis of NAD+ boosters reveals the role of liver-nerve axis in metabolic health	Yasmine Liu	Received

THU-451	Long-term outcomes of metabolic dysfunction associated steatotic liver disease (MASLD) patients in a prospective, german real-world cohort	Monika Rau	Received

WED-451	Comparison of the pathophysiology of "metabolic" and "genetic" MASLD: a multiOmics cohort study	Mario Masarone	Received

THU-452	Intravenous infusions of fatty acids and ethanol induce hepatic mitochondrial reductive stress in humans	Riikka Sane	Received

WED-452	Development of novel supervised machine learning models to predict the population at risk of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in a spanish mediterranean population	Marta Cedenilla	Received

FRI-452	Bispecific small interfering RNA targeting YAP1/WWTR1 reduces low-density lipoprotein-cholesterol via proprotein convertase subtilisin/kexin type 9 transcriptional regulation in metabolic dysfunction-associated steatotic liver diseases	Yuki Yamada	Received

THU-453	Evaluation of liver steatosis and advanced fibrosis assessed by transient elastography in general population: a prospective study from north-eastern Romania	Robert Nastasa	Received

FRI-453	Proteomics reveals the effect of liraglutide in enhancing fatty acid metabolism and reducing fibrosis in metabolic dysfunction-associated steatotic liver disease	Yang Jingyi	Received

SAT-453	MASH resolution index, a novel, highly sensitive non-invasive measure of histologic improvement, predicts high rates of MASH resolution with pemvidutide treatment of metabolic dysfunction-associated steatohepatitis (MASH)	Shaheen Tomah	Received

WED-453	Referral algorithm from primary care based on the risk calculation for significant fibrosis	Marta Hernández Conde	Received

THU-454	Coagulation imbalance is associated with hepatic and vascular complications in patients with MASLD and diabetes: key role of factor VIII	Rosa Lombardi	Received

SAT-454	Therapeutic Effects of GLP-1 agonist versus SGLT2-i on patients with T2D and MASLD	Ermina Stratina	Received

FRI-454	BTB and CNC homology 1 aggravates metabolic dysfunction-associated steatohepatitis by activating calreticulin	Zhiping Wan	Received

WED-454	Decoding fibrosis: transcriptomic and clinical insights via AI-derived collagen clusters in MASLD	Marta Wojciechowska	Received

THU-455	Real-world assessment of clinical burden and healthcare resource utilisation among patients with metabolic dysfunction-associated steatohepatitis with additional cardiovascular, renal and metabolic comorbidities in France, Italy, Germany and Canada	Riku Ota	Received

WED-455	Sampling variability of liver fibrosis assessed by digital pathology in pre-cirrhotic patients with MASH	Mathieu Petitjean	Received

SAT-455	A single centre, comparative study of Saroglitazar combined with vitamin E versus Saroglitazar alone in managing steatotic liver disease and/or metabolic dysfunction among liver transplant recipients	Swapnil Dhampalwar	Received

FRI-455	The impact of donor and recipient HSD17B13, PNPLA3 and TM6SF2 genotype on post-transplant fibrosis, steatosis and survival in liver transplant recipients	Maria Rosina Troppmair	Received

THU-456	The impact of chronic hepatitis B on fibrosis progression in metabolic dysfunction-associated steatotic liver disease	&27861;&23071; &33454;	Received

WED-456	Intra-abdominal fat thickness measured by ultrasound correlates with CAP (Controlled Attenuation Parameter) measured by FibroScan® in a cohort of patients followed for MASLD/MASH at an urban liver centre: Impact of utilization in clinical practice	Magdy Elkhashab	Received

SAT-456	Current evidence on dietary interventions in people with metabolic-dysfunction associated fatty liver disease and MetALD – a systematic review and meta-analysis of randomized controlled trials	Ute Stern	Received

TOP-457	Statin, but not aspirin use, is inversely associated with steatotic liver disease and liver fibrosis: results from two large population based studies	Jesse Pustjens	Received

TOP-458	qFibrosis enables earlier detection of fibrosis response in Efruxifermin-treated patients with F2-F3 MASH in 96-week HARMONY study	Jörn Schattenberg	Received

TOP-459	MetALD has a higher rate of extrahepatic cancer and cardiovascular events compared to other subtypes of steatotic liver disease	Katrina Pekarska	Received

TOP-460	Urinary proteomics identifies complement as potential biomarkers in severe alcohol-associated hepatitis patients	Laura Nagy	Received

THU-461	Genetic risk score correlates with Cytokine expression and risk of HCC and cirrhosis in MASLD patients from Latin America	Siyu Fu	Received

FRI-461	Impact of pre-transplant infection and multi-drug resistant organisms colonization on in-hospital post-transplant survival in subjects with pre-transplant liver failure	massimo puoti	Received

WED-461	Potential issues with practical implementation of EASL-EASD-EASO clinical practice guidelines on management of metabolic-associated steatotic liver disease in a Swedish healthcare setting	Merle Roeren	Received

SAT-461	The early impact of bariatric surgery on liver fibrosis and steatosis in MASLD patients	Valentina Cossiga	Received

WED-462	Determinants of liver stiffness improvements and worsening in metabolic dysfunction associated steatotic liver disease: insights from two cohorts	Mirko Zoncapè	Received

SAT-462	First-in-human single and multiple ascending dose study of AZD2389, a potent inhibitor of fibroblast activation protein, in healthy participants to evaluate safety, tolerability, pharmacokinetics and target engagement	Samuel Daniels	Received

FRI-462	Benefits of calcineurin inhibitor sparing regimen in a biopsy-guided personalized immunosuppression program after liver transplantation	Alisa Kielkowski	Received

THU-463	Coexistence of fatty acid desaturase 2 (FADS2) and PNPLA3 risk alleles contributes to fibrosis progression in MASLD	Shunsuke Ikejima	Received

WED-463	Three-tier testing pathways are required in metabolic dysfunction-associated steatotic liver disease for improved detection of advanced fibrosis	Mirko Zoncapè	Received

FRI-463	Effect of donor and recipient CYP3A5 genotypes on the pharmacokinetics of tacrolimus after liver transplantation	Ana Pascual-Dapena	Received

SAT-463	A prospective study on hepatic fibrosis evaluation in an alcohol withdrawal unit of an university hospital: role of FIB-4 and elastometry. FIBRADDICT study	Armand ABERGEL	Received

THU-464	Type 2 diabetes increases the risk of progression to metabolic dysfunction-associated steatohepatitis-related cirrhosis in a real world setting	Sabine Kahl	Received

SAT-464	Prospective evaluation of undiagnosed MetALD prevalence in MASLD patients using the ani score	Carlos Alventosa-Mateu	Received

WED-464	Gaps in screening and management of metabolic dysfunction-associated steatotic liver disease: a retrospective audit of patients at cardiometabolic risk in a secondary care setting	Monica Cucco	Received

FRI-464	How immunosuppression influences cancer survival in liver transplant recipients: insights from a tertiary care center	Carmen Alonso Martin	Received

THU-465	Long term outcomes of liver transplantation for patients with metabolic dysfunction and alcohol associated/related liver disease (MetALD) versus alcohol associated liver disease (ALD)	Swapnil Dhampalwar	Received

FRI-465	Sexual health after liver transplantation is significantly impacted and varies by gender	Sarah Lieber	Received

SAT-465	Performance of MELD 3.0 in predicting 90- and 180-day mortality in alcoholic hepatitis	Ana Suárez-Saro Fernández	Received

WED-465	Association of hepatic steatosis biomarkers with hepatic steatosis prevalence and risk of developing MASLD fibrosis in patients with type 2 diabetes mellitus in eastern Croatia: a pilot study	Martina Smolic	Received

WED-466	Serum biomolecules improve liver enzyme-based prediction scores of significant liver fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis	Nateneal Beyene	Received

SAT-466	Plasma exchange as a rescue therapy for patients with severe alcohol-associated hepatitis	ANAND KULKARNI	Received

THU-466	Development of a machine learning model for predicting cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study from UK Biobank	Tae Seop Lim	Received

SAT-467	Fibroblast activation assessed by PRO-C3 and PRO-C6 is associated to accumulation of key bile acids - A hallmark of fibrosis initiation and mortality in alcohol-related liver disease	Andressa de Zawadzki	Received

FRI-467	Incidence and risk factors for incisional hernias following liver transplantation: a retrospective single-centre european study	Callum Riley	Received

WED-467	Low sensitivity of the 2024 EASL screening criteria for identifying MASLD fibrosis in the NHANES cohort	Nicolas Goossens	Received

SAT-468	Hot & cold fibrosis: fibro-inflammatory biomarkers as prognostic tools in alcohol-related liver disease	Andressa de Zawadzki	Received

THU-468	Adverse outcomes and HBsAg seroclearance of chronic hepatitis B complicated with metabolic dysfunction-associated steatotic liver disease: a cohort study	Ai-Rong Hu	Received

FRI-469	Sodium and lactate levels during hypothermic oxygenated machine perfusion as predictive biomarkers for early allograft dysfunction in liver transplantation	David Pereyra	Received

SAT-469	Maintaining a low to moderate alcohol consumption over time in MASLD patients increases the risk of fibrosis progression over moderate drinkers and MetALD patients	Ares Villagrasa	Received

THU-469	Long-term clinical outcomes across biopsy-confirmed steatotic liver disease categories: a multicenter prospective cohort study using merged data	Won Kim	Received

THU-470	Liver-related events are uncommon in patients meeting AASLD criteria for Resmetirom and are not seen in those with a liver stiffness measurement < 10 kPa	Hua Xuan Yeow	Received

FRI-470	Retrospective study on simultaneous liver kidney transplantation: renal outcome and prevalence of acute cellular rejection	Dorien Pint	Received

WED-470	AI improves non-invasive diagnosis and screening of advanced MASLD	Paul Calès	Received

WED-471	Noninvasive fibrosis indices are less effective in predicting significant fibrosis in younger adults with metabolic dysfunction-associated steatotic liver disease	Ahlim Lee	Received

SAT-471	Bacterial infections in patients with severe alcoholic hepatitis: drivers of organ failure and mortality	Laura Buttler	Received

FRI-472	Factors associated with retransplantation-free survival in patients receiving TIPS after liver transplantation : results of a french multicenter retrospective study	Delphine Weil-Verhoeven	Received

SAT-472	Misclassification of alcohol use disorder in MASLD and MetALD: prevalence, clinical characteristics, and outcomes	DAE WON JUN	Received

TOP-473	Histological features predict response to corticosteroids and short-term survival in severe alcohol-associated hepatitis	Rudolf Stauber	Received

TOP-474	Bio-molecular characterization of albumin identifies predictors of disease severity and early mortality in severe alcohol associated hepatitis	SUSHMITA PANDEY	Received

FRI-475	The effect of dual hypothermic oxygenated machine perfusion on the incidence of post-transplant diabetes mellitus in recipients of livers donated after circulatory death	Efrayim H. Küükerbil	Received

SAT-475	Unemployment and social isolation predict relapse in patients with alcohol related cirrhosis	Christopher Oldroyd	Received

WED-476	Misclassification in non-invasive tests for liver fibrosis is expected: an example predicting liver stiffness in an international cohort	Rickard Strandberg	Received

THU-476	Rising trends in preventable premature MASLD-related deaths: disparities across urban and rural U.S. counties (2011–2021)	Carey Escheik	Received

SAT-476	Liver death trajectories differ in patients with alcohol consumption and/or metabolic syndrome: a 13-year nationwide study	Claire Delacte	Received

FRI-476	Current status of endoscopic treatment for anastomotic biliary stricture after living donor liver transplantation at our institution	Eisuke Ozawa	Received

WED-477	Validating non-invasive tests for diagnostic prediction of fibrosis in patients with biopsy-proven MASLD: CORE, LiverRisk, and FIB-4	Rickard Strandberg	Received

THU-477	Serum bile acid is associated with clinically significant pruritus in patients with metabolic dysfunction-associated steatotic liver disease	Carey Escheik	Received

FRI-477	Recurrence of primary sclerosing cholangitis after liver transplantation: a single centre experience	Emil Bik	Received

SAT-477	Feasibility and effectiveness of a liver health check clinic in community alcohol services	Daniel Gutmann	Received

WED-478	Novel multiparametric MRI imaging predicts histologic response in resmetirom versus placebo in the multicentre, international, Maestro NASH phase 3 trial	Rohit Loomba	Received

FRI-478	Outcome and predictors of major adverse cardiovascular events after liver transplantation: a single center experience	Eugenia Vittoria Pesatori	Received

THU-478	Metabolic dysfunction-associated steatotic liver disease (MASLD) screening according to EASL guideline is cost-effective	Carey Escheik	Received

THU-479	Plasma exosome antigens as prognostic biomarkers in alcohol-associated hepatitis	Anna Brujats	Received

FRI-479	AI-driven prediction of fibrosis progression in liver transplant recipients using a temporal deep learning framework	Xiang Xuan Eunice Tan	Received

WED-479	Assessment of the metabolic dysfunction-associated steatohepatitis resolution index and component biomarkers in prediction of histology response to denifanstat in the FASCINATE-2 trial	Wen-Wei Tsai	Received

WED-480	Denifanstat-mediated reduction of plasma glycine- and taurine-conjugated bile acids correlates with histological improvements in denifanstat-treated metabolic dysfunction-associated steatohepatitis patients in phase 2b FASCINATE-2 study	Wen-Wei Tsai	Received

FRI-480	Changes in sarcopenia and adipose tissue alterations do not predict post-transplant outcomes in patients with cirrhosis and hepatocellular carcinoma undergoing liver transplantation	Francesca DArcangelo	Received

FRI-481	Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma	Giuliana Amaddeo	Received

SAT-481	Performance of six biomarkers compared to histological fibrosis stage as surrogate markers of clinical endpoints in drug trials of patients with MetALD and ALD - a dual biopsy study	Ellen Lyngbeck Jensen	Received

THU-481	Gut microbiota derived immunological signature in metabolic alcohol associated liver disease	Jung A Eom	Received

WED-481	Advanced metabolic-dysfunction associated steatotic liver disease fibrosis: low number-needed-to screen in multiple lines of care	Stan Driessen	Received

THU-482	Outcomes in a real-world patient group started on Acamprosate for alcohol use disorder (AUD) with co-existent advanced fibrosis: adherence, efficacy and clinical impact over 24 months	Helen White	Received

FRI-482	Coronary atherosclerosis progression in patients with cirrhosis: effect of liver transplantation and association with early post-LT kidney dysfunction	Giulia Pagano	Received

WED-482	Leveraging natural language processing (CogStack) to analyse FibroScan data: a seven-year exploration (2016–2023) of socioeconomic disparities, ethnic variations, and fibrosis trends	Saima Ajaz	Received

SAT-482	Prospective study of phosphatidylethanol as a quantitative, objective biomarker to detect under-reported alcohol use in steatotic liver disease	Federica Tavaglione	Received

SAT-483	Younger, sicker, higher mortality; the burden of alcohol related liver disease in Ireland	Clare Foley	Received

WED-483	Development of a deep learning-based model for predicting liver-related events in steatotic liver disease using specific health checkup data	Shunichi Wakabayashi	Received

FRI-483	Adherence to the mediterranean diet and physical activity levels among liver transplant recipients in Greece: relationship to the metabolic syndrome	Kleoniki Chatzistavridou	Received

SAT-484	Impact of alcohol binge duration and metabolic features on liver stiffness in steatotic liver disease	Frances Lee	Received

FRI-484	Machine learning in predicting 3-month mortality for liver transplant candidates with HCC: a paradigm shift	Ilias Kounis	Received

THU-484	Digital pathology biomarkers describe fibrosis severity and disease activity in the FAT-MASH murine model and response to preventative treatment with mannose	Mathieu Petitjean	Received

WED-484	The culprits behind methotrexate-proposed hepatotoxicity are modifiable risk factors	Sinan Sharba	Received

SAT-485	Comorbidities at diagnosis of alcohol-related liver cirrhosis compared to the general population: a population-based case-control study of 11,989 patients	Gustav Jakobsson	Received

FRI-485	Development of an explainable machine learning model for predicting waitlist mortality in liver transplant candidates	Ilias Kounis	Received

THU-485	Prevalence, genetic risks, and cardiovascular outcomes of Met-ALD in a longitudinal multiethnic U.S. cohort	Jie Yao	Received

WED-485	US markers and necroinflammation, steatosis, and fibrosis in metabolic dysfunction-associated steatotic liver disease: the iLEAD study	Katsutoshi Sugimoto	Received

THU-486	The anticoagulant Edoxaban improves portal hypertension and liver injury in progressive liver disease	Katharina Bonitz	Received

SAT-486	Fecal microbiota transplantation is associated with improvement in survival compared to standard of care in severe alcoholic hepatitis: systematic review and meta-analysis	Jakub Hoferica	Received

FRI-486	NT-proBNP predicts the development of acute-on-chronic liver failure and mortality in patients with cirrhosis listed for liver transplantation	Juan Manuel Diaz	Received

WED-486	First construction and validation of new circulating markers (NITs) to assess the risk of early-fibrosis (eF) occurrence in outpatients with type-2 diabetes (T2D) and elevated transaminases	Peta Valentina	Received

FRI-487	Treatment of grafts not meeting criteria for transplantation with nor-ursodeoxycholic acid during normothermic machine perfusion reduces apoptosis and biliary injury markers	Jule Dingfelder	Received

THU-487	Liver-targeted mRNA therapeutics through fibroblast growth factor 21 and apolipoprotein A1 delivery in experimental acute pancreatitis	Maite G Fernandez-Barrena	Received

WED-487	The blood-based SteatoTest-2 score identifies a previously invisible early steatosis phenotype	Peta Valentina	Received

SAT-487	Disease severity is more important than age and underlying cirrhosis at predicting mortality from alcohol related hepatitis	Huw Purssell	Received

FRI-488	Concomitant sarcopenia and myosteatosis in patients with cirrhosis is associated with longer recovery and mortality after liver transplantation	Ellina Lytvyak	Received

SAT-488	Alcohol as a mediator of genetic and metabolic risk for fibrosis and steatosis in SLD	Jan Embacher	Received

THU-488	A new translational dietary rat model allows studying MetALD natural history and assesing the efficacy of various therapeutic interventions	María Martínez-Gómez	Received

WED-488	Weight loss-related changes in MRI-derived measures of body composition and liver health: a large-scale analysis from the UK biobank	Magdalena Nowak	Received

SAT-489	Monitoring hepatic function at 90 days of abstinence predicts recompensation and reduced liver-related mortality in patients with decompensated alcohol-related cirrhosis	Jan Embacher	Received

THU-489	Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease	Laura Nagy	Received

FRI-489	Coronary angiography in the preoperative work-up for liver transplantation (LT): a multicenter italian cohort study	Margherita Saracco	Received

WED-490	Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunction-associated steatotic liver disease and metabolic parameters	Valentina Flagiello	Received

FRI-490	Reintegration into working life for liver transplant recipients: cross-disciplinary evaluation of risk factors for unemployment	Margherita Saracco	Received

SAT-490	ALD is diagnosed at more advanced stages of fibrosis as compared to MetALD and MASLD in the general population	Jordi Gratacós Ginès	Received

THU-490	Cytokine release assay QuantiFERON Monitor predicts 90-day mortality in patients with severe alcohol-related hepatitis	Paula Boeira	Received

SAT-491	ELIBIO MRI-based Digital liver biopsy correlates with elastography and blood test in patients with chronic liver diseases (CLD)	Renaud Winzenrieth	Received

FRI-491	Outcomes of ABO-incompatible deceased donor liver transplantation in adults with acute liver failure: a study from a Costa Rican hospital	Maria Lynch-Mejia	Received

WED-491	Longitudinal validation of the AGA, AASLD and EASL care pathways for metabolic dysfunction-associated steatotic liver disease (masld) in a prospective cohort of individuals with type 2 diabetes	Veeral Ajmera	Received

THU-491	Metabolomic and transcriptomic insights into gender-specific PFAS effects on liver disease	Shashank Gupta	Received

SAT-492	Colorectal cancer incidence in steatotic liver disease (MASLD, MetALD, and ALD)	Takefumi Kimura	Received

THU-492	Altered high density lipoprotein 3 and associated proteins signatures contribute to immune dysfunction in alcohol associated liver cirrhosis	Shivani Gautam	Received

WED-492	Liver fibrosis is a strong predictor of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease independent from metabolic syndrome	weiwei xu	Received

FRI-492	Torque Teno virus as a biomarker of immune status and attenuated immune response to vaccination in liver transplant recipients	Ezequiel Mauro	Received

THU-493	Single-cell RNA sequencing and lipidomics identify synergistic effects of alcohol and PNPLA3 I148M on hepatic pathology	Stephen Hoang	Received

FRI-493	Conversion from standard-release to prolonged-release tacrolimus mitigates calcineurin-induced nephrotoxicity in patients after liver transplantation	Maximilian Joseph Brol	Received

SAT-493	A call to action - shortfalls and variation in care for inpatients with alcohol related liver disease in the UK: results of the ALERT UK national audit	Laura Burke	Received

WED-493	Evaluating noninvasive tests for significant fibrosis in a population-based MASLD cohort: insights from NHANES 2017–2020	Winston Dunn	Received

WED-494	Development and validation of two NIS2+®-based models for the detection of MASH resolution and fibrosis improvement	Yacine Hajji	Received

SAT-494	Validating the association between alcohol-related hepatitis and alcohol-related cirrhosis: a population-based study	Lucy Wilson	Received

FRI-494	Graft rejection and biliary complications affect liver stiffness measurements in the first year after liver transplantation	Michele Sagasta	Received

THU-495	The role of aryl hydrocarbon receptor across different cellular targets in pectin´s improvement of alcohol-associated liver disease	Wanchao Hu	Received

SAT-495	Stratification of liver fibrosis in individuals at-risk of metabolic dysfunction and alcohol-associated liver disease (MetALD)	Luis Antonio Diaz	Received

FRI-495	Hypothermic oxygenated machine perfusion (HOPE) treatment prior to organ transplant alters key immune modulators in patients receiving liver transplantation	Maike Rebecca Pollmanns	Received

WED-495	Liver stiffness measurement as a tool for identifying risk of hepatic-related hospitalizations: insights from a large real-world cohort	YAEL MILGROM	Received

FRI-496	Impact of donor-recipient age disparity on survival and recurrence in liver transplantation for hepatocellular carcinoma	NADA ELDOMIATY	Received

SAT-496	Steatosis independent of fibrosis predict hepatic decompensation and mortality in patients with MetALD and ALD	Mette Andersen	Received

THU-496	Allied health professionals are essential for facilitating initial evaluation and optimisation of patients for liver transplantation	Abigail Greenwell	Received

WED-497	Steatotic liver disease as a mortality risk enhancer in the presence of metabolic syndrome	weiwei xu	Received

THU-497	The challenge of adherence in Wilson disease: a prospective study	Zoe Mariño	Received

FRI-498	Prognostic impact of multi-resistant bacteria gut colonization in patients undergoing liver transplantation	Marina Orti-Cuerva	Received

THU-498	Demonstration of the success of a nurse led service surveying for hepatocellular carcinoma and other cirrhosis associated complications	Amy Thatcher	Received

WED-498	Hepatic collagen percent by morphometry correlates with non-invasive tests in metabolic dysfunction associated steatotic liver disease	Carey Escheik	Received

SAT-498	Cause-specific mortality across the spectrum of steatotic liver disease: a nationwide cohort study	Pedro Ochoa-Allemant	Received

THU-499	Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial	Annika Olsson	Received

FRI-499	Hepatic artery atherosclerosis is a risk factor for biliary strictures after liver transplantation	Paloma Elma Alañon Martinez	Received

SAT-499	Will individuals with alcohol use disorder participate in screening for chronic liver disease?	Pernille Dahlin	Received

WED-499	Validation of small transient elastography device for liver fibrosis and steatosis detection in a population-based study	Anna Soria	Received

WED-500	Evaluation of novel point-of-care ultrasound for hepatitis "PUSH" for healthcare workers managing hepatitis B infection in Zambia	Costanza Bertoni	Received

FRI-500	Association between pre-transplant body mass index and survival after liver transplantation in an adult recipient cohort from Johannesburg, South Africa	Preyanka Pillay	Received

THU-500	Community liver health checks are a valuable tool to support early diagnosis of liver disease	Bethia Featherstone	Received

WED-501	Prognostication of liver disease patients via ARFI-based liver stiffness measurement using the WFUMB "Rule-of-4" algorithm	Christian Sebesta	Received

THU-501	Malnutrition, sarcopenia and inadequate dietary intake before liver transplant: a time for action	Brooke Chapman	Received

SAT-501	Steatosis predicts poor abstinence rates in patients with alcohol use disorder	Queralt Herms Rubió	Received

FRI-501	Extensive portal vein thrombosis in patients with cirrhosis undergoing liver transplantation : results of a national multicenter retrospective study	Romain BARUSSEAU	Received

FRI-502	An audit to assess adherence to local guidelines for prophylaxis and monitoring of herpes simplex virus (HSV) in patients following orthotopic liver transplant in a tertiary transplant centre	Rachel McGaw	Received

THU-502	Non-weight-based ribavirin dosing for hepatitis E in immunosuppressed patients: a single-centre experience	Fatema Jessa	Received

SAT-502	Prevalence and predictors of early re-hospitalization or death among a national cohort of veterans hospitalized for alcohol-associated hepatitis in the United States	Robert Wong	Received

WED-503	Clinical decision tree for non-invasive diagnosis of graft steatosis in liver transplant patients	Dominik Lüttgen	Received

THU-503	Internal consistency and diagnostic validity of SARC-F questionnaire in chronic liver disease patients with sarcopenia on liver transplant wait list	GANESH SANKARRAJAN	Received

SAT-503	Cardiac performance is impaired in patients with proven alcohol related hepatitis and and predicts 3-month mortality in this patient population	Valainathan Shantha	Received

WED-504	Multi-omic machine learning for risk prediction of cholangiocarcinoma in population-based cohorts	Felix Van Haag	Received

FRI-504	Nephrocheck as a predicitve tool for post-operative acute kidney injury following liver transplant for chronic liver disease	Rosemary Worrall	Received

SAT-504	Rising proportion of young adults and women on the U.S. liver transplant waitlist for end-stage liver disease attributed to rising alcohol-associated liver disease following the COVID-19 pandemic	Shyam Patel	Received

THU-504	Negative consequences of screening for steatotic liver disease	Helle Lindholm Schnefeld	Received

TOP-505	Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States	Xiaolong Qi	Received

TOP-506	Outcomes for patients listed for liver transplantation with low MELD-Na scores: high frequency of MELD-Na score increases, liver transplantation, death and removal from waitlist	Alan Hutchison	Received

TOP-507	Quantifying liver function by cholate clearance in extracorporeal circuits with a genetically modified porcine liver and brain-dead human decedent	Greg Everson	Received

TOP-508	Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus	Milan Sonneveld	Received

WED-509	Decoding the dynamics: minimal detectable difference in non-invasive tests may exceed proposed thresholds for meaningful changes	Georg Semmler	Received

THU-509	Improving clinical efficiency of Hepatology clinics by optimising patient adherence with blood test monitoring	Jennifer Finn	Received

FRI-509	Assessing the safety and efficacy of advanced therapies to treat inflammatory bowel disease in patients with a liver transplant	Samantha Campbell	Received

SAT-509	Affinity-tuning chimeric antigen receptors could improve the therapeutic efficacy of regulatory t cells in liver transplantation	Ada Kurt	Received

THU-510	Impact of hepatitis delta infection on quality of life: results from the Nora-hepatitis B study	Judit Romero-Vico	Received

SAT-510	Reconstruction of native biliary networks in decellularized rat liver scaffolds with human intrahepatic cholangiocyte organoids	Javier Martínez-García	Received

THU-511	Evaluation of the utility of the Nora-hepatitis B mobile application: a comparative study between chronic infection and HBeAg-negative chronic hepatitis	Judit Romero-Vico	Received

WED-511	FIB-4 for identifying chronic liver disease patients requiring HCC surveillance	Jan Embacher	Received

SAT-511	Extracellular nicotinamide adenine dinucleotide as an independent prognostic marker for long-term survival after liver transplantation	Can Kamali	Received

FRI-511	QEL-001 LIBERATE study expansion cohort, CAR (Chimeric Antigen Receptor) T regulatory (Treg) cells engraftment and expansion following rATG (rabbit anti-thymocyte globulin) conditioning in post liver transplantation	Alberto Sanchez-Fueyo	Received

WED-512	Validation of Baveno VII criteria for non-invasive diagnosis of clinically significant portal hypertension: systematic review and individual patient data meta-analysis	Juan Bañares	Received

THU-512	Long-term real-world outcomes of obeticholic acid treatment for primary biliary cholangitis: insights from a pharmacy-led single-centre study	Kate Greener	Received

SAT-512	HepatoPredict has a good prognostic value in patients with hepatocellular carcinoma independently of biopsied nodule	Joana Cardoso	Received

FRI-512	TAVI in liver transplant candidates: a retrospective analysis from a high-volume transplant center	Marta Sánchez-Ric	Received

WED-513	Role of liver and spleen stiffness in predicting hepatic decompensation following transarterial chemoembolization in patients with hepatocellular carcinoma	Kessarin Thanapirom	Received

THU-513	Should all patients referred for liver transplantation undergo a review in a dedicated multidisciplinary assessment clinic prior to formal liver transplant work up?	Katie McCollum	Received

SAT-514	High-risk PNPLA3 rs738409 genotype is associated with higher CCL2 concentrations in liver transplant candidates with alcohol - related liver disease	Tomislav Kelava	Received

THU-514	Patient-perceived quality of care – effectiveness of the quality liver nursing care model	Maria Hjorth	Received

FRI-514	Dynamic changes of spleen stiffness in liver transplanted patients:preliminary findings from a single-center study	SOFIA RIDOLFO	Received

WED-514	Prediction of esophageal varices in fontan associated liver disease (FALD)	Victoria Kusztos	Received

SAT-515	"The feasibility of cell-free DNA for monitoring liver graft rejection: a pilot study perspective"	Joanna Raszeja-Wyszomirska	Received

THU-515	Impact of consensus guidelines on hepatitis B reactivation risk assessment and management in immunosuppressive therapy	Naz Kanani Alviri	Received

WED-515	Phase angle by BIA is useful for screening for malnutrition in patients with cirrhosis	Masafumi Haraguchi	Received

FRI-515	Evolving trends and the role of mitigating performance status decline on the liver transplant waitlist	Tomohiro Tanaka	Received

SAT-516	3D engineered endothelial cell implants protect liver explant viability ex vivo and reduce liver inflammation	Mireia Medrano-Bosch	Received

WED-516	Bile acids drive fibroblast activation, fibrogenesis, interstitial matrix fibrosis and outcomes in PSC	Andressa de Zawadzki	Received

THU-516	Nurse-led clinic for patients with decompensated liver cirrhosis	Palle Bager	Received

WED-517	Weight dependent, weight independent and non-pharmacological effects on fibroblast activity in metabolic dysfunction associated steatotic liver disease (MASLD)	Morten Karsdal	Received

THU-517	iCARE: Insights on competency advancement and recommendations for nurses managing HBV/HDV with bulevirtide – findings from a european advisory board	Patrizia Künzler-Heule	Received

WED-518	Comparing ultrasound and magnetic resonance imaging for hepatocellular carcinoma screening in high-risk populations: a systematic review and meta-analysis of prospective cohorts	Pedro Passos	Received

FRI-518	Depression is highly prevalent amongst patients listed for liver transplant and unrelated to liver disease severity	Victoria Kronsten	Received

SAT-518	The recovery failure of fecal microbiota diversity in patients after liver transplant is associated with a complicated postoperative course	Maike Rebecca Pollmanns	Received

THU-518	Multi-displinary team initiation of GLP-1/GIP agonist Tirzepatide in patients with metabolic-dysfunction associated steatotic liver disease (MASLD): single-centre UK study	Rachel Halley	Received

FRI-519	The post-operative recurrence rate is significantly higher in patients with HBV-HCC compared to those with HCV-HCC	Tsung-Han Wu	Received

SAT-519	Kallikrein-Kinin system activation in hepatic ischemia/Reperfusion injury: a key driver of Edema and thrombosis	Rajni Yadav	Received

THU-519	Prescribing for pain and symptom management in hospital patients with advanced liver disease: a single centre, retrospective clinical audit	Sarah Phillips	Received

WED-520	Prognostic utility of serum ammonia in cirrhosis: a systematic review and meta-analysis	Yevedzo Ntuli	Received

FRI-520	Rising global burden of liver transplants attributable to metabolic-associated steatotic hepatitis: trends from 68 countries (2009–2023)	Carey Escheik	Received

SAT-520	Effective in vivo transplantation of revascularized porcine liver scaffolds in pigs for extended function over one month	Sandra Meliton Barbancho	Received

TOP-522	Health-related quality of life, events of decompensation and mortality – effectiveness of the quality liver nursing care model	Maria Hjorth	Received

EASL Congress 2025

7-10 May Amsterdam

About us

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 07/05/2025 TO 10/05/2025

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.EASL2025.2025



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access